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Preface
The predecessor to this edition was titled Osteosarcoma: Biology, Behavior, and 
Mechanisms, and was the brainchild of my good friend Dr. Kurt Weiss and col-
league Dr. Kanya Honoki. They sought to draw attention and enthusiasm to the
recent advances in basic and clinical science research pertaining to osteosarcoma. 
There had been a relative stagnation in clinical advances over past decades in this
rare cancer in comparison to other oncologic diseases. We began to understand the
molecular biology and genetics of osteosarcoma but were unable to translate this
into longer survival or improved prognosis. However, this was on the precipice of
change with recent technological developments in big data genomics, improved 
understanding of molecular pathways, and discovery of new methods of epigenetic
tumor regulation.
This edition is titled Osteosarcoma—Diagnosis, Mechanisms, and Translational 
Developments, and focuses on recent advancements and novel ideas in osteosarcoma
research.  In a manner of speaking, we have taken the multidisciplinary mindset
essential for treating osteosarcoma and broadened it to include other areas of
cancer research. By learning from gains in other areas of oncology, such as new
lncRNAs, the understanding of cancer metabolism and oxidative phosphorylation, 
and new chemotherapy agents, we can apply them to the niche of osteosarcoma
for treatment development. By drawing more attention to these novel and clever
discoveries, we hope to continue this enthusiasm for advancements in basic and 
translational research in the field of osteosarcoma.
Matthew Gregory Cable, MD
Assistant Professor,
Louisiana State University Health Sciences Center,
Department of Orthopaedic Surgery,
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Integrating Basic Science with 
a Multidisciplinary Clinical 
Approach for Osteosarcoma
Scott Barnett and Matthew G. Cable
1. Introduction
Primary bone neoplasms are relatively uncommon. Among these tumors, 
osteosarcoma is the most common bone sarcoma, comprising approximately 35% 
of all malignant bone tumors [1]. Osteosarcoma affects approximately 500 chil-
dren and adolescents annually in the United States with incidence peaking in the 
second decade of life during periods of rapid bone turnover and growth spurts [2]. 
Osteosarcoma arises from sites of rapid bone turnover, making the distal femur, 
proximal tibia and proximal humerus the most typical locations [3].
Although a genetic predisposition with mutations in various tumor-suppressor 
genes incurs a higher likelihood of developing osteosarcoma, most cases of osteo-
sarcoma are sporadic. These chromosomal abnormalities yield defects in proteins 
involved in cell cycle regulation, resulting in uncontrolled cell proliferation [4]. 
These mutations are seen in a variety of disorders including Li-Fraumeni syndrome, 
which involves the p53 gene, or retinoblastoma, which involves the RB1 gene [5]. 
Some existing bone diseases such as Paget disease, fibrous dysplasia, enchon-
dromatosis, and hereditary multiple exostosis in addition to environmental risk 
factors, including radiation, have been identified as contributors to developing 
osteosarcoma.
Osteosarcoma serves as a broad term used to envelop the several different types 
of osteosarcoma that exist. These subtypes distinguish themselves through both 
clinical appearance as well as behavior. Unfortunately, the histological pictures 
of bone tumors do not definitively differentiate between osteogenic sarcoma, 
benign tumors, or other malignancies of bone [6]. Therefore, incorporation of both 
radiological and clinical tools is required to make the final diagnosis of osteogenic 
sarcoma [7].
In the setting of osteosarcoma, advanced imaging is warranted to evaluate the 
extent of tumor invasion, neurovascular involvement, bone marrow replacement, 
and presence of discontinuous metastases. Combination of MRI and CT imaging 
are helpful in demonstrating both soft tissue parameters of the tumor as well as cor-
tical integrity and the presence of pathologic fracture [8, 9]. New focus on advanced 
techniques in medical image processing for the detection and analysis of osteosar-
coma aims to better evaluate tumor locations, size, infiltrations of surrounding 
tissues, and identify the presence of satellite metastasis. Current research work 
utilizes positron emission tomography (PET) combined with MRI volumetry to 
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improvements in classification accuracy compared single modality evaluation [10]. 
The coupling of FDG-PET and MRI volumes offers improved prognostic and 
predicting capabilities for assessing the aggressiveness of tumors and aiding earlier 
clinical decisions regarding the utility of treatment options for patients.
A multidisciplinary approach is used for the treatment of patients with osteosar-
coma, offering survival rates of greater than 70% with metastatic disease [11, 12]. 
For high-grade osteosarcoma, treatment involves preoperative chemotherapy, wide 
surgical resection, and postoperative chemotherapy. Intratumor heterogeneity, 
a resultant of tumor evolution, is the fundamental challenge in cancer medicine. 
From heterogeneity stems disease relapse, metastatic behaviors, and drug resis-
tance [13]. Recent studies of cancer stem cells report a metabolism pathway that 
is predominantly through oxidative phosphorylation rather than glycolysis [14]. 
Targeting this metabolic pathway presents a potential therapeutic option against 
tumor cells. Within the mitochondria, a “two metabolic hit” theory has been 
proposed to utilize the synergistic effects of combining oxidative phosphorylation 
inhibition with c-Myc inhibition, which target both the oxidative phosphorylation-
dominant cancer stem cells and glycolysis-dominant non-cancer stem cells [15]. 
Novel compounds such as pterostilbene and honokiol have emerged as dual 
metabolic inhibition compounds that may lead to improvements in osteosarcoma 
prognosis, especially in the setting of metastatic disease [16].
Additional studies have shown that molecules belonging to the non-protein 
coding transcriptome may play essential roles in biological processes [17]. These 
non-protein coding RNAs are involved in gene expression regulation and have 
been found to play an important role in cancer development, progression, and 
chemoresistance of different tumors, including osteosarcoma [18]. Non-coding 
RNAs have emerged as potential prognostic biomarkers and therapeutic targets, 
being involved in cell signal transduction pathways, cell cycle and death regulation, 
chromatin remodeling, and gene expression regulation at both transcriptional and 
posttranscriptional levels [19]. Several tumors, such as urothelial carcinoma, colon 
carcinoma, and hepatocellular carcinoma have exhibited aberrant expression of 
non-coding RNAs, suggesting a new means of observation that may be exploited for 
diagnostic, prognostic preventative, or therapeutic processes [20]. A large number 
of long non-coding chain RNAs (lncRNAs) with oncogenic or tumor suppressive 
activity are differentially expressed in osteosarcoma. MALAT-1 (metastasis-
associated lung adenocarcinoma transcript 1), a lncRNA involved in recruiting 
mRNA splicing factors to transcription sites, is overexpressed in osteosarcoma and 
has expression levels linked to tumor metastatic potential [21]. The identification of 
lncRNAs serves as a catalyst for further research validating lncRNAs as prognostic 
and predictive biomarkers, therapeutic targets, and structural models for future 
mimicking pharmaceutical agents.
New targetable compounds generate hope for novel osteosarcoma treatment 
regimens, specifically with the affected pediatric population where chemotherapy 
has become the mainstay of treatment. Surgical resection yielded a high frequency 
of relapse and metastasis for children with osteosarcoma, shifting the focus to 
intense chemotherapy [22]. Similar to the discovery of lncRNAs, new molecular 
biologic factors that determine sensitivity to chemotherapy, invasive and metastatic 
potential of the tumor, and the prognosis of the disease have been elucidated in 
recent pediatric osteosarcoma research. Expression of methylguanine methyltrans-
ferase (MGMT) as well as MGMT methylation is correlated with poor histological 
response in osteosarcoma patients undergoing cisplatin treatment [23]. Other 
molecular factors such as vascular endothelial growth factor (VEGF) and c-Myc are 
under intense focus for characterizing tumor behavior, response to treatment, and 
dictating further treatment protocols [24]. Although there is significant relapse and 
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refractory rates for children diagnosed with metastatic osteosarcoma, comprehen-
sive assessments of these markers for histological response to chemotherapy may 
enhance current treatment protocols and guide future regimens.
Emphasis on basic science research remains a prime avenue for uncovering 
molecular mechanisms and biologic pathways that may lead to additional targeted 
therapies, less-toxic agents, and improved long-term survival in osteosarcoma [25]. 
Molecular biomarkers such as non-coding RNAs and cell-cycle regulator proteins 
are an area of current interest for the development of sensitive screening modalities 
as well as target-selective chemotherapeutic drugs. Progress in combined advanced 
imaging techniques offer better, non-invasive means for evaluating tumor, size, 
location and behavior, which facilitates clinical decision making. Treatment of 
osteosarcoma, an aggressive and malignant tumor, requires a multidisciplinary 
approach that incorporates progressive basic science research at all levels of care 
including diagnosis, treatment, and surveillance.
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Osteogenic Tumors in the Context
of Osteosarcoma
Mulazim Hussain Bukhari, Samina Qamar and Farwa Batool
Abstract
Primary bone tumors are rare, but osteosarcoma (OS) is the fourth commonest
non-hematological primary neoplasm of the bone in the adolescence, and the other
three commonest neoplasms, in descending order, are leukemia, brain tumors, and
lymphoma. The commonest presenting complaints are swelling and aches. These
tumors cannot be diagnosed without the help of radiology. There is a wide age range
of these neoplasms commonly appearing in the second and third decade of life with a
peak incidence in early teens. Males are affected more than females. The exact cause
of osteosarcoma is unknown. However, a number of risk factors, like genetic predis-
position, some existing bone diseases, environmental risk factors, and radiations,
have been identified. If the bone tumors are viewed by clinical, radiological, and
histopathological perspectives, the correct diagnosis can be made easily. Chemother-
apy combined with surgery is the standard treatment modality with better 5-year
survival rates. Elevated AKP is an important prognostic factor in this malignancy.
Keywords: aggressive osteoblastoma, osteogenic tumors, osteoma,
osteoid osteoma, osteoblastoma, osteogenic sarcoma
1. Introduction
Primary neoplasm of the bones is relatively uncommon. Among these tumors,
the osteosarcoma is the commonest primary malignant tumor, comprising of
approximately 35% of all bone malignant tumors, followed by others like
chondrosarcoma (25%), Ewing sarcoma (EWS) (16%), and chordomas (8%).
This malignant tumor can arise from any bone, mainly usually in the metaphyseal
(growth plates) long bones of the extremities, but the jaw, pelvis, and ribs may be
the sites of origin [1].
The nomenclature of bone tumors are described in “the World Health Organi-
zation (WHO)” classification system [2]. We are adopting a table from this classi-
fication to review the pathological diagnostic criteria of these lesions. A number of
variants of osteosarcoma exist, including conventional types (osteoblastic,
chondroblastic, fibroblastic, telangiectatic, multifocal, parosteal, and periosteal)
(Table 1) [3].
The histological pictures of bone tumors alone are not enough to make a differ-
entiation between osteosarcoma and benign tumors or other malignancies of the
bone; therefore, radiological and clinical help is needed to make the final diagnosis
of osteogenic sarcoma. Therefore, the chapter will not only address osteosarcoma
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1. Introduction
Primary neoplasm of the bones is relatively uncommon. Among these tumors,
the osteosarcoma is the commonest primary malignant tumor, comprising of
approximately 35% of all bone malignant tumors, followed by others like
chondrosarcoma (25%), Ewing sarcoma (EWS) (16%), and chordomas (8%).
This malignant tumor can arise from any bone, mainly usually in the metaphyseal
(growth plates) long bones of the extremities, but the jaw, pelvis, and ribs may be
the sites of origin [1].
The nomenclature of bone tumors are described in “the World Health Organi-
zation (WHO)” classification system [2]. We are adopting a table from this classi-
fication to review the pathological diagnostic criteria of these lesions. A number of
variants of osteosarcoma exist, including conventional types (osteoblastic,
chondroblastic, fibroblastic, telangiectatic, multifocal, parosteal, and periosteal)
(Table 1) [3].
The histological pictures of bone tumors alone are not enough to make a differ-
entiation between osteosarcoma and benign tumors or other malignancies of the
bone; therefore, radiological and clinical help is needed to make the final diagnosis
of osteogenic sarcoma. Therefore, the chapter will not only address osteosarcoma
but will also discuss all osteogenic tumors stepwise [1].
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This chapter will mainly focus on general clinical, imaging, and histopathological
characteristics, which will aid in diagnosis but may add a little to advances in tumor
biology or treatment of the multitude of bone tumors described in this chapter.
The exact cause of osteosarcoma is unknown. However, a number of risk factors,
like genetic predisposition, some existing (Paget disease, fibrous dysplasia,
enchondromatosis, and hereditary multiple exostoses and retinoblastoma) bone
diseases, environmental risk factors, and radiations, have been identified.
Keeping in mind the importance of this malignancy, it is therefore important to
understand the other osteogenic tumors before reaching the importance of osteo-
sarcoma; we will describe the differential diagnosis of osteogenic tumors in the
context of osteosarcoma.
2. Osteoma
It is a benign neoplasm exclusively seen in flat bone of skull and face. Micro-
scopically it consists of the mature lamellar bone. Multiple osteomas are associated
with Gardner’s syndrome (colonic polyposis). Sometimes it involves other than the
skull and face, as surface lesions of parosteal type (Figure 1 and Tables 1 and 2) [4].
Benign Intermediate Malignant
Osteoma Osteoblastoma Low-grade central osteosarcoma (OS)











WHO-based classification of osteogenic tumors of the bone.
Figure 1.
Radiological aspect of osteoma, (A) shows sharply radiodense lesions (black ring), (B) photomicrograph
(H&E 40x) similar to normal cortex, revealing mature bone (arrow), with less stroma and no atypia.
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3. Osteoid osteoma
It is a benign tumor of medullary metaphysis origin with a <2 cm lucent nidus,
encompassed by the solid periosteal reaction. The characteristic features are its
association with nocturnal pain (due to release of prostaglandin via Cox-1 and
Cox-2 pathway) which can be relieved by aspirin, a salicylate analgesic. Histologi-
cally it comprised of three zones, nidus, fibrovascular stroma, and mineralized
sclerotic bone. The nidus is composed of interconnected newly formed blood ves-
sels and new bone-forming cells (osteoblasts and osteoid) [5–7] (Table 3, Figure 2).
These tumors should be differentiated from osteomyelitis, stress fractures,
osteoblastoma, osteosarcoma, and other lesions [8, 9].
4. Osteoblastoma
It arises from the medullary metaphysis, but most cases arise from spongiosa of
the bone. It is a rare benign tumor of the bone. These tumors are now considered in
intermediated groups as they may be locally aggressive and tend to affect the axial
skeleton more often than osteoid osteoma. They are less painful and have poor
response with aspirin [10, 11]. These have many osteoclasts like giant cells and less
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Table 2.
Differential diagnosis of osteoma with osteoid osteoma, ossifying fibroma, and parosteal osteosarcoma.
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Figure 2.
Radiology of the osteoid osteoma (A) shows sharply radiodense lesions with nidus (black ring), similar to
normal cortex, (B) photomicrograph (40X) of osteoid osteomas reveals irregular trabeculae of lamellar bone
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rimming with osteoblasts, osteoid, and rich vascularity as compared to osteoid
osteoma (Table 4, Figure 3) [6, 12, 13]. This is also called giant osteoid osteoma
more than 2 cm in size; it does not have the surrounding reactive bone as compared
to osteoid osteoma and is not associated with nocturnal aches [13].
4.1 Aggressive osteoblastoma
It is a rare variant of osteoblastoma, which commonly arises from the vertebrae,
long bones, and bones of jaws; it is characterized by the presence of epithelioid
osteoblasts in the stroma with aggressive behavior. The tumor has propensity for
local invasion and recurrence, but still no metastasis has been seen in any case in the
literature [14, 15].
5. Osteosarcoma (OS)
It is the most common primary bone tumors (20%) of mesenchymal origin
second to multiple myeloma; the main histologic feature of this tumor is direct
production of malignant osteoid from malignant cells without normal osteogenic
process through fibrous and cartilage way; the cartilage or fibrous tissue may
present elsewhere or in other osteogenic portions. Malignant osteoid is the charac-
teristic finding of all types of OSs, and it is a eosinophilic, homogenous, glassy
appearing lacelike material [16, 17].
Osteosarcoma is very rare in young children (0.5 cases per million per year in
children <5 years). However, the incidence increases steadily with age [13].
It can affect all ages, but 75% appears in young age, it can affect all bones most
commonly in metaphysis of long bones, and knee joint is commonly involved
Figure 3.
(A) Radiology (left ankle bone) shows osteoblastoma, with well-circumscribed nondestructive but
sometimes with ABC changes (ring). The lesions are predominantly lytic, with a rim of reactive sclerosis.
(B) Photomicrograph (H&E 40X) showing irregular anastomosing trabeculae of osteoid and woven bone,
variable mineralization, and thickness of woven osteoid trabeculae (thick arrows). Numerous osteoclast-like
giant cells (thin arrow). No peripheral rim of fibrovascular tissue like in nidus.
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(60%). There is no gender difference, but males are affected more as compared to
females [13].
There are many morphological variants of OS with anastomosing, reticular oste-
oid and oval, spindled to epithelioid stromal cells. The cells may form rosettes to
small sheets in different patterns. There are several subtypes of OS, which can be,
differentiated on the basis of the site, degree of histological differentiation, and
association with underlying disease [12, 13, 16, 17].
5.1 Conventional intermedullary OS
This type of OS shows the male predominance and bimodal age, pediatric and
adult sarcoma. It has some association with hereditary effect, e.g., with mutation of
RB gene, Li-Fraumeni syndrome, Ollier disease, fibrous dysplasia, and Paget
disease (secondary OS). Radiation also plays a role in its pathogenesis. The long
bones are commonly involved showing classical “Codman triangle” to moth-eaten
picture due to permeation and destruction of medullary as well as cortical bone
on radiology [18, 19].
It is composed of hyperchromatic cells forming sarcomatous component around
the classical osteoid (Figure 4). This comprised of chondroblastic OS (25%), fibro-
blastic OS (25%), and osteoblastic OS (50%). Other subtypes are small cell-type OS,
giant cell-rich OS, telengiactatic-type OS, surface-type OS, periosteal OS, and
parosteal OS. Histologically it has two grades, low- and high-grade OS. Immuno-
histochemistry has some role in its differentiation from cartilage and other bone
tumors, i.e., ALK, VIM, variable SMA, and desmin. The S100 is always negative
except there is chondroid differentiation. EMA and keratin are negative in tumors
[16, 20–23].
Figure 4.
Radiological examination (A) showing intramedullary OS of left lower tibia with osteolytic and sclerotic lesion
in lower end above ankle joint (rings). There is a medullary and cortical destruction of bone. The
photomicrograph of (B & C) (40X with H&E) based characteristic of conventional osteosarcoma, is the
identification of osteoid (arrows), which is a dense, pink, amorphous extracellular material containing large
amounts of collagen type I. (C) The tumor cells (atypical osteoblast) and cytoplasm are eosinophilic, are larger
than normal osteoblasts (arrows), and vary in size with nuclear atypia.
17
Differential Diagnosis of Osteogenic Tumors in the Context of Osteosarcoma
DOI: http://dx.doi.org/10.5772/intechopen.85190
rimming with osteoblasts, osteoid, and rich vascularity as compared to osteoid
osteoma (Table 4, Figure 3) [6, 12, 13]. This is also called giant osteoid osteoma
more than 2 cm in size; it does not have the surrounding reactive bone as compared
to osteoid osteoma and is not associated with nocturnal aches [13].
4.1 Aggressive osteoblastoma
It is a rare variant of osteoblastoma, which commonly arises from the vertebrae,
long bones, and bones of jaws; it is characterized by the presence of epithelioid
osteoblasts in the stroma with aggressive behavior. The tumor has propensity for
local invasion and recurrence, but still no metastasis has been seen in any case in the
literature [14, 15].
5. Osteosarcoma (OS)
It is the most common primary bone tumors (20%) of mesenchymal origin
second to multiple myeloma; the main histologic feature of this tumor is direct
production of malignant osteoid from malignant cells without normal osteogenic
process through fibrous and cartilage way; the cartilage or fibrous tissue may
present elsewhere or in other osteogenic portions. Malignant osteoid is the charac-
teristic finding of all types of OSs, and it is a eosinophilic, homogenous, glassy
appearing lacelike material [16, 17].
Osteosarcoma is very rare in young children (0.5 cases per million per year in
children <5 years). However, the incidence increases steadily with age [13].
It can affect all ages, but 75% appears in young age, it can affect all bones most
commonly in metaphysis of long bones, and knee joint is commonly involved
Figure 3.
(A) Radiology (left ankle bone) shows osteoblastoma, with well-circumscribed nondestructive but
sometimes with ABC changes (ring). The lesions are predominantly lytic, with a rim of reactive sclerosis.
(B) Photomicrograph (H&E 40X) showing irregular anastomosing trabeculae of osteoid and woven bone,
variable mineralization, and thickness of woven osteoid trabeculae (thick arrows). Numerous osteoclast-like
giant cells (thin arrow). No peripheral rim of fibrovascular tissue like in nidus.
16
Osteosarcoma – Diagnosis, Mechanisms, and Translational Developments
(60%). There is no gender difference, but males are affected more as compared to
females [13].
There are many morphological variants of OS with anastomosing, reticular oste-
oid and oval, spindled to epithelioid stromal cells. The cells may form rosettes to
small sheets in different patterns. There are several subtypes of OS, which can be,
differentiated on the basis of the site, degree of histological differentiation, and
association with underlying disease [12, 13, 16, 17].
5.1 Conventional intermedullary OS
This type of OS shows the male predominance and bimodal age, pediatric and
adult sarcoma. It has some association with hereditary effect, e.g., with mutation of
RB gene, Li-Fraumeni syndrome, Ollier disease, fibrous dysplasia, and Paget
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6. Differential diagnosis of conventional OS
6.1 Fracture callus and stress fracture
Sometime fracture callus may be confused with OS, because there is formation
of spindle cells and cartilage with new bones, but all these elements are arranged
with orderly maturation as compared to haphazard and abrupt arrangement in OS
(Table 5). Postmenopausal women may have insufficiency fractures in the pelvis
resembling metastatic carcinoma [24, 25].
The osteoid and maturation level are the main difference between two lesions.
The osteoid of the callus woven bone is mature and shows a parallel pattern with
prominent osteoblastic rimming. Malignant osteoid is a eosinophilic, amorphous,
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two types of tumor osteoid, early-tumor osteoid, lacelike pattern around tumor
cells, and late-tumor osteoid, a mineralized one having an appearance of a woven
bone, but an important feature is that tumor osteoid is not rimmed by osteoblasts [16].
6.2 Osteomyelitis
Osteomyelitis is an important cause of morbidity and mortality in children and
adults due to acute and chronic bacterial infection. More common sites are the
metaphysis and epiphysis of the lower limbs and vertebrae [26–28].
Primary (hematogenous) osteomyelitis is associated with fever and local painful
mass and may have fistula formation. A history of recent trauma with open fracture
is significant for secondary osteomyelitis. The radiology and MRI are more helpful
in the diagnosis of these lesions [26]. The C-reactive protein and erythrocyte sedi-
mentation rate (ESR) are markedly elevated. Biopsy shows necrotic bone, fibrotic
marrow, and chronic inflammation with or without an acute inflammatory compo-
nent. Reactive bone is usually produced as part of an associated periosteal reaction,
readily differentiated using histological features [24] (Table 6).
6.3 Osteoblastoma
It is a benign osteoid-producing tumor with roughly the same age and sex
distribution as osteosarcoma. In conventional radiography, there is a well-defined
round expansile mass with central radiolucent zone (>1.5 cm) and a peripheral rim
of sclerosis (sclerosis may not be as extensive as in osteoid osteoma). On biopsy,
there is an irregular interlacing network of osteoid with prominent osteoblastic
rimming and features of woven bone; the differential diagnosis from OS is
sometimes difficult when the OS is well differentiated and OB is showing bizarre
osteoblasts due to degenerative activities [24] (Table 4).
6.4 Aneurysmal bone cyst (ABC)
ABC has the same age range and location as osteosarcoma. It presents with pain
and occasional pathological fracture. Secondary aneurysmal bone cysts can be seen
in older patients, superimposed on other primary neoplasms. Conventional radio-
graphs show radiolucent expansile bone lesion. MRI shows fluid levels on T2-
weighted images. Biopsy can differentiate from telangiectatic osteosarcoma (TOS),
which displays obvious histological features of malignancy (marked cellular pleo-
morphism, high and abnormal mitotic activity) (Figure 5) [24, 29] (Table 7).
6.5 Fibrous dysplasia (FD)
It is a nonneoplastic intramedullary condition, associated with two forms,
monostotic (seen in the ribs, femur, and tibia in young adults) and polyostotic
(endocrine dysfunctions). The presentation of polyostotic fibrous dysplasia com-
monly includes bone deformity and pathological fracture. It has wide age range at
presentation and no gender preference. The radiographs show a fusiform
expanded swelling with thinning of cortex not associated soft with tissue
mass. There are generally no aggressive radiographical features. Pathological frac-
ture may be seen [24].
Microscopically, there are curved and irregularly shaped trabeculae-like fish-
hook configuration. These are interspersed in fibrous stroma of variable cellularity.
These poorly moralized bony trabeculae have no rimming of osteoblasts, and carti-
laginous islands are present in 10% of cases [30].
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6. Differential diagnosis of conventional OS
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two types of tumor osteoid, early-tumor osteoid, lacelike pattern around tumor
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It should be differentiated from other bony lesions, cemento-ossifying fibroma
(rimming of osteoblast), chondrosarcoma (binucleation), Paget’s disease (mosaic
pattern bone histologically), non-ossifying fibroma (metaphyseal fibrous defect in
tibia with the absence of osteoid), simple bony cyst, and osteofibrous dysplasia/
ossifying fibroma (exclusively seen in the tibia almost, with anterior bowing of the
bone, in the cortex; rimming is seen around lamellar bony trabeculae) [30].
Some immunomarkers are helpful in the diagnosis of FD. Fibroblastic cells in FD
and ossifying fibroma show strong Runx2 expression in the nucleus, while
osteocalcin is seen in calcified regions in FD, and G protein genes (GNAS) are
positive in extragnathic FD. FD shows GNAS (G protein gene) mutation not seen
15 in other lesions. FD is negative for osteocalcin [31, 32] (Table 6).
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Differential diagnosis of osteosarcoma, with osteomyelitis, Langerhans granuloma, and fibrous dysplasia.
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6.6 Ewing’s sarcoma
It is the second commonest primary malignant bone tumor of the childhood
after osteosarcoma. It typically arises from the medullary cavity and invades the
Haversian system. Radiologically, It presents as moth-eaten and destructive perme-
ated lucent lesions in the shaft of the long bones. It appears typical onionskin
appendence due to periostitis. It may also involve flat bones and appears sclerotic in
up to 30% of cases [33].
Same age range and predilection for males. Type II symptoms (e.g., fever, night
sweats) are usually seen. Conventional radiographs show a metaphyseal or diaphy-
seal tumor with a predominantly lytic appearance. No bone matrix is radiographi-
cally identified. Onionskin appearance in ES on radiology. MRI shows a large soft
tissue mass.
Biopsy shows small round blue cell tumor with no osteoid production.
Cytogenetic and/or molecular studies show the typical translocations/molecular
aberrations of Ewing sarcoma family of tumors and help rule out small cell
osteosarcoma (a rare subtype of osteosarcoma with very little osteoid production).
CD 99 is positive in EWS [6, 33] (Table 5).
6.7 Chondrosarcoma
It is a cartilage-producing sarcoma with these differences with osteosarcoma. It is
most common in patients between 50 and 60 years of age and not seen in less than
20 years. The tumor has a predilection for the pelvic bones and a slower growth
rate. Conventional radiographs show a lytic lesion centered in the long bone
metaphysis, with a permeative growth pattern scalloping the cortex and showing
intra-tumoral calcifications, with a flocculent or ring-shaped appearance. The
Figure 5.
(A) Radiological examination of telangiectatic osteosarcoma revealing a lytic/expansile, (ring) permeative
lesion in the proximal fibula metaphysis with a wide zone of transition and cortical destruction, (B&C)
histological examination of the photomicrographs (B; 5X and C; 400X, H&E) blood-filled spaces (thin
arrows), separated by septa containing highly malignant cells (small arrows).
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cortex is usually thickened with a slightly expanded fusiform appearance, mainly
due to the slow permeative growth of the tumor (chronic periosteal reaction).
Scalloping of the inner cortex is a radiographic sign worrisome for malignancy.
Biopsy is the confirmatory test. Low-grade CS with ossification may mimic OS, but
the cartilaginous component in OS, if seen, is always high-grade and malignant
osteoids are essential for its diagnosis. Dedifferentiated CS has a well-differentiated
benign chondral lesion or chondrosarcoma and sharply juxtaposed with a high-
grade non-cartilaginous component; typically, there is an abrupt transition between
the two tissue types. The non-cartilaginous component of dedifferentiated
chondrosarcoma is generally osteosarcoma, a fibrosarcoma, or a malignant fibrous
histiocytoma. Dedifferentiation to leiomyosarcoma, giant cell tumor, and, rarely,
clear-cell chondrosarcoma or rhabdomyosarcoma has been reported. Always look
the age, site and radiology for help. The S-100 is negative in OS [34].
6.8 Giant cell tumor (GCT) of the bone
The GCT is usually benign and arises from long bone epiphysis and metaphysis.
It is rare in vertebrae, but when they occur in a vertebra, the body and not the arch
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overexpression of a tumor necrosis factor receptor (RANK/RANKL) which results
in a hyper-proliferation of osteoclasts [16]. Histologically, the GCTs are character-
ized by the presence of osteoclast-like, giant cells and round-to-oval polygonal
mononuclear cells. Frequent mitotic figures in the mononuclear cells may be seen,
especially in pregnant women or those on the oral contraceptive pill (due to
increased hormone levels) [16, 35]. Important features are given below (Table 5).
This lesion is most common in skeletally mature women with closed epiphysis
which usually presents with bone pain and sometimes pathological fractures. It
involves epiphysis and extends to joint articular cartilage. Conventional radiographs
show tumor with an osteolytic appearance located in the epiphysis of long bones,
with the distal femur and proximal tibia being the most commonly affected. No
doubt it is benign but is locally aggressive. This translates radiographically into the
absence of an osteosclerotic rim at its periphery as well as the presence of a soft
tissue mass. No bone/osteoid formation is identified. Radiology is soap bubble
appearance. Biopsy shows typical appearance of evenly distributed giant cells in a
mononuclear stroma. The nuclei of the giant cells resemble the nuclei of the histio-
cytes. There is atypia or mitosis, potentially malignant with 50% recurrence rate
and 10% metastasis [32].
6.9 Primary lymphoma of the bones
These are rare manifestation than secondary lymphoma involving the bone. It is
rare, accounting for <5% of bone tumors and <1% of non-Hodgkin lymphoma. It is
more common in old age males as compared to OS. The patient presents with type II
general symptoms like night sweatings, fever, and weight loss. The conventional
radiographs may be normal (tumor cells tend to grow between patient’s bony
trabeculae with little bone destruction). There may be multiple or single bone
involvement. MRI shows focal change in the marrow signal. Bone marrow biopsy is
usually the confirmatory test. Flow cytometric studies should be considered in
patients suspected of having lymphoma. Leukocyte common antigen (LCA) is
positive in lymphomas while negative in OS [24, 36]. Usually it should be differen-
tiated from infections, small cell OS, Ewing’s sarcoma, eosinophilic granuloma, and
metastatic lesions [36, 37].
6.10 Langerhans cell histiocytosis
It is a multisystem but rare disease. It is associated with a wide and heteroge-
neous clinical spectrum and extent of multisystem involvement. The age range is
5–15 years, more common in the children and early teens. The males are more
affected than females (M/F ratio is 3:2) [38, 39]. It has a predilection for the bones
of the skull, the calvarium, but any other bone like the humerus, femur, and ribs
can be involved. There is local pain and swelling. Radiographically there are multi-
ple lytic lesions with significant periosteal reaction. Biopsy shows a proliferation of
neoplastic Langerhans cells in an inflammatory background [24] (Table 6).
6.11 Metastases from other malignancies
Generally it occurs in older age group than osteosarcoma. There is usual history
of a primary malignancy known to metastasis to bone, such as breast, lung, thyroid,
kidney, and prostate. Conventional radiographs and radionuclide scans usually
show osteolytic lesions (rarely osteoblastic) involving multiple bones. CT imaging
may reveal other organs affected by metastatic disease. Biopsy usually confirms the
diagnosis [35].
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7. Special variants of OS with differential diagnosis
7.1 Telangiectatic OS
It is an uncommon variant of OS in the second decade with a mean age of
20 years. It comprises of 2.5–12% of all osteosarcomas. Almost all osteosarcomas
have telangiectatic component. In order to diagnose telangiectatic osteosarcoma,
there should be more than 90% component with telangiectatic features. It is more
common in males like conventional OS (with a ratio of 2:1 for male to female) [24]
better than conventional OS [13].
Multiple cyst-like spaces resemble an aneurysmal bone cyst, except that the septa
of the cysts contain stromal cells (mononuclear and multinucleated) with cytologi-
cally malignant changes. Mitotic figures are present, including atypical forms. Some-
times the malignant stromal cells are floating in the center of the large hemorrhagic
cysts; identification of the stromal cells may be difficult, requiring multiple sections.
The TOS may arise in other bony diseases like fibrous dysplasia, Paget’s disease, or
postradiation therapy. Malignant osteoid can be difficult to identify, usually focal and
found in a delicate lacelike pattern [24, 40] (Figure 5 and Table 7).
Advice: If the diagnosis of aneurysmal bone cyst is being considered, all tissue
should be evaluated histologically for evidence of malignant stroma to rule out
telangiectatic osteosarcoma radiological correlation.
7.2 Differential diagnosis of TOS
7.2.1 Aneurysmal bone cyst
The aneurysmal bone cysts are usually seen in young age with slight female
preponderance in flat and vertebral areas but may involve long bones. Radiology
shows a lucent expansile lesion in the metaphysis of long bones with thin reactive
covering of periosteal bone. CT and MRI show some fluid levels in the ABC.
Microscopically, thin blood filled spaces. These spaces are not lined by endothelium
but only fibroblastic cells are there. The stroma of the ABC may be cellular but
typically lacks cytological atypia and atypical mitoses and may contain reactive
bone with atypical osteoblasts. Cytologic malignant features and atypical mitoses
are absent (Figure 6, Table 7).
7.2.2 Conventional osteosarcoma
Radiographically, these tumors are not purely lytic. Intramedullary osteosarcoma
may contain focal telangiectatic areas, which should not be overinterpreted (Table 8).
7.3 Well-differentiated intraosseous low-grade osteosarcoma
The low-grade OS is a rare subtype of osteosarcoma, usually occurring in young
adults in their tibia and femur. Microscopically, there may be components of heavy
osteoid and fibrocollagenous stroma, and the cells appear benign but with invasion
of cortex and surrounding soft tissue. The spindle cells are with mild atypia, marked
collagen production, scant atypia, and abundant osteoid production (Figure 9). The
patients present with pain and swelling in older people. It arises from metaphysis of
long bone of lower extremity, while other sites are uncommon. Radiologically, there
are irregularly sclerotic lesions with poorly defined sclerotic margins, and mineral-
ized matrix is common (Figure 7A–C).
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7.4 Differential diagnosis of well-differentiated OS
7.4.1 Chondroblastoma
Chondroblastoma is a rare primary bone tumor of young people that typically
arises at the ends of the long bones. Radiologic investigations show a small,
circumscribed, lytic lesion. The tumor is characterized histologically by the prolif-
eration of chondroblasts along with areas of mature cartilage, giant cells, and,
occasionally, secondary aneurysmal bone cyst formation. Chondroblastoma, how-
ever, may also present with atypical features, such as prominent hemosiderin
deposition, numerous giant cells, or the presence of a large aneurysmal bone cyst
component.
A rare variant of osteosarcoma with CB features may be seen and can be difficult
to distinguish from CB, as both tumors can present in young patients as a lytic lesion
in an epiphyseal location. Histologically, this OS may reveal small round-oval cells
with eosinophilic cytoplasm and scattered giant cells and therefore may cause
confusion with CB, especially on a small biopsy specimen. Clues to the appropriate
malignant diagnosis include a more aggressive, infiltrative lesion on radiological
studies, and the presence of nuclear atypia, atypical mitoses, and/or malignant
osteoid production on histologic examination (Table 5).
7.4.2 Fibrous dysplasia
It is usually seen in young ages (10–30 years) and more common in males. It is
commonly found in metaphysis, diaphysis of ribs, jaw, skull, tibia, and femur. It is
locally aggressive tumor and may be monostotic or polyostotic and associated with
Figure 6.
(A) Radiological examination reveals (ring) homogenous cystic areas (aneurysmal bone cyst) without cortical
destructions. (B) Photomicrograph (H&E 10X) revealing cystic lesions (arrow), with giant cells (red arrow)
separated by fibrous septa (black arrows), alternating with solid areas and septa lined by fibroblasts,
myofibroblasts, and histiocytes but not endothelium (C).
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Figure 6.
(A) Radiological examination reveals (ring) homogenous cystic areas (aneurysmal bone cyst) without cortical
destructions. (B) Photomicrograph (H&E 10X) revealing cystic lesions (arrow), with giant cells (red arrow)
separated by fibrous septa (black arrows), alternating with solid areas and septa lined by fibroblasts,
myofibroblasts, and histiocytes but not endothelium (C).
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DLBCL; Diffuse large B cell lymphoma, MFH; Malignant Fibrous Histiocytoma.
Table 8.
Differential diagnosis of osteosarcoma with malignant fibrous histiocytoma, lymphoma, and osteoblastoma.
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endocrine disorders. Radiologically, it is circumscribed radiolucent lesions, within
the medullary cavity.
There are irregularly shaped bony trabeculae without rimming of osteoblasts.
The osteoids are of mature woven bones, and irregular in FD, while mature
osteoids are present in WDIOS. There is no cortical destruction on X-rays seen in
Figure 7.
(A) Radiological examination showing medullary and cortical bone destruction wide zone of transition (ring
and arrow), permeative or moth-eaten appearance. (B) Photomicrograph of (10X H&E) of conventional
intramedullary osteosarcoma and bony osteoid (thick arrow) surrounded by pleomorphic stroma and mitoses
(thin arrows) (20X H&E) (C).
Figure 8.
X-ray of parosteal osteosarcoma (ring) showing surface-attached mass (A). Photomicrograph (H&E 20X)
revealing continuously branching bony trabeculae (thick arrow) with spindle cell proliferation of malignant
cells (thin arrow) (B and C).
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FD, while there are irregularly sclerotic lesions with poorly defined sclerotic mar-
gins. The mineralized matrix is common in WDIOS while lacking in FD
(Tables 6 and 9).
7.4.3 Non-ossifying fibroma (cortical fibrous defect)
Usually seen in young persons, it is a benign lesion. Microscopically, no osteoid
and bony trabeculae but only storiform spindle stroma, giant cells, and hemosid-
erin-laden microphages are seen. Radiologically, these are eccentric sharply defined
lytic lesions in metaphyseal cortex in young people.
7.4.4 Parosteal osteosarcoma (PAOS)
This infrequent variant occurs in a juxtacortical position in the metaphyses of
long bones and grows very slowly. It grows, as a lobulated mass around the bone
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Note: Well-differentiated intramedullary osteosarcoma (WDIOS), parosteal osteosarcoma (PAOS), fibrous dysplasia (FD),
conventional osteosarcoma (COS).
Table 9.
Differential diagnosis of WD intramedullary osteosarcoma, parosteal osteosarcoma, conventional OS,
periosteal osteosarcoma, and fibrous dysplasia.
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osteoid, variable cartilage, and highly fibrous spindle cell stroma in disorganized
manner. In some cases there may be hypocellularity, but there is always mild atypia
in the stroma. These tumors have a slight female predominance, with a male-to-
female ratio of 1:1.5, and occur predominantly in the third decade. About three
fourths of cases involve the distal posterior femur, with the proximal tibia as the
second most common site. Clinically it presents as a painless mass of long
duration; pain may occur late in the course of this tumor but is not evident initially.
Microscopically, there is disorderly arrangement of well-formed bony trabeculae
and osteoid and exceptionally osteoclast-like giant cells. There are spindle-shaped
stroma with mild atypia and variable amount of cartilage (Table 9) compared to
conventional OS (Figure 8 and Table 9). Radiodense, bosselated, or mushroom-
shaped mass arises on the surface of a bone; in long-term lesions, tumor may
encircle the bone [41].
7.5 Differential diagnosis PAOS
7.5.1 Osteochondroma
It is a benign disorder where the medullary spaces contain adipose tissue or
marrow hematopoietic tissue with cartilaginous cap. The bony trabeculae are nor-
mally arranged as compared to the PAOS.
7.5.2 Myositis ossificans
The myositis ossificans (MO) is distinguished from PAOS by its orderly pattern
of maturation. Radiologically, things appear inverse in the MO as compared to
PAOS. There is the dense ossification in the center in MO and opaque bone at the
periphery, making it eggshell in appearance. Histologically there is zonal arrange-
ment. Maturation toward lamellar bone and marrow adipose tissue begins
Figure 9.
X-ray of periosteal osteosarcoma (ring) showing broad-based lesion thickening of cortical areas of the femur
(A). Photomicrograph (H&E 40X) revealing bony trabeculae with spindle cell proliferation (arrow) of
malignant cells and cartilage (red arrow) differentiation (B and C).
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peripherally and extends centrally in this proliferative process, which is the reverse
in parosteal osteosarcoma [41].
7.5.3 Osteochondroma
The osteochondroma shows continuity of corticomedullary areas of the tumor
and the underlying medullary canal, but these features are lacking in PAOS. Med-
ullary spaces contain adipose tissue or marrow hematopoietic tissue,
cartilaginous cap.
7.5.4 Periosteal osteosarcoma
Abundant cartilage is present. Higher-grade osseous component and evidence of
periosteal reaction.
7.5.5 Periosteal osteosarcoma (PEOS)
This malignant bone tumor is commonly seen in routine biopsies, entirely dif-
ferent from PAOS (juxtacortical OS) despite its similarity with terminology. It
arises on surface of long bones (upper tibia and femur). The PEOS affects a slightly
older age group (10–20 years) as compared to conventional osteosarcoma. Malig-
nant osteoid must be present, but the predominant pattern of tumor is represented
by lobulated chondromatous tissue with cytologic features of grade 2 or 3
chondrosarcoma. Tumor is located on the surface of the bone and may extend into
soft tissue. The lesions are limited to the cortex and rarely invade the medullary
cavity. The tumor appears perpendicular to the shaft. Sometimes high-grade ana-
plastic sarcomatous spindle cell component may separate lobules of the malignant
chondroid component [24] (Figure 9 and Table 10) [20, 42].
7.6 Differential diagnosis of PEOS
7.6.1 Periosteal chondroma
It is usually smaller and better defined and composed of benign chondroid tissue
and does not contain malignant tumor osteoid [24].
7.6.2 Periosteal chondrosarcoma
Radiographically, it contains “popcorn” calcifications, and histologically, it is a
low-grade chondrosarcoma containing no tumor osteoid [20, 24].
7.6.3 Parosteal osteosarcoma
Radiographically, this tumor is more radiodense, and histologically this is
a low-grade malignant fibro-osseous tumor without chondroid differentiation [20, 24].
7.6.4 Conventional intramedullary osteosarcoma
This is a higher-grade osteosarcoma involving the medullary cavity. Periosteal
osteosarcoma does not involve the medullary cavity [24].
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7.6.5 High-grade surface osteosarcoma
It lacks cartilaginous differentiation. Osteoid component is pleomorphic and
high grade [12, 13].
8. High-grade surface osteosarcoma
This is a high-grade osteosarcomawith similar histological features to those of
conventional intramedullary osteosarcoma. The tumor grows on the surface and
lacks significant medullary involvement. Radiographically it mimics periosteal
osteosarcoma, except it has cumulus cloud-like patterns of mineralization. It is a large,
lobulated surface mass with variable consistency ranging from soft to firm and
may contain hemorrhagic areas. It should not significantly involve the medullary
region [13, 24].
8.1 Differential diagnosis of high-grade OS
8.1.1 Dedifferentiated parosteal osteosarcoma
It usually has residual low-grade malignant fibroblastic stromal component.
Parosteal osteosarcoma lacks high-grade anaplastic appearance [12, 24].
8.1.2 Conventional intramedullary osteosarcoma
Significant medullary component (minimal medullary component in a
high-grade surface osteosarcoma) [24].
8.1.3 Low-grade central osteosarcoma
It is a large, poorly marginated intramedullary mass that either is sclerotic or
exhibits trabeculations and histologically similar to parosteal osteosarcoma [12, 24].
9. Summary
Osteosarcoma (OS) is a high-grade malignancy of the bone with high-mortality
rate. The exact cause of the condition is unknown, and presently, it is not possible to
prevent an osteosarcoma occurrence. It is mainly divided into two types, primary
and secondary, based on etiology, while based on where they occur, osteosarcoma is
classified as medullary osteosarcoma (occurring in the bone cavity) and surface
osteosarcoma (occurring on the bone surface). OS has a bimodal age distribution,
having the first peak during adolescence and the second peak in older adulthood,
while a little bit more common in males. Some genetic mutations, like mutation of
RB and P53 genes, are associated with osteosarcoma. Radiation affected persons,
patients of Paget’s disease of the bone, fibrous dysplasia, osteoblastoma, Ollier
disease, and chemotherapy, are other conditions and disorders that are thought to
be associated with Osteosarcomas. The tumor grows slowly in the initial phase of
the tumors and may be asymptomatic. Then tumors grow at a moderate rate, and
then they suddenly start to rapidly progress. Pathological fractures are commonly
seen in long bones.
Three parameters are used for its diagnosis, physical examination with medical
history, radiological support (X-rays, CT, MRI), and biopsy for microscopic
32
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examination. To approach the remedy of patient, grading and staging with good
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Abstract
Long noncoding RNAs (lncRNAs) are noncoding transcripts consisting of a
diverse class of long RNAs of more than 200 nucleotides in length. Recent studies
have shown that lncRNAs are involved in cell signal transduction pathways, cell
cycle and cell death regulation, chromatin remodeling, and gene expression regula-
tion at the transcriptional and posttranscriptional levels. They are also involved in
the metastatic process of different types of tumors, such as urothelial carcinoma,
colon carcinoma, breast carcinoma, lung carcinoma, and hepatocellular carcinoma.
In addition, lncRNAs demonstrate precise expression patterns in specific tissues and
cells and therefore play important roles in cell differentiation and tissue develop-
ment. In this chapter, we review the molecular mechanisms of lncRNA cell func-
tions and their involvement in the pathogenesis, progression, and metastasis of
osteosarcoma, a rare bone tumor of childhood and adolescence. We also review
emerging clinical implications of lncRNA use as potential prognostic biomarkers
and therapeutic targets, as well as their putative involvement in drug resistance, in
osteosarcoma progression, and in therapeutic interventions.
Keywords: lncRNAs, osteosarcoma, pathogenesis, prognosis, metastasis,
drug resistance
1. Introduction
Osteosarcoma is a rare malignant tumor and the most frequent primary malig-
nant tumor of the bone affecting most often young people in childhood and adoles-
cence [1–3]. It is of mesenchymal histogenetic origin and is characterized by the
production of osteoid and fibrous stroma. It has a tendency to be highly anaplastic
with cytological pleomorphism consisting of cells of epithelioid, spindle, ovoid, or
giant multinucleated appearance and in most cases a mixture of them [4]. It is
genetically unstable and exhibits structural chromosomal alterations [5–8]. It rep-
resents different pathological entities based on clinical, radiological, and histopath-
ological features. Depending on histopathological features, osteosarcoma displays
different subtypes, the most common among them are osteoblastic osteosarcoma,
chondroblastic osteosarcoma, and fibroblastic osteosarcoma. Less frequent are tel-
angiectatic osteosarcoma, small cell osteosarcoma, low-grade osteosarcoma, high-
grade osteosarcoma, parosteal osteosarcoma, and periosteal osteosarcoma [4, 9–11].
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Its incidence is about three to five cases per million population every year
worldwide with a propensity of aggressive biological behavior, local infiltrating
growth, and distant metastasis [1–3]. About 10–25% of patients are diagnosed with
pulmonary metastasis due to hematogenous dissemination, which is the main cause
of osteosarcoma mortality [12–14].
Despite its high mortality rates, the combination of ablative resection surgery
with chemotherapy or/and radiation therapy has elevated the cure rates of local
tumor from less than 20% during 1960s to 65–75% at present days [12–17].
However, patients with disseminated disease demonstrate a 5-year survival rate
around 11–30% due to resistance to chemotherapeutic regimens [16–18]. Therefore,
developing multimodal more effective treatments along with precise prognostic and
preventive biomarkers is imperative, and efforts are on the way to better
understand the molecular mechanisms involved in osteosarcoma pathogenesis and
define new therapeutic targets.
Recent studies have shown that molecules belonging to the nonprotein-coding
transcriptome may play essential roles in a wide range of biological processes
[19–21]. These molecules belong to the vast family of nonprotein-coding RNAs
which can be classified according to their size or function in two classes: the short
noncoding RNAs (sncRNAs) and the long noncoding RNAs (lncRNAs) [22, 23].
Short noncoding RNAs, with a length less than 200 nucleotides, such as
microRNAs (miRNAs), transfer RNAs, small interfering RNAs (siRNAs), piwi-
interacting RNAs, and some ribosomal RNAs, are estimated to be, till now, about
2500 different types. They are involved in gene expression regulation and have
been demonstrated to play important roles in cancer development, progression, and
chemoresistance of different tumors including osteosarcoma [22, 23].
On the other hand, lncRNAs are noncoding transcripts consisting of a diverse
and heterogeneous class of long RNAs of more than 200 nucleotides 100 kb in
length lacking the Kozak consensus sequence and without open reading frame.
Their transcription is processed through RNA polymerase II and is regulated by the
transcriptional activators of the nucleosome remodeling complex SWI/SNF [23–26].
They are divided in different categories such as intronic lncRNAs, intergenic
lncRNAs, UTR-associated lncRNAs, bidirectional lncRNAs, promoter-associated
lncRNAs, sense lncRNAs, and antisense lncRNAs [27, 28]. They participate in vital
biological processes, such as cell signal transduction, cell cycle and cell death regu-
lation, chromatin remodeling, transcriptional and posttranscriptional processing, as
well as in epigenetic gene regulation. They can act as decoys to compete with
different proteins, function as sponge to a large number of microRNAs, and interact
with RNA-binding proteins. In addition, lncRNAs demonstrate precise expression
patterns in specific tissues and cells and therefore play important roles in cell
differentiation and tissue development. [29–31]. LncRNA misregulation has been
implicated in cancer development, metastatic process, and drug resistance of dif-
ferent types of tumors, such as urothelial carcinoma, colon carcinoma, breast carci-
noma, and hepatocellular carcinoma. Aberrant expression of lncRNAs has been seen
in different human tumors, an observation that might be exploited for diagnostic,
prognostic, preventive, or therapeutic purposes [32–41]. Some of these lncRNAs
have also been reported to play a crucial role in osteosarcoma pathogenesis and
metastatic process as well as in chemotherapy drug resistance. Thus, they are
considered candidate molecules as prognostic or preventive biomarkers and/or
novel therapeutic targets [42–47].
In this chapter, we review the molecular mechanisms of lncRNA cell functions
and their involvement in the pathogenesis, progression, and metastasis of osteosar-
coma. We also review emerging clinical implications of lncRNA use as potential
40
Osteosarcoma – Diagnosis, Mechanisms, and Translational Developments
prognostic biomarkers and therapeutic targets, as well as their putative involvement
in drug resistance, in osteosarcoma progression, and in therapeutic interventions.
2. LncRNAs and signal transduction pathways in osteosarcoma
Osteosarcomagenesis is initiated in bone epiphyseal growth plates with rapid
turnover during childhood and adolescence and has also been observed in high
incidence in patients affected by Paget’s disease, a pathological entity characterized
by excessive osteoid formation and breakdown. These findings suggest that molec-
ular disturbances in osteoblast proliferation and differentiation are involved in
osteosarcoma pathogenesis through dysregulation of major signal transduction
pathways and osteogenic transcriptional factors [4, 42–47]. Several major signal
transduction pathways, mainly Wnt/β-catenin, bone morphogenetic protein
(BMP), Hedgehog, HIF1α, Notch, PI3K/Akt, JNK and NF-κB pathways are impli-
cated in osteosarcoma development and metastatic progression [48–50].
The canonical Wnt/β-catenin pathway, which plays a crucial role in osteoblast
differentiation, has been found to lead to osteoblast proliferation and suppression of
osteogenic differentiation in adult mesenchymal cells through expression of Wnt3a
[51–54]. Moreover, aberrations of Wnt signaling pathway have been associated with
osteosarcoma tumorigenesis and osteosarcoma drug resistance through upregulation
of factors, such as c-Met, leading to stem-cell phenotypes [4, 55–58]. LncRNA H19
has been found to increaseWnt signaling through epigenetical regulation of theWnt
pathway antagonist NKD1 via EZH2 recruitment [59]. Wnt pathway is also activated
through TCF7 whose expression is triggered by the recruitment of SWI/SNF
nucleosome remodeling complex to the TCF7 promoter by lncTCF7 [60, 61].
Hedgehog (Hh) signaling pathway plays a crucial role during vertebrate
embryogenesis acting as a morphogen and mitogen in different tissue development
including bone morphogenesis [62–66].
Dysregulation of Hh signaling pathway has been demonstrated to contribute to
promigratory effects in osteoblastic osteosarcoma and is related to poor prognosis
[67, 68]. Moreover Hedgehog signaling is upregulated in osteosarcoma leading to
overexpression of oncogenic yes-associated protein 1(Yap1) which in turn induces
the aberrant expression of lncRNA H19 [69].
Bone morphogenetic protein (BMP) signaling pathways synergistically act with
Runx2 factor, the most important regulator of bone development, leading to the
induction of many terminal differentiation factors and eventually to osteogenic
commitment of mesenchymal stem cells. This signaling cascade is initiated by BMP
ligand heterodimers (BMPR I and II) binding through Smad and mitogen-activated
protein kinase (MAPK) phosphorylation [70–73]. Suppression of osteoblast differ-
entiation has been observed, in one study, after BMP2 treatment of C3H10T1/2
MSCs by downregulation of mouselncRNA0231 and EGFR via Runx2 and osterix
regulation [74]. In another study, anti-differentiation lncRNA (ANCR) has been
found to suppress osteoblastogenesis through inhibition of Runx2 expression.
ANCR interacts with the enhancer of zeste homolog 2 (EZH2); this interaction leads
to H3K27me3 catalysis in Runx2 promoter resulting in inhibition of Runx2 expres-
sion [75]. Bone morphogenetic protein (BMP) signaling pathways play also an
important role in osteosarcoma through RhoA-ROCK-LIMK2 by promoting inva-
sion and metastasis [76, 77].
HIF1α expression levels are elevated in osteosarcoma tissues and are associated
with poorer prognosis. Moreover, HIF1α signaling pathway is implicated in osteo-
sarcoma cell invasion through induction of VEGF-A expression [78, 79]. A novel
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lncRNA, hypoxia-inducible factor-2α (HIF-2α) promoter upstream transcript
(HIF2PUT) has been demonstrated to regulate the expression of HIF-2α in osteo-
sarcoma stem cells. Overexpression of HIF2PUT significantly inhibited cell prolif-
eration and migration of MG63 osteosarcoma cells, while HIF2PUT knockdown led
to the opposite effect [80].
LncRNA hypoxia-inducible factor 1α-antisense 1 (HIF1α-AS1) is another
lncRNA involved in osteoblast differentiation. HIF1α-AS1 expression is repressed
by overexpression of histone deacetylase sirtuin 1 (SIRT1), a regulator of osteoblas-
togenesis, and lower levels of SIRT1 expression lead to upregulation of HIF1α-AS1
in bone marrow stem cells resulting in the activation of osteoblastogenesis [81].
Other studies have also shown the involvement of Notch and JNK signaling
pathways in osteosarcoma proliferation, metastasis, angiogenesis, and stemness-
associated factors [82, 83].
The phosphatidylinositol 3-kinase PI3K/Akt pathway is considered one of the
most critical pathways in osteosarcoma pathogenesis regulating osteosarcoma cell
proliferation, invasion, metastasis, and drug sensitivity or resistance [84, 85].
A large number of lncRNAs has been found to be differentially expressed in
osteosarcoma either with oncogenic or tumor suppressive activity. Particularly, in a
study by Li et al., 25,733 lncRNAs were detected, including 403 constitutively
upregulated in 34 pathways and 798 constitutively downregulated in 32 pathways
(twofold, P < 0.05) [86]. Among them metastasis-associated lung adenocarcinoma
transcript 1 (MALAT-1), a lncRNA involved in regulating the recruitment of pre-
mRNA-splicing factors to transcription sites, is overexpressed in osteosarcoma, and
its expression level is highly related to the metastatic potential of the tumor. In
another study, Dong et al. also found that MALAT-1 acts through the PI3K/Akt
pathway to promote osteosarcoma cell proliferation, migration, invasion, and pul-
monary metastasis [87]. MALAT-1 knockdown or siRNA interference experiments,
carried out by Dong et al. and Cai et al., respectively, showed that MALAT1 inhibi-
tion suppressed osteosarcoma cell proliferation and metastasis via the PI3K/Akt and
RhoA/ROCK signaling pathway by decreasing the expression levels of proliferating
cell nuclear antigen (PCNA), Act and phosphorylated PI3Kp85α, as well as MMP-9
metalloproteinase [87, 88].
Another lncRNA, named P50-associated COX-2 extragenic RNA (PACER), has
been found to be overexpressed in osteosarcoma clinical specimens and cell lines.
PACER has oncogenic effects in osteosarcoma functioning by activating COX-2
gene via the NF-κB signaling cascade [89]. Deregulated NF-κB has been linked to
osteosarcoma cell proliferation and metastatic process, and expression of NF-κB has
been observed to have clinical value in osteosarcoma patients [90, 91].
3. LncRNAs and regulation of cell growth/proliferation in osteosarcoma
Recent studies have demonstrated the involvement of lncRNAs in cell growth
and proliferation of osteosarcoma. Aberrant expression of lncRNAs is implicated in
osteosarcoma tumorigenesis through overexpression of oncogenic lncRNAs and
inhibition of tumor suppressive lncRNAs [42–44, 92]. These lncRNAs are summa-
rized in Table 1 along with their function and mechanisms.
3.1 Oncogenic lncRNAs
In recent years, a significant number of oncogenic lncRNAs such as 91H, HULC,
FGFR3-AS1, MALAT1, BCAR4, HIF2PUT, TUG1, UCA1, HOTTIP, and HOTAIR
have been identified to be implicated in cell growth and proliferation of osteosarcoma.
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PACER has oncogenic effects in osteosarcoma functioning by activating COX-2
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rized in Table 1 along with their function and mechanisms.
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have been identified to be implicated in cell growth and proliferation of osteosarcoma.
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H19 antisense RNA (91H) has a transcript length of 2.3 kb and is transcribed
from the H19/IGF2 genomic imprinted cluster, and its gene is located on chromo-
some 11p15.5 [93]. It is involved in insulin-like growth factor 2 (IGF2) transcrip-
tional regulation [94, 95]. It has also been observed that the IGF2 and H19 genes are
imprinted in the majority of normal human tissues and IGF2 transcriptional repres-
sion is regulated through CTCF binding to the H19 imprinting control region [96].
On the other hand, imprinting is lost in various tumor types. Osteosarcoma speci-
mens show maintenance or loss of IGF2/H19 imprinting depending on allele-
specific differential methylation of the CTCF-binding regulatory site upstream of
H19 gene [97]. Loss of imprinting of IGF2 or H19 in osteosarcoma is mutually
exclusive [97]. H19 antisense RNA expression has been found to be elevated in
osteosarcoma clinical specimens and osteosarcoma cell line and was correlated with
advanced clinical stage. It was considered an independent prognostic factor for
overall survival in treated osteosarcoma patients [98]. Moreover, H19 antisense
RNA knockdown led to cell death promotion and inhibition of osteosarcoma prolif-
eration, the mechanism of which needs to be elucidated [98].
Antidifferentiation noncoding RNA (ANCR), also called DANCR, is a
lncRNA that has been found to suppress osteoblastogenesis through inhibition of
Runx2 expression. ANCR interacts with the enhancer of zeste homolog 2 (EZH2).
This interaction leads to H3K27me3 catalysis in Runx2 promoter resulting in inhi-
bition of Runx2 expression and suppression of osteogenic differentiation [99].
ANCR also controls the cell cycle progression of osteosarcoma cells through regula-
tion of expression levels of p21, CDK2, and CDK4 and other cell cycle-related pro-
teins as well [100, 101].
Breast cancer antiestrogen resistance 4 (BCAR4) is another lncRNA that has
been found to be involved in antiestrogen resistance in breast cancer cell lines
[102, 103]. It also promotes cell growth and proliferation as well as invasion and
metastasis in breast cancer cell lines, via the noncanonical Hedgehog/GLI2 pathway
[75, 98]. In osteosarcoma, BCAR4 exerts its oncogenic action by activating GLI2-
dependent gene transcription via direct promoter binding [104]. Upregulation of
BCAR4 has been observed in osteosarcoma pathological specimens and is correlated
with poor overall survival. Knockdown BCAR4 experiments have shown that sup-
pression of BCAR4 inhibits proliferation and migration in vitro and in vivo through
GLI2 target genes [105].
Fibroblast growth factor receptor 3 antisense transcript 1 (FGFR3-AS1),
previously known as lncRNA-BX537709, is complimentary to FGFR3 in an anti-
sense direction and increases the mRNA stability and expression of FGFR3 through
antisense pairing with the FGFR3 3΄UTR [106]. FGFR3-AS1 is upregulated in oste-
osarcoma along with FGFR3 and is correlated with poor clinical outcome. Knock-
down FGFR3-AS1 experiments in osteosarcoma cell lines have demonstrated that
suppression of FGFR3-AS1 function leads to inhibition of cell cycle progression and
cell proliferation [107].
HIF-2α promoter upstream transcript (HIF2PUT), also named as
TCONS_00004241, is located on chromosome 2p21 [80, 108]. It belongs to the class
of promoter upstream transcripts lncRNAs (PROMPTs) which regulate host gene
transcription [109–111]. In knockdown experiments, suppression of HIF2PUT led
to inhibition of expression of HIF-2α and stemness-related genes such as Oct4, Sox,
and CD44, resulting in inhibition of cancer stem-cell properties [112]. In osteosar-
coma, HIF-2α mRNA and HIF2PUT expression levels are increased and are corre-
lated with advanced clinical stage and poor disease-free and overall survival
[80, 108]. HIF2PUT action in osteosarcoma tumorigenesis needs further elucidation
in order to understand better its role in osteosarcoma cell self-renewal and
stemness.
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HOX transcript antisense RNA (HOTAIR) is a 2337-bp-long lncRNA with
high expression levels in osteosarcoma tissue clinical specimens [113]. It is impli-
cated in the pathogenesis of various tumors including hepatocellular carcinoma,
lung carcinoma, and breast and ovarian cancers [114–117]. It promotes tumor cell
growth and proliferation by inhibiting gene expression through histone H3K27
trimethylation, functioning as a modular scaffold by binding PRC2 through the 5΄
domain and LSD1/CoREST/REST complexes through the 3΄ domain [118, 119]. This
molecular mechanism is implicated in other cancer types but remains to be eluci-
dated in osteosarcoma. Interestingly, a genetic variant of HOTAIR, rs7958904, is
associated with decreased risk of osteosarcoma in a two-stage case-control study in
Chinese population with 900 osteosarcoma cases and 900 controls [120].
HOXA transcript at the distal tip (HOTTIP) is a lncRNA which is
overexpressed in osteosarcoma specimens and is correlated with advanced
clinical stage and high metastatic potential [121]. Elevated expression of HOTTIP
is associated with increased tumor cell proliferation, migration, and invasion in a
variety of malignant tumors [122–125]. It exerts its action through regulation of
(i) EMT-related molecules such as E-cadherin, Snail1, Slug, etc., (ii) RNA-binding
proteins, and (iii) HOXA genes such as HOXA13 [126, 127]. HOTTIP knockdown
inhibits cell proliferation, migration, and invasion in osteosarcoma cell lines
[42, 128].
Highly upregulated in liver cancer lncRNA (HULC) was initially identified to
be upregulated in human hepatocellular carcinoma which has an oncogenic func-
tion. Its gene is located on chromosomal locus 6p24.3, has a transcript length of
500 bp, and associates with ribosomes [129, 130]. HULC acts as a sponge for
different miRNAs, such as miR200a-3p, miR-9, and miR107, by reducing their
expression [131, 132]. It promotes tumor cell growth, invasion, and angiogenesis in
hepatocellular and colorectal carcinoma cell lines [133, 134]. HULC is overexpressed
in osteosarcoma cell lines and tissue specimens, and its overexpression is correlated
with advanced clinical stage and poor overall survival in osteosarcoma patients.
HULC inhibition reduces cell proliferation and invasion in osteosarcoma cell lines
[135, 136].
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), also
called noncoding nuclear-enriched abundant transcrip. 2 (NEAT-2), has a 8.7-kb
transcript, and its chromosomal locus is on 11q13 [137]. It is a nuclear lncRNA,
initially found to be upregulated in non-small cell lung adenocarcinoma [137, 138].
MALAT-1 functions as a competitive endogenous RNA (ceRNA) by binding to
different miRNAs that regulate the transcription of genes such as cell division cycle
2 (cdc2) through miR-1 in breast carcinoma cells [139], Slug through miR-204 in
lung adenocarcinoma [140] and metalloproteinase-14 (MMP14), and Snail through
miR-22 in melanoma [141]. MALAT-1 is highly expressed in osteosarcoma tissue
samples and is correlated with metastatic dissemination and advanced clinical stage
[142, 143]. MALAT-1 acts through the PI3K/Akt pathway to promote osteosarcoma
cell proliferation, migration, invasion, and pulmonary metastasis [87]. Further-
more, MALAT-1 inhibition suppressed osteosarcoma cell proliferation and metas-
tasis via the PI3K/Akt and RhoA/ROCK signaling pathway by decreasing the
expression levels of proliferating cell nuclear antigen (PCNA), Act and phosphory-
lated PI3Kp85α, as well as MMP-9 metalloproteinase, as mentioned in the signal
transduction section [87, 88]. In addition, MALAT-1 may contribute to osteosar-
coma tumorigenesis and progression by competing miR376A and promotes TGFα
upregulation [144]. MALAT-1 downregulation is also involved in Myc-6 osteosar-
coma suppressor activity in MG63 osteosarcoma cell line [145].
Taurine upregulated gene 1 (TUG1) is a 7.1-kb lncRNA, and its gene is located
on chromosomal locus 22q12.2 [146]. It seems to be induced by p53, interacts with
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H19 antisense RNA (91H) has a transcript length of 2.3 kb and is transcribed
from the H19/IGF2 genomic imprinted cluster, and its gene is located on chromo-
some 11p15.5 [93]. It is involved in insulin-like growth factor 2 (IGF2) transcrip-
tional regulation [94, 95]. It has also been observed that the IGF2 and H19 genes are
imprinted in the majority of normal human tissues and IGF2 transcriptional repres-
sion is regulated through CTCF binding to the H19 imprinting control region [96].
On the other hand, imprinting is lost in various tumor types. Osteosarcoma speci-
mens show maintenance or loss of IGF2/H19 imprinting depending on allele-
specific differential methylation of the CTCF-binding regulatory site upstream of
H19 gene [97]. Loss of imprinting of IGF2 or H19 in osteosarcoma is mutually
exclusive [97]. H19 antisense RNA expression has been found to be elevated in
osteosarcoma clinical specimens and osteosarcoma cell line and was correlated with
advanced clinical stage. It was considered an independent prognostic factor for
overall survival in treated osteosarcoma patients [98]. Moreover, H19 antisense
RNA knockdown led to cell death promotion and inhibition of osteosarcoma prolif-
eration, the mechanism of which needs to be elucidated [98].
Antidifferentiation noncoding RNA (ANCR), also called DANCR, is a
lncRNA that has been found to suppress osteoblastogenesis through inhibition of
Runx2 expression. ANCR interacts with the enhancer of zeste homolog 2 (EZH2).
This interaction leads to H3K27me3 catalysis in Runx2 promoter resulting in inhi-
bition of Runx2 expression and suppression of osteogenic differentiation [99].
ANCR also controls the cell cycle progression of osteosarcoma cells through regula-
tion of expression levels of p21, CDK2, and CDK4 and other cell cycle-related pro-
teins as well [100, 101].
Breast cancer antiestrogen resistance 4 (BCAR4) is another lncRNA that has
been found to be involved in antiestrogen resistance in breast cancer cell lines
[102, 103]. It also promotes cell growth and proliferation as well as invasion and
metastasis in breast cancer cell lines, via the noncanonical Hedgehog/GLI2 pathway
[75, 98]. In osteosarcoma, BCAR4 exerts its oncogenic action by activating GLI2-
dependent gene transcription via direct promoter binding [104]. Upregulation of
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with poor overall survival. Knockdown BCAR4 experiments have shown that sup-
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sense direction and increases the mRNA stability and expression of FGFR3 through
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osarcoma along with FGFR3 and is correlated with poor clinical outcome. Knock-
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suppression of FGFR3-AS1 function leads to inhibition of cell cycle progression and
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TCONS_00004241, is located on chromosome 2p21 [80, 108]. It belongs to the class
of promoter upstream transcripts lncRNAs (PROMPTs) which regulate host gene
transcription [109–111]. In knockdown experiments, suppression of HIF2PUT led
to inhibition of expression of HIF-2α and stemness-related genes such as Oct4, Sox,
and CD44, resulting in inhibition of cancer stem-cell properties [112]. In osteosar-
coma, HIF-2α mRNA and HIF2PUT expression levels are increased and are corre-
lated with advanced clinical stage and poor disease-free and overall survival
[80, 108]. HIF2PUT action in osteosarcoma tumorigenesis needs further elucidation
in order to understand better its role in osteosarcoma cell self-renewal and
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growth and proliferation by inhibiting gene expression through histone H3K27
trimethylation, functioning as a modular scaffold by binding PRC2 through the 5΄
domain and LSD1/CoREST/REST complexes through the 3΄ domain [118, 119]. This
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polycomb repressive complex 2 (PRC2), and suppresses specific genes involved in
the G0/G1 cell cycle arrest, facilitating osteosarcoma tumorigenesis [147]. In this
context, TUG1 acts as a sponge for miR-9-5p and decreases the expression of POU
class 2 homeobox 1 (POUF2F1) supporting the presence of a competitive miR-
lncRNA regulatory network [148]. It also promotes osteosarcoma tumorigenesis
through EZH2 upregulation via miR-144-3p [149] . Additionally, TUG1 knockdown
represses the activation of Wnt/β-catenin pathway, which is reversed by EZH2
upregulation [149]. TUG1 is also involved in osteosarcoma cell proliferation and
invasion through inhibition of miR-212-3p [150]. Interestingly, osteosarcoma tissue
clinical samples exhibit high expression levels of TUG1, and impairment of TUG1
expression in osteosarcoma cell line U2OS inhibits cell proliferation and promotes
cell death [151]. TUG1 is overexpressed in osteosarcoma tissue specimens, and its
overexpression is associated with unfavorable prognosis [152].
Urothelial carcinoma associated 1 (UCA1) is a 2314-bp lncRNA located on
chromosome 19 and initially identified in bladder carcinoma [153]. It is upregulated
in many different tumor types including osteosarcoma, and its overexpression is
correlated with high tumor grade, distant metastatic dissemination, advanced clin-
ical stage, and poor clinical outcome [154–156]. Overexpression of UCA1 promotes
cancer cell proliferation through interactions with CREB, BRG1, miR-216b, or
hnRNP1 [158–161]. On the other hand, UCA1 overexpression inhibits cell death
through Akt/Bax/Bcl-2 signaling pathway and promotes migration, invasion, and
metastasis via the miR-216b/FGFR1/ERK signal transduction pathway [157–160].
UCA1 upregulation has also been found to be implicated in increased drug resis-
tance through SPRK1, Wnt6, and Wnt signaling pathways [162–164]. UCA1
knockdown experiments in osteosarcoma cell lines have shown that suppression of
UCA1 function leads to promotion of cell death and inhibition of cell cycle progres-
sion, cell proliferation, cell migration, and invasion, whereas UCA1 upregulation
displays opposite effects [160, 165].
Other lncRNAs that play important role in osteosarcoma cell proliferation and
display oncogenic properties are:
Modified frailty index 2 (MFI2) is implicated in osteosarcoma development
and proliferation by enhancing forkhead box P4 (FOXP4) expression [166].
Small nucleolar RNA host gene 12 (SNHG12) acts by increasing expression of
angiomotin gene in human osteosarcoma cell lines and through this action regulates
cell proliferation [167]. SNHG12 is also involved in the promotion of osteosarco-
magenesis and metastasis through upregulation of Notch2, acting as a sponge for
miR-195-p2 in 143B and U2OS osteosarcoma cells [168].
ZEB1 Antisense 1 (ZEB1-AS1) is upregulated in osteosarcoma and promotes
osteosarcoma cell proliferation via epigenetic regulation of ZEB1 transcription
[169]. ZEB1-AS1 also acts as a sponge for miR-200s and through this action reverses
the ZEB1 inhibition caused by miR-200s [170].
3.2 Tumor suppression lncRNAs
Another lncRNA category that plays a significant role in osteosarcoma tumori-
genesis includes lncRNAs with tumor suppressive properties such as Loc285194,
MEG3, and TUSC7. These lncRNAs are summarized in Table 1 along with their
function and mechanisms.
Loc285194, also named LSAMP antisense RNA3, is a 2105-bp lncRNA encoded
on chromosomal locus 3q13.31, also called as osteo3q13.31, a locus with frequent
copy number alterations and loss of heterozygocity in osteosarcoma [171, 172].
Loc285194 is downregulated in osteosarcoma cell lines and tissue specimens.
Loc285194 loss leads to increased osteoblast proliferation through regulation of cell
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cycle and cell death-related transcripts. It is also implicated in the regulation of
VEGF1 transcript [171]. Studies on HCT-116 colon cancer cell line have shown that
Loc285194 transcription is regulated by p53 [173, 174] and acts as a tumor suppres-
sor by direct repression of miR-211 in a reciprocal negative feedback loop [175].
This mechanism has not yet been established in osteosarcoma cell lines.
Maternally expressed gene 3 (MEG3) is a lncRNA transcribed by an imprinted
gene located on the chromosome 14q32.3 DLK1-MEG3 locus [176]. Reduced or loss
of MEG3 expression has been found in many different tumor types such as non-
small lung cancer, gastric cancer, colorectal cancer and bladder cancer [177]. The
underlying mechanism is through epigenetic promoter or intergenic
hypermethylation [178]. Induced expression of MEG3 in different cancer cell lines
leads to inhibition of cell proliferation, suppression of migration and invasion, and
promotion of apoptosis as well [179–182]. MEG3 overexpression also reduced the
expression level of miR21-5p in cervical cancer cells [183], increased the levels of
p53, and stimulated the transcription of p53-dependent genes such as MDM2 [184]
It is also implicated in the Wnt/β-catenin signaling pathway through regulation of
p53, β-catenin, and survivin [185, 186]. Osteosarcoma tissue samples display
reduced MEG3 expression levels, and its low expression is associated with distant
metastatic dissemination [187, 188]. Further studies are needed to confirm the role
of MEG3 in osteosarcoma pathogenesis.
Tumor Suppressor Candidate 7 (TUSC7) is a lncRNA which is downregulated
in osteosarcoma cell lines resulting in cell proliferation promotion and increased
colony formation in vitro. Decreased expression levels in osteosarcoma tissue spec-
imens are associated with poor survival in osteosarcoma patients. TUSC7 silencing
in HOS and MG63 osteosarcoma cells affects the expression of proapoptotic pro-
teins resulting in decreased levels, but with no effect on cell cycle regulation.
Moreover MG63 xenografts in nude mice showed tumor growth in vivo after
TUSC7 silencing [189, 190].
4. LncRNAs and cell death in osteosarcoma
It is well known that tumor cells enhance their viability by inhibiting apoptosis
and anoikis and can survive and metastasize in distant body sites and diverse
microenvironments. By inhibiting or reducing the activity of cell death machinery,
tumors become resistant to various therapeutic interventions and progress to
advanced clinical stages [191–194]. Recent studies have demonstrated the involve-
ment of lncRNAs in osteosarcoma cell death and make them putative therapeutic
targets for more efficient osteosarcoma treatment [195, 196].
Reduced 91H lncRNA expression levels promote osteosarcoma apoptosis via
upregulation of miR-141. Overexpression of miR-141 in hFOB1.19 cells leads to
osteosarcoma cell apoptosis through the suppression of H19 and miR-675 expression
resulting in reduced Bcl-2/Bax ratio and caspase-3 expression [197]. Moreover,
knockdown of H19 lncRNA leads to cell death promotion and inhibition of osteo-
sarcoma proliferation.
Inhibition of BRAF-activated noncoding RNA (BANCR) lncRNA suppresses
MG63 osteosarcoma cell proliferation and invasion in vitro and promotes cell death
as well [198].
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) lncRNA
affects the apoptotic osteosarcoma cell machinery through the RhoA/ROCK signal
transduction pathway [88]. MALAT1also regulates osteosarcoma cell proliferation
and apoptosis through upregulation of histone deacetylase 4 (HDAC4) by decoying
miR-140-5p [199].
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through EZH2 upregulation via miR-144-3p [149] . Additionally, TUG1 knockdown
represses the activation of Wnt/β-catenin pathway, which is reversed by EZH2
upregulation [149]. TUG1 is also involved in osteosarcoma cell proliferation and
invasion through inhibition of miR-212-3p [150]. Interestingly, osteosarcoma tissue
clinical samples exhibit high expression levels of TUG1, and impairment of TUG1
expression in osteosarcoma cell line U2OS inhibits cell proliferation and promotes
cell death [151]. TUG1 is overexpressed in osteosarcoma tissue specimens, and its
overexpression is associated with unfavorable prognosis [152].
Urothelial carcinoma associated 1 (UCA1) is a 2314-bp lncRNA located on
chromosome 19 and initially identified in bladder carcinoma [153]. It is upregulated
in many different tumor types including osteosarcoma, and its overexpression is
correlated with high tumor grade, distant metastatic dissemination, advanced clin-
ical stage, and poor clinical outcome [154–156]. Overexpression of UCA1 promotes
cancer cell proliferation through interactions with CREB, BRG1, miR-216b, or
hnRNP1 [158–161]. On the other hand, UCA1 overexpression inhibits cell death
through Akt/Bax/Bcl-2 signaling pathway and promotes migration, invasion, and
metastasis via the miR-216b/FGFR1/ERK signal transduction pathway [157–160].
UCA1 upregulation has also been found to be implicated in increased drug resis-
tance through SPRK1, Wnt6, and Wnt signaling pathways [162–164]. UCA1
knockdown experiments in osteosarcoma cell lines have shown that suppression of
UCA1 function leads to promotion of cell death and inhibition of cell cycle progres-
sion, cell proliferation, cell migration, and invasion, whereas UCA1 upregulation
displays opposite effects [160, 165].
Other lncRNAs that play important role in osteosarcoma cell proliferation and
display oncogenic properties are:
Modified frailty index 2 (MFI2) is implicated in osteosarcoma development
and proliferation by enhancing forkhead box P4 (FOXP4) expression [166].
Small nucleolar RNA host gene 12 (SNHG12) acts by increasing expression of
angiomotin gene in human osteosarcoma cell lines and through this action regulates
cell proliferation [167]. SNHG12 is also involved in the promotion of osteosarco-
magenesis and metastasis through upregulation of Notch2, acting as a sponge for
miR-195-p2 in 143B and U2OS osteosarcoma cells [168].
ZEB1 Antisense 1 (ZEB1-AS1) is upregulated in osteosarcoma and promotes
osteosarcoma cell proliferation via epigenetic regulation of ZEB1 transcription
[169]. ZEB1-AS1 also acts as a sponge for miR-200s and through this action reverses
the ZEB1 inhibition caused by miR-200s [170].
3.2 Tumor suppression lncRNAs
Another lncRNA category that plays a significant role in osteosarcoma tumori-
genesis includes lncRNAs with tumor suppressive properties such as Loc285194,
MEG3, and TUSC7. These lncRNAs are summarized in Table 1 along with their
function and mechanisms.
Loc285194, also named LSAMP antisense RNA3, is a 2105-bp lncRNA encoded
on chromosomal locus 3q13.31, also called as osteo3q13.31, a locus with frequent
copy number alterations and loss of heterozygocity in osteosarcoma [171, 172].
Loc285194 is downregulated in osteosarcoma cell lines and tissue specimens.
Loc285194 loss leads to increased osteoblast proliferation through regulation of cell
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cycle and cell death-related transcripts. It is also implicated in the regulation of
VEGF1 transcript [171]. Studies on HCT-116 colon cancer cell line have shown that
Loc285194 transcription is regulated by p53 [173, 174] and acts as a tumor suppres-
sor by direct repression of miR-211 in a reciprocal negative feedback loop [175].
This mechanism has not yet been established in osteosarcoma cell lines.
Maternally expressed gene 3 (MEG3) is a lncRNA transcribed by an imprinted
gene located on the chromosome 14q32.3 DLK1-MEG3 locus [176]. Reduced or loss
of MEG3 expression has been found in many different tumor types such as non-
small lung cancer, gastric cancer, colorectal cancer and bladder cancer [177]. The
underlying mechanism is through epigenetic promoter or intergenic
hypermethylation [178]. Induced expression of MEG3 in different cancer cell lines
leads to inhibition of cell proliferation, suppression of migration and invasion, and
promotion of apoptosis as well [179–182]. MEG3 overexpression also reduced the
expression level of miR21-5p in cervical cancer cells [183], increased the levels of
p53, and stimulated the transcription of p53-dependent genes such as MDM2 [184]
It is also implicated in the Wnt/β-catenin signaling pathway through regulation of
p53, β-catenin, and survivin [185, 186]. Osteosarcoma tissue samples display
reduced MEG3 expression levels, and its low expression is associated with distant
metastatic dissemination [187, 188]. Further studies are needed to confirm the role
of MEG3 in osteosarcoma pathogenesis.
Tumor Suppressor Candidate 7 (TUSC7) is a lncRNA which is downregulated
in osteosarcoma cell lines resulting in cell proliferation promotion and increased
colony formation in vitro. Decreased expression levels in osteosarcoma tissue spec-
imens are associated with poor survival in osteosarcoma patients. TUSC7 silencing
in HOS and MG63 osteosarcoma cells affects the expression of proapoptotic pro-
teins resulting in decreased levels, but with no effect on cell cycle regulation.
Moreover MG63 xenografts in nude mice showed tumor growth in vivo after
TUSC7 silencing [189, 190].
4. LncRNAs and cell death in osteosarcoma
It is well known that tumor cells enhance their viability by inhibiting apoptosis
and anoikis and can survive and metastasize in distant body sites and diverse
microenvironments. By inhibiting or reducing the activity of cell death machinery,
tumors become resistant to various therapeutic interventions and progress to
advanced clinical stages [191–194]. Recent studies have demonstrated the involve-
ment of lncRNAs in osteosarcoma cell death and make them putative therapeutic
targets for more efficient osteosarcoma treatment [195, 196].
Reduced 91H lncRNA expression levels promote osteosarcoma apoptosis via
upregulation of miR-141. Overexpression of miR-141 in hFOB1.19 cells leads to
osteosarcoma cell apoptosis through the suppression of H19 and miR-675 expression
resulting in reduced Bcl-2/Bax ratio and caspase-3 expression [197]. Moreover,
knockdown of H19 lncRNA leads to cell death promotion and inhibition of osteo-
sarcoma proliferation.
Inhibition of BRAF-activated noncoding RNA (BANCR) lncRNA suppresses
MG63 osteosarcoma cell proliferation and invasion in vitro and promotes cell death
as well [198].
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) lncRNA
affects the apoptotic osteosarcoma cell machinery through the RhoA/ROCK signal
transduction pathway [88]. MALAT1also regulates osteosarcoma cell proliferation
and apoptosis through upregulation of histone deacetylase 4 (HDAC4) by decoying
miR-140-5p [199].
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Overexpression of MF12 lncRNA suppresses osteosarcoma cell apoptosis
through FOXP4 transcription regulation. Additionally, MF12 knockdown in MG-63
and Saos-2 osteosarcoma cell lines induces apoptosis and reduces cell growth,
migration and invasion. [166].
Taurine upregulated gene 1 (TUG1) lncRNA overexpression promotes osteo-
sarcoma tumorigenesis by suppressing specific genes involved in the G0/G1 cell
cycle arrest [147]. In this context, TUG1 acts as a sponge for miR-9-5p and decreases
the expression of POU class 2 homeobox 1 (POUF2F1) [148]. Suppression of TUG1
has been demonstrated that inhibits cell proliferation and significantly promotes
osteosarcoma apoptosis [151].
Silencing of tumor suppressor lncRNA TUSC7 in HOS and MG63 osteosarcoma
cells reduces the expression levels of proapoptotic proteins and results in apoptotic
cell reduction [189, 190].
Further studies are needed to explore the role and the precise mechanisms of
these lncRNAs in osteosarcoma cell death in an attempt to modulate their action for
therapeutic reasons.
5. LncRNAs and invasion/metastasis in osteosarcoma
Despite the introduction of modern treatment approaches by applying
multimodality therapies in osteosarcoma patients and the improvement in disease-
free survival, the overall long-term survival remains relatively low. In patients with
localized disease, the 5-year relapse-free survival is around 75–80% for the good
chemoresponders, compared with 45–55% for the poor chemoresponders, in the
adjuvant setting and after surgical removal of the bone tumor. The rest of the
patients will display mainly pulmonary metastasis by relapsing within the first 5
years, probably because of the presence of undetectable metastatic disease at the
time of the initial diagnosis. Approximately, 20–25% of newly diagnosed osteosar-
coma patients are presenting with metastatic disease at the initial diagnosis. These
patients have an unfavorable prognosis with overall survival rates around 10–30%.
It is obvious that the main cause of the high mortality seen in those patients is the
development of metastasis, mainly in the lungs [12–18]. Thus, it is important, in
order to improve the outcome of patients with metastatic disease, to get insight into
the underlying mechanism of osteosarcoma metastasis and develop new therapeutic
agents against the metastasis regulatory pathways.
The metastatic process may occur through three main pathways in general:
(1) direct invasion of adjacent organs or seeding of body cavities, (2) lymphatic
spread, and (3) hematogenous spread. The latter is the main pathway of osteosar-
coma metastatic dissemination. A major role in the metastatic cascade plays the
phenomenon of epithelial to mesenchymal transition (EMT) whereby epithelial
cells lose their epithelial features and acquire mesenchymal cells traits which allow
them to invade adjacent tissues and display migratory properties. The metastatic
cascade is a multistep complex process and can be divided in the following phases:
(1) invasion of the extracellular matrix (ECM) and degradation of ECM proteins
through the activity of matrix metalloproteinases (MMPs), (2) intravasation,
(3) resistance to anoikis and survival in the peripheral blood, (4) extravasation, and
(5) seeding of a distant body site by clones of neoplastic cells with high metastatic
potential [192, 200, 201]. A number of studies have shown the involvement of
lncRNAs in the metastatic progression of osteosarcoma through modulation of
metalloproteinase expression, especially MMP-2 and MMP-9 [202, 203].
Breast cancer antiestrogen resistance 4 (BCAR4) is a lncRNA whose expres-
sion has been found to be increased in osteosarcoma tissue specimen in patients
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with lung metastasis [204]. It acts through transcriptional activation of GLI2-
dependent genes via direct promoter binding. Suppression of BCAR4 leads to inhi-
bition of proliferation and migration of osteosarcoma cells in vitro and in vivo
through GLI2 target genes [104, 205].
Differentiation antagonizing non-protein coding RNA (DANCR), also
named ANCR, is a lncRNA that has been found to be overexpressed in osteosarcoma
tissue specimens and in osteosarcoma cell lines. It is involved in osteosarcoma cell
proliferation and metastasis through Rho-associated coiled-coil-containing protein
kinase 1 (ROCK1) mediation via decoying both miR-335-5p and miR-1972
microRNAs. In this context DANCR acts as a metastasis-promoting lncRNA by
playing the role of a competing endogenous RNA (ceRNA) [206].
HOX transcript antisense RNA (HOTAIR) is highly expressed in osteosar-
coma and is correlated with distant metastasis and advanced clinical stages. It
promotes osteosarcoma invasion through upregulation of metalloproteinases
MMP-2 and MMP-9 [207].
Highly up-regulated in liver cancer lncRNA (HULC) acts as a sponge for
different miRNAs, such as miR200a-2p, miR-9, and miR107, by reducing their
expression [131, 132]. HULC is overexpressed in osteosarcoma cell lines and tissue
specimens, and its overexpression is correlated with distant metastasis, advanced
clinical stage, and poor overall survival in osteosarcoma patients [135]. It promotes
tumor cell growth, invasion, and angiogenesis in different cell lines, and its
inhibition reduces cell proliferation and invasion in osteosarcoma cell lines [136].
Long noncoding RNA activated by transforming growth factor-β (lncRNA-
ATB) is a novel lncRNA which is activated by the TGF-β and plays a crucial role in
many cancers [208]. EMT, and thus invasiveness, can be enhanced by the involve-
ment of the lncRNA-ATB, which acts by interfering the action of miR-200s, a
microRNA that suppresses ZEB1 and ZEB2 action [209]. LncRNA-ATB expression
levels are high in hepatocellular carcinoma as compared to normal liver samples and
are correlated with vascular invasion [210]. Moreover, orthotopic mice injected by
hepatocellular carcinoma cells overexpressing lncRNA-ATB developed distant
metastasis [211]. LncRNA-ATB promotes osteosarcoma cell proliferation, migration
and invasion by inhibiting miR-200s and upregulating the ZEB1 and ZEB2
miR-200s target genes. LncRNA-ATB is also overexpressed in osteosarcoma tissue
samples and cell lines and positively correlated with advanced clinical stage, metas-
tasis, and recurrence [212]. The role of lncRNA-ATB in osteosarcoma metastasis is
not yet well established, and more studies need to be done in order to elucidate its
involvement.
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) facili-
tates osteosarcoma invasion and metastasis by suppressing the microRNA 376A
(miR376A) and promoting TGFα upregulation [144]. MALAT-1 also acts through
the PI3K/Akt pathway to promote osteosarcoma cell proliferation, migration, inva-
sion, and pulmonary metastasis. Furthermore, MALAT-1 knockdown or siRNA
interference experiments, carried out by Dong et al. and Cai et al., respectively,
showed that MALAT1 inhibition suppressed osteosarcoma cell proliferation and
metastasis via the PI3K/Akt and RhoA/ROCK signaling pathways by modulating the
expression of MMP-9 metalloproteinase [85, 87, 88]. MALAT-1 is highly expressed
in osteosarcoma tissue samples and is correlated with metastatic dissemination and
advanced clinical stage [142, 143].
Nuclear factor – κB interacting lncRNA (NKILA) is a 2.5-kb lncRNA that
negatively regulates the NF-κB pathway. NF-κB is a transcription factor that medi-
ates inflammatory signal transduction processes [213]. It is constitutively active in
various tumor types, and its activity can be modulated by interacting with NKILA
(nuclear factor-κB interacting lncRNA). NKILA regulates NF-κB activity via
51
Long Noncoding RNAs in Osteosarcoma: Mechanisms and Potential Clinical Implications
DOI: http://dx.doi.org/10.5772/intechopen.83847
Overexpression of MF12 lncRNA suppresses osteosarcoma cell apoptosis
through FOXP4 transcription regulation. Additionally, MF12 knockdown in MG-63
and Saos-2 osteosarcoma cell lines induces apoptosis and reduces cell growth,
migration and invasion. [166].
Taurine upregulated gene 1 (TUG1) lncRNA overexpression promotes osteo-
sarcoma tumorigenesis by suppressing specific genes involved in the G0/G1 cell
cycle arrest [147]. In this context, TUG1 acts as a sponge for miR-9-5p and decreases
the expression of POU class 2 homeobox 1 (POUF2F1) [148]. Suppression of TUG1
has been demonstrated that inhibits cell proliferation and significantly promotes
osteosarcoma apoptosis [151].
Silencing of tumor suppressor lncRNA TUSC7 in HOS and MG63 osteosarcoma
cells reduces the expression levels of proapoptotic proteins and results in apoptotic
cell reduction [189, 190].
Further studies are needed to explore the role and the precise mechanisms of
these lncRNAs in osteosarcoma cell death in an attempt to modulate their action for
therapeutic reasons.
5. LncRNAs and invasion/metastasis in osteosarcoma
Despite the introduction of modern treatment approaches by applying
multimodality therapies in osteosarcoma patients and the improvement in disease-
free survival, the overall long-term survival remains relatively low. In patients with
localized disease, the 5-year relapse-free survival is around 75–80% for the good
chemoresponders, compared with 45–55% for the poor chemoresponders, in the
adjuvant setting and after surgical removal of the bone tumor. The rest of the
patients will display mainly pulmonary metastasis by relapsing within the first 5
years, probably because of the presence of undetectable metastatic disease at the
time of the initial diagnosis. Approximately, 20–25% of newly diagnosed osteosar-
coma patients are presenting with metastatic disease at the initial diagnosis. These
patients have an unfavorable prognosis with overall survival rates around 10–30%.
It is obvious that the main cause of the high mortality seen in those patients is the
development of metastasis, mainly in the lungs [12–18]. Thus, it is important, in
order to improve the outcome of patients with metastatic disease, to get insight into
the underlying mechanism of osteosarcoma metastasis and develop new therapeutic
agents against the metastasis regulatory pathways.
The metastatic process may occur through three main pathways in general:
(1) direct invasion of adjacent organs or seeding of body cavities, (2) lymphatic
spread, and (3) hematogenous spread. The latter is the main pathway of osteosar-
coma metastatic dissemination. A major role in the metastatic cascade plays the
phenomenon of epithelial to mesenchymal transition (EMT) whereby epithelial
cells lose their epithelial features and acquire mesenchymal cells traits which allow
them to invade adjacent tissues and display migratory properties. The metastatic
cascade is a multistep complex process and can be divided in the following phases:
(1) invasion of the extracellular matrix (ECM) and degradation of ECM proteins
through the activity of matrix metalloproteinases (MMPs), (2) intravasation,
(3) resistance to anoikis and survival in the peripheral blood, (4) extravasation, and
(5) seeding of a distant body site by clones of neoplastic cells with high metastatic
potential [192, 200, 201]. A number of studies have shown the involvement of
lncRNAs in the metastatic progression of osteosarcoma through modulation of
metalloproteinase expression, especially MMP-2 and MMP-9 [202, 203].
Breast cancer antiestrogen resistance 4 (BCAR4) is a lncRNA whose expres-
sion has been found to be increased in osteosarcoma tissue specimen in patients
50
Osteosarcoma – Diagnosis, Mechanisms, and Translational Developments
with lung metastasis [204]. It acts through transcriptional activation of GLI2-
dependent genes via direct promoter binding. Suppression of BCAR4 leads to inhi-
bition of proliferation and migration of osteosarcoma cells in vitro and in vivo
through GLI2 target genes [104, 205].
Differentiation antagonizing non-protein coding RNA (DANCR), also
named ANCR, is a lncRNA that has been found to be overexpressed in osteosarcoma
tissue specimens and in osteosarcoma cell lines. It is involved in osteosarcoma cell
proliferation and metastasis through Rho-associated coiled-coil-containing protein
kinase 1 (ROCK1) mediation via decoying both miR-335-5p and miR-1972
microRNAs. In this context DANCR acts as a metastasis-promoting lncRNA by
playing the role of a competing endogenous RNA (ceRNA) [206].
HOX transcript antisense RNA (HOTAIR) is highly expressed in osteosar-
coma and is correlated with distant metastasis and advanced clinical stages. It
promotes osteosarcoma invasion through upregulation of metalloproteinases
MMP-2 and MMP-9 [207].
Highly up-regulated in liver cancer lncRNA (HULC) acts as a sponge for
different miRNAs, such as miR200a-2p, miR-9, and miR107, by reducing their
expression [131, 132]. HULC is overexpressed in osteosarcoma cell lines and tissue
specimens, and its overexpression is correlated with distant metastasis, advanced
clinical stage, and poor overall survival in osteosarcoma patients [135]. It promotes
tumor cell growth, invasion, and angiogenesis in different cell lines, and its
inhibition reduces cell proliferation and invasion in osteosarcoma cell lines [136].
Long noncoding RNA activated by transforming growth factor-β (lncRNA-
ATB) is a novel lncRNA which is activated by the TGF-β and plays a crucial role in
many cancers [208]. EMT, and thus invasiveness, can be enhanced by the involve-
ment of the lncRNA-ATB, which acts by interfering the action of miR-200s, a
microRNA that suppresses ZEB1 and ZEB2 action [209]. LncRNA-ATB expression
levels are high in hepatocellular carcinoma as compared to normal liver samples and
are correlated with vascular invasion [210]. Moreover, orthotopic mice injected by
hepatocellular carcinoma cells overexpressing lncRNA-ATB developed distant
metastasis [211]. LncRNA-ATB promotes osteosarcoma cell proliferation, migration
and invasion by inhibiting miR-200s and upregulating the ZEB1 and ZEB2
miR-200s target genes. LncRNA-ATB is also overexpressed in osteosarcoma tissue
samples and cell lines and positively correlated with advanced clinical stage, metas-
tasis, and recurrence [212]. The role of lncRNA-ATB in osteosarcoma metastasis is
not yet well established, and more studies need to be done in order to elucidate its
involvement.
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) facili-
tates osteosarcoma invasion and metastasis by suppressing the microRNA 376A
(miR376A) and promoting TGFα upregulation [144]. MALAT-1 also acts through
the PI3K/Akt pathway to promote osteosarcoma cell proliferation, migration, inva-
sion, and pulmonary metastasis. Furthermore, MALAT-1 knockdown or siRNA
interference experiments, carried out by Dong et al. and Cai et al., respectively,
showed that MALAT1 inhibition suppressed osteosarcoma cell proliferation and
metastasis via the PI3K/Akt and RhoA/ROCK signaling pathways by modulating the
expression of MMP-9 metalloproteinase [85, 87, 88]. MALAT-1 is highly expressed
in osteosarcoma tissue samples and is correlated with metastatic dissemination and
advanced clinical stage [142, 143].
Nuclear factor – κB interacting lncRNA (NKILA) is a 2.5-kb lncRNA that
negatively regulates the NF-κB pathway. NF-κB is a transcription factor that medi-
ates inflammatory signal transduction processes [213]. It is constitutively active in
various tumor types, and its activity can be modulated by interacting with NKILA
(nuclear factor-κB interacting lncRNA). NKILA regulates NF-κB activity via
51
Long Noncoding RNAs in Osteosarcoma: Mechanisms and Potential Clinical Implications
DOI: http://dx.doi.org/10.5772/intechopen.83847
interaction with IκBα, a negative regulator of NF-κB translocation from the cyto-
plasm to the nucleus, thus preventing the transcriptional activation of NF-κB
dependent genes [214]. Loss or low expression of NKILA is correlated with
advanced clinical stage and metastatic dissemination in breast cancer patients [215].
The role of NKILA in osteosarcoma metastatic dissemination is not well known and
remains to be confirmed.
Osteosarcoma doxorubicin resistance-related up-regulated lncRNA
(ODRUL) expression levels have been found to be elevated in osteosarcoma tissue
specimens of patients with pulmonary metastasis [216]. ODRUL upregulates MMP2
expression through direct competing interaction with miR-3182 and thus promotes
invasion and metastasis [217]. ODRUL knockdown experiments in osteosarcoma
cell lines led to inhibition of tumor proliferation and invasion by decreasing matrix
metalloproteinase (MMP) expression, showing an important role in osteosarcoma
metastatic process [217].
P50-associated COX-2 extragenic RNA (PACER) is another lncRNA that acts
by promoting osteosarcoma invasion and metastasis through NF-κB-dependent
upregulation of COX-2 gene [89].
Small nuclear RNA host gene 12 (SNHG12) lncRNA has been demonstrated to
be implicated in the induction of osteosarcoma cell proliferation and migration
through the angiomotin upregulation which in turn controls the expression levels of
MMP-2 and MMP-9 [167]. SNHG12 is also involved in the promotion of osteosar-
comagenesis and metastasis through upregulation of Notch2, acting as a sponge for
miR-195-p2 in 143B and U2OS osteosarcoma cells [168].
Zinc finger E-box binding homeobox 1 Antisense 1 (ZEB1-AS1) has been
found to display elevated expression levels in metastatic osteosarcoma and regulate
the metastatic process by increasing ZEB1 transcription [169]. ZEB1, in turn, pro-
motes invasion and metastasis by inducing epithelial-mesenchymal transition
(EMT). ZEB1-AS1 also acts as a sponge for miR-200s and through this action
reverses the ZEB1 inhibition caused by miR-200s [170].
Other lncRNAs that play an important role in osteosarcoma invasion and
metastasis are:
LncRNAMF12 that has been shown to promote migration of osteosarcoma cells
via FOXP4 upregulation [166]. In addition, overexpression of urothelial carci-
noma associated 1 (UCA1) and BRAF-activated noncoding RNA (BANCR)
lncRNAs is correlated with metastasis in distant body sites [165, 198].
All the abovementioned lncRNAs are summarized in Table 1 along with their
function and mechanisms.
Further unraveling the mechanism of osteosarcoma invasiveness and metastatic
dissemination and the possible involvement of lncRNAs in this process will provide
useful insights to develop new therapeutic targets for the management of metastatic
osteosarcoma and improve the long-term survival of patients.
6. LncRNAs as prognostic biomarkers in osteosarcoma
The efficacy of osteosarcoma treatment and the accurate prognosis of the clinical
outcome depend on clinical, histopathological, and molecular factors, and there-
fore, it is important to identify and incorporate prognostic factors into a holistic
therapeutic strategy. Age, gender, anatomic location, tumor size, and a variety of
biological molecules have been used and proposed as a tool to predict the treatment
responsiveness and the clinical outcome/prognosis. Recent studies have indicated
that lncRNAs may be of clinical value and may be used as prognostic biomarkers in
osteosarcoma [106, 128, 218].
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Upregulation of fibroblast growth factor receptor 3 antisense transcript 1
(FGFR3-AS1) lncRNA is correlated with advanced Enneking surgical stage, large
tumor size, and poor clinical outcome and survival [107]. Based on these observa-
tions, its expression levels could serve as a prognostic factor.
Interestingly, in a two-stage case-control study in Chinese population performed
by Zhou et al., they found that a genetic variant of HOTAIR, rs7958904 the CC
genotype, was associated with decreased risk of osteosarcoma compared with the G
allele (OR, 0.77; 95% CI, 0.67–0.90; P = 6.77  104). About 900 osteosarcoma
patients and 900 control subjects have been evaluated, and the findings suggested
that HOTAIR rs7958904 CC genotype patients had significant lower HOTAIR
expression levels compared to other genotype patients, as well as lower osteosar-
coma risk. Therefore HOTAIR can be used as a prognostic factor for osteosarcoma
risk assessment [120].
HOXA transcript at the distal tip (HOTTIP) lncRNA overexpression in oste-
osarcoma human tissue specimens is associated with distant metastasis, advanced
clinical stage, and unfavorable prognosis. Elevated HOTTIP expression levels have
been demonstrated to correlate with poor overall survival and to be an independent
prognostic factor [121].
Highly upregulated in liver cancer (HULC) lncRNA is overexpressed in
osteosarcoma cell lines and tissue specimens, and its overexpression is correlated
with advanced clinical stage and poor overall survival in osteosarcoma patients
[135, 136]. HULC acts as a sponge for different miRNAs, such as miR200a-2p,
miR-9, andmiR107, by reducing their expression, and leads to increased cell
proliferation, cellmigration, and invasion in osteosarcomacell lines [131, 132, 134, 205].
Inactivation of HULC via knockdown experiments and/or upregulation of miR-122 via
transfection of osteosarcoma cell lines results in inactivation of PI3K/Act, Notch, and
Jak/Stat pathways leading in reduced proliferation, migration, and invasion [219].
Therefore, HULCcould be used as a prognostic factor for osteosarcomapatients as high
expression levels are positively correlatedwith distantmetastasis and advanced clinical
stage.
Activated by transforming growth factor beta (lncRNA-ATB) displays high
expression levels in osteosarcoma cell lines and tissues. Patients with osteosarcoma
have elevated serum expression levels of lncRNA-ATB, and this overexpression is
correlated with local recurrence, distant metastasis, and advanced clinical stage
[208, 212]. Thus, lncRNA-ATB could be used as a prognostic and recurrence mon-
itoring factor for osteosarcoma patients.
Maternally expressed gene 3 (MEG3) lncRNA expression levels are decreased
in osteosarcoma tissues compared with adjacent normal tissues and are associated
with distant metastasis, advanced clinical stage, and poor overall survival [177, 220].
Its expression is regulated by lncRNA Ewing sarcoma associated transcript 1
(EWSAT1) and downregulation of MEG3 in the presence of EWSAT1 induces oste-
osarcoma cell proliferation, invasion, and metastasis [221]. Therefore, high levels of
MEG3 could be an indicator of favorable prognosis in osteosarcoma patients.
Taurine upregulated gene 1 (TUG1) lncRNA has been found to be
overexpressed in osteosarcoma human samples compared with normal matched
tissues (P < 0.01), and expression levels were associated with tumor size, postop-
erative chemotherapy responsiveness and Enneking surgical stage [152]. Moreover,
TUG1 high expression levels were significantly correlated with unfavorable prog-
nosis and were an independent prognostic factor for disease-free survival
(HR = 1.81; 95% CI = 1.01–3.54; P = 0.037) and long-term overall survival
(HR = 2.78; 95% CI = 1.29–6.00; P = 0.009). Interestingly, TUG1 elevated plasma
levels are associated with disease progression or relapse [152]. Thus, TUG1 might be
used as a prognostic and monitoring biomarker for osteosarcoma patients.
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Upregulation of fibroblast growth factor receptor 3 antisense transcript 1
(FGFR3-AS1) lncRNA is correlated with advanced Enneking surgical stage, large
tumor size, and poor clinical outcome and survival [107]. Based on these observa-
tions, its expression levels could serve as a prognostic factor.
Interestingly, in a two-stage case-control study in Chinese population performed
by Zhou et al., they found that a genetic variant of HOTAIR, rs7958904 the CC
genotype, was associated with decreased risk of osteosarcoma compared with the G
allele (OR, 0.77; 95% CI, 0.67–0.90; P = 6.77  104). About 900 osteosarcoma
patients and 900 control subjects have been evaluated, and the findings suggested
that HOTAIR rs7958904 CC genotype patients had significant lower HOTAIR
expression levels compared to other genotype patients, as well as lower osteosar-
coma risk. Therefore HOTAIR can be used as a prognostic factor for osteosarcoma
risk assessment [120].
HOXA transcript at the distal tip (HOTTIP) lncRNA overexpression in oste-
osarcoma human tissue specimens is associated with distant metastasis, advanced
clinical stage, and unfavorable prognosis. Elevated HOTTIP expression levels have
been demonstrated to correlate with poor overall survival and to be an independent
prognostic factor [121].
Highly upregulated in liver cancer (HULC) lncRNA is overexpressed in
osteosarcoma cell lines and tissue specimens, and its overexpression is correlated
with advanced clinical stage and poor overall survival in osteosarcoma patients
[135, 136]. HULC acts as a sponge for different miRNAs, such as miR200a-2p,
miR-9, andmiR107, by reducing their expression, and leads to increased cell
proliferation, cellmigration, and invasion in osteosarcomacell lines [131, 132, 134, 205].
Inactivation of HULC via knockdown experiments and/or upregulation of miR-122 via
transfection of osteosarcoma cell lines results in inactivation of PI3K/Act, Notch, and
Jak/Stat pathways leading in reduced proliferation, migration, and invasion [219].
Therefore, HULCcould be used as a prognostic factor for osteosarcomapatients as high
expression levels are positively correlatedwith distantmetastasis and advanced clinical
stage.
Activated by transforming growth factor beta (lncRNA-ATB) displays high
expression levels in osteosarcoma cell lines and tissues. Patients with osteosarcoma
have elevated serum expression levels of lncRNA-ATB, and this overexpression is
correlated with local recurrence, distant metastasis, and advanced clinical stage
[208, 212]. Thus, lncRNA-ATB could be used as a prognostic and recurrence mon-
itoring factor for osteosarcoma patients.
Maternally expressed gene 3 (MEG3) lncRNA expression levels are decreased
in osteosarcoma tissues compared with adjacent normal tissues and are associated
with distant metastasis, advanced clinical stage, and poor overall survival [177, 220].
Its expression is regulated by lncRNA Ewing sarcoma associated transcript 1
(EWSAT1) and downregulation of MEG3 in the presence of EWSAT1 induces oste-
osarcoma cell proliferation, invasion, and metastasis [221]. Therefore, high levels of
MEG3 could be an indicator of favorable prognosis in osteosarcoma patients.
Taurine upregulated gene 1 (TUG1) lncRNA has been found to be
overexpressed in osteosarcoma human samples compared with normal matched
tissues (P < 0.01), and expression levels were associated with tumor size, postop-
erative chemotherapy responsiveness and Enneking surgical stage [152]. Moreover,
TUG1 high expression levels were significantly correlated with unfavorable prog-
nosis and were an independent prognostic factor for disease-free survival
(HR = 1.81; 95% CI = 1.01–3.54; P = 0.037) and long-term overall survival
(HR = 2.78; 95% CI = 1.29–6.00; P = 0.009). Interestingly, TUG1 elevated plasma
levels are associated with disease progression or relapse [152]. Thus, TUG1 might be
used as a prognostic and monitoring biomarker for osteosarcoma patients.
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Zinc finger E-box binding homeobox 1 antisense 1 (ZEB1-AS1) has been
found to display elevated expression levels in metastatic osteosarcoma and regulate
the metastatic process by increasing ZEB1 transcription [169, 170]. Overexpression
of ZEB1-AS1 is associated with advanced clinical stage, large tumor size, distant
metastatic dissemination, and unfavorable progression-free and overall survival
[169]. In clinical setting, ZEB1-AS1 could serve as a prognostic marker for osteo-
sarcoma patients.
All the abovementioned lncRNAs are summarized in Table 2.
7. LncRNAs as predictive biomarkers and drug resistance in
osteosarcoma
A number of research teams have demonstrated the involvement of lncRNAs in
chemoresistance and chemosensitivity of different types of cancer [222–227]. In
osteosarcoma, chemotherapy plays an important role, but its efficacy is limited by
acquired resistance to different chemotherapeutic drugs, mainly cisplatin and
doxorubicin [228]. Recent studies have revealed the role of several lncRNAs that are
related to osteosarcoma drug resistance such as FENDRR, ENST00000563280,
HOTTIP, LINC00161, LUCAT1, NR-036444, and ODRUL [106].
FENDRR is another lncRNA which is significantly downregulated in
doxorubicin-resistant osteosarcoma cell lines compared with the doxorubicin-
sensitive counterparts (MG63/DXR vs. MG63, KH-OS/DXR vs. KH-OS, and U2-OS/
DXR vs. U2-OS). In a microarray study FENDRR displayed a 22-fold decrease of its
expression in doxorubicin-resistant MG63/DXR cells relative to their parental cell
line MG63. It has been demonstrated that it acts as a suppressor of doxorubicin drug
resistance by inhibiting ABCB1 and ABCC1 expressions [229].
Another lncRNA related with doxorubicin resistance in osteosarcoma cell lines is
forkhead box protein C2 antisense 1 (FOXC2-AS1) also known as
ENST00000563280. FOXC2-AS1 has been found to have elevated expression levels
in osteosarcoma tissues and osteosarcoma cell lines resistant to doxorubicin, such as
MG-63 and KH-OS. FOXC2-AS1 overexpression is associated with unfavorable
clinical outcome and promotion of doxorubicin resistance in cell cultures. FOXC2-
AS1 knockdown reversed the doxorubicin resistant phenotype and increased the
doxorubicin sensitivity in osteosarcoma cells resistant to doxorubicin [230]. In
addition, FOXC2 is overexpressed in osteosarcoma doxorubicin-resistant human
tissues and cell lines, such as MG63/DXR and KH-OS/DXR, and its levels show
positive correlation with FOXC2-AS1 expression. Both FOXC2-AS1 and FOXC2 are
involved in doxorubicin resistance by inducing the expression of ABCB1 multidrug
resistance gene [230]. Therefore, FOXC2-AS1 might serve as a predictive factor for
doxorubicin sensitivity or resistance in osteosarcoma patients.
HOTTIP lncRNA is overexpressed in osteosarcoma specimens and is correlated
with advanced clinical stage and high metastatic potential [121]. In a recent study,
Li et al. found that overexpression of HOTTIP confers resistance to cisplatin in
osteosarcoma cells in vitro through activation of the Wnt/β-catenin pathway.
Moreover, treatment with Wnt/β-catenin inhibitor XAV939 or downregulation of
HOTTIP reverses the cisplatin resistance [231]. Thus, HOTTIP expression levels
might serve as a predictive biomarker regarding cisplatin resistance in
osteosarcoma.
Long intergenic non-protein coding RNA 161 (LINC00161) is a lncRNA
located on chromosome 21q21 locus and has been found to be overexpressed in
cisplatin-treated osteosarcoma cells facilitating the cisplatin-induced apoptosis.
Upregulation of LINC00161 in osteosarcoma cells promotes apoptosis by increasing
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IFIT2 expression levels through the impairment of miR-645 action. In this context,
LINC00161 acts as a sponge for miR-645, a microRNA that controls IFIT2 tran-
scription [232].
Lung cancer associated transcript 1 (LUCAT1) lncRNA has been found to be
overexpressed in osteosarcoma tissue samples and in MG63 and HOX osteosarcoma
cell lines resistant to methotrexate, a drug that is used widely in osteosarcoma
patients [233–235]. MG63 and HOX, resistant to methotrexate, also overexpress the
ATP-binding cassette subfamily B member 1 (ABCB1), a drug resistance-related
protein. LUCAT1 interacts with ABCB1 through miR-200c binding to the 3΄UTR of
ABCB1. Moreover, miR-200c expression is regulated in a LUCAT1-dependent
manner. In addition, LUCAT1 knockdown experiments resulted in decreased
expression levels of drug resistance-related genes MDR1, MRP5, and LRP1 in
methotrexate-treated osteosarcoma cell lines and led to reduced osteosarcoma
cell invasiveness [235]. Therefore, LUCAT1 expression levels might be used as a
predictive biomarker providing information regarding methotrexate resistance or
sensitivity.
NR-036444 is another lncRNA involved in an lncRNA-mRNA coexpression
network and has been found to interact with doxorubicin-resistance related genes
such as ABCB1, HIF1A, and FOXC2 in osteosarcoma cells and thus could serve as a
predictive biomarker for chemoresistance [236].
Osteosarcoma doxorubicin resistance-related up-regulated lncRNA
(ODRUL) has been initially found to be highly upregulated in the human osteosar-
coma doxorubicin-resistant cell line MG63/DXR. Moreover ODRUL expression is
elevated in human tissue osteosarcoma specimens from patients with poor response
to doxorubicin therapy and lung metastasis. It has also been found that
doxorubicin-sensitive osteosarcoma cell lines have reduced ODRUL expression
levels. Additionally, ODRUL knockdown experiments in osteosarcoma cell lines led
to inhibition of tumor proliferation and invasion and partly reversed the doxorubi-
cin resistant phenotype through suppression of the multidrug resistance ABCB1
(ATP-binding cassette, subfamily B, member 1) gene [217, 237].
All the abovementioned lncRNAs are summarized in Table 2.
Further studies are needed to elucidate the role of lncRNAs in osteosarcoma
drug resistance and exploit their potential as predictive biomarkers and candidates
to develop novel therapeutic approaches in order to reverse the osteosarcoma resis-
tance to chemotherapy.
8. LncRNAs as therapeutic targets in osteosarcoma
Treating osteosarcoma is a challenge in the practice of oncology. The main
therapeutic approach is surgical removal of the tumor following by the application
of chemotherapeutic agents such as doxorubicin, cisplatin, methotrexate in combi-
nation with leucovorin (folinic acid), and ifosfamide [13, 233]. This multimodal
osteosarcoma management increased the progression-free survival rates from 10 to
20% up to 60% in recent years. Despite the relatively good cure rates of patients
with localized tumor, unfortunately a percentage of 20–25% of newly diagnosed
osteosarcoma patients are presenting with metastatic disease at the time of initial
diagnosis. These patients have an unfavorable prognosis with overall survival rates
around 10–30% [12–18]. In addition many patients develop resistance to available
chemotherapeutic modalities and subsequently metastatic dissemination with
unfavorable clinical outcome [228]. In recent years there are great efforts to exploit
the molecular mechanisms of the metastatic process and drug resistance of osteo-
sarcoma in order to develop novel therapeutic agents targeting biomolecules
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involved in these processes. Such biomolecules, among others, are the lncRNAs
which play important roles in the pathogenesis and progression of osteosarcoma
[238–240].
Breast cancer antiestrogen resistance 4 (BCAR4) is another lncRNA that
promotes cell growth and proliferation as well as invasion and metastasis in breast
cancer cell lines cultures, via the noncanonical Hedgehog/GLI2 pathway [103, 104].
In osteosarcoma, BCAR4 exerts its oncogenic action by activating GLI2-dependent
gene transcription via direct promoter binding [104]. Upregulation of BCAR4 has
been observed in osteosarcoma pathological specimens and is correlated with
advanced clinical stage, lung metastasis, and poor overall survival [105]. Knock-
down BCAR4 experiments have shown that suppression of BCAR4 leads to inhibi-
tion of cell proliferation and migration in vitro and in vivo through downregulation
of GLI2 target genes, such as IL-6, TGF-beta, RPS3, and MUC5AC [104]. Thus
BCAR4 could be used as a target in osteosarcoma therapeutic management [205].
Cancer susceptibility candidate 2 (CASC2) was first discovered in patients
with endometrial carcinoma as a potential tumor suppressor [241]. It is also signif-
icantly downregulated in osteosarcoma human specimens and various osteosarcoma
cell lines such as MG-63, Saos-2, U2OS, and SOSP-9607, and its low expression
levels correlate with poor survival and advanced clinical stage [241]. Interestingly,
overexpression of CASC2 results in inhibition of osteosarcoma cell proliferation,
colony formation, and invasion in vitro. Ectopic expression of CASC2 suppresses
miR-181a expression and leads to upregulation of miR-181a target genes such as
RASSF6, PTEN, and ATM in osteosarcoma cell lines. RASSF6 has been observed to
positively correlate with CASC2 expression levels, and low RASSF6 levels have been
found in osteosarcoma. In addition, in vivo implantation studies using pcDNA-
CASC2 resulted in reduced tumor growth, while experiments using short interfer-
ing CASC2 exhibited enhanced tumor growth [242]. Consequently, CASC2 mimics
might be of clinical value in osteosarcoma treatment in order to reduce tumor
growth and slow down adverse clinical progression.
LncRNA growth arrest-specific 5 (GAS5) functions as an oncosuppressor
lncRNA by repressing osteosarcoma cell proliferation and migration through
sponging of miR-203a. In addition, silencing of lncRNA GAS5 significantly pro-
motes osteosarcoma cell growth, migration, and invasion through upregulation of
Cyclin D1, Cyclin B1, CDK1, and CDK4 expressions. Moreover, suppression of miR-
203a leads to the reversion of GAS5 silencing effects [243]. GAS5 also functions as a
ceRNA by binding to miR-221 resulting in the suppression of epithelial-
mesenchymal transition and arrest of cell growth in osteosarcoma cell lines through
regulation of the miR-221/ARHI axis [244]. Thus, GAS5 mimics could be used to
slow down or suppress the osteosarcoma metastatic process.
Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is an
oncogenic lncRNA that is overexpressed in various osteosarcoma cell lines such as
U2OS, Saos-2, and HOS and in human osteosarcoma tissue samples as well. Its
overexpression is highly related to the metastatic potential of the tumor [142, 143].
MALAT1 acts through the PI3K/Akt and the RhoA/ROCK signaling pathway to
promote osteosarcoma cell proliferation, migration, invasion, and pulmonary
metastasis [87]. Downregulation of MALAT1 leads to reduced expression levels of
RhoA and ROCK1 and 2 in osteosarcoma cell lines [87, 88]. Moreover, MALAT1
knockdown induces cell cycle arrest at the G0/G1 to S phase leading to reduced cell
proliferation and invasion and enhanced apoptosis in HOS and U2OS cell lines. In
addition, MALAT1 knockdown affects negatively the ability of osteosarcoma cells
to form new blood circulatory networks in three-dimensional cell cultures [88, 245].
In addition, MALAT1 knockdown inactivates the Rac1/JNK signal transduction
pathway through activation of miR-509 and downregulation of high mobility group
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protein B1 (HMGB1) [246, 247]. It is obvious that inactivation of MALAT1 results
in inhibition of osteosarcoma cell proliferation and invasion and induces the apo-
ptotic machinery. Therefore, MALAT1 might be used as specific therapeutic target
to inhibit osteosarcoma progression.
MF12 is another lncRNA that is overexpressed in osteosarcoma human tissue
samples and is associated with cell proliferation, migration, and invasion in osteo-
sarcoma cell lines MG63 and Saos-2. It promotes osteosarcoma cell growth and
enhances invasiveness through regulation of FOXP4 [166]. In this context, targeting
MF12 could reduce osteosarcoma growth and clinical progression.
Neuroblastoma-associated transcript 1 (NBAT1) has been found to be
downregulated in osteosarcoma human samples and various osteosarcoma cell lines
such as MG-63, KHOA, U2OS, LM7, and 143b [248]. Clinically, low expression
levels of NBAT1 are associated with osteosarcoma metastatic dissemination and
unfavorable prognosis. NBAT1 knockdown or silencing leads to enhanced osteosar-
coma tumor growth, cell proliferation, migration and invasion in vitro. Induction of
NBAT1, in order to be overexpressed in vitro, results in the opposite effects. It has
also been demonstrated that NBAT1 positively regulates the transcription of PTEN,
PDCD4 and RECK, which act as tumor suppressor, and cell death and metastasis
suppressor genes, respectively, through miR-21 inactivation. Overexpression of
miR-21 leads to the opposite effect [248]. Thus, NBAT1 mimics might be used to
reduce osteosarcoma growth and metastatic ability.
p21-associated ncRNA DNA damage activated (PANDA) is a lncRNA which
is overexpressed in osteosarcoma tissue specimens and osteosarcoma cell lines
[249]. Its expression is induced up to 40-fold by DNA damage related to doxorubi-
cin and etoposide treatment and is positively regulated by p53. PANDA is involved
in positive regulation of the osteosarcoma cell cycle through p18 associated tran-
scriptional repression. Moreover, PANDA silencing results in cell cycle arrest in G1/
S transition through upregulation of cyclin-dependent kinase inhibitor p18 in U2OS
osteosarcoma cell line. Depletion of PANDA leads to cell death of doxorubicin
treated cells through upregulation of apoptotic activators APAF1, BIK, FAS, and
LRDD [249, 250]. Taken together, these findings imply that inhibition of PANDA
might serve as a therapeutic intervention to induce cell cycle arrest and apoptosis in
osteosarcoma.
PVT1 is another lncRNA that is overexpressed in osteosarcoma cell lines and
tissue specimens, and its upregulation is correlated with decreased survival in
osteosarcoma patients. PVT1 overexpression is associated with osteosarcoma cell
proliferation, migration, and invasion, and silencing of its function via siRNA has
the opposite effects and promotes apoptosis and cell cycle arrest as well. Moreover,
silencing of PVT1 by siRNA leads to downregulation of BCL2, CCND1, and FASN
expressions through miR-195 in osteosarcoma cells [251]. PVT1 is also involved in
the Warburg effect in osteosarcoma cells by promoting anaerobic glycolysis and
tumor progression through regulation of the miR-497/HK2 axis [252]. Taken
together, PVT1 could serve as a target in the therapeutic management of
osteosarcoma.
TP73 antisense RNA 1 (TP73-AS1) is a novel oncogenic long noncoding RNA
which is significantly overexpressed in osteosarcoma tissue samples and cell lines.
Moreover, high expression of TP73-AS1 is correlated with advanced clinical stage,
large tumor size, high metastatic potential, and poor overall survival [253]. TP73-
AS1 overexpression promotes osteosarcoma cell proliferation, migration, and inva-
sion by acting as a sponge for miR-142 to positively regulate Rac1 function [254].
TP73-AS1 might constitute a potential therapeutic target in the treatment of osteo-
sarcoma.
All the above mentioned lncRNAs are summarized in Table 2.
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TP73-AS1 might constitute a potential therapeutic target in the treatment of osteo-
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All the above mentioned lncRNAs are summarized in Table 2.
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Different methods and approaches could be used to inhibit or mimic the func-
tion of lncRNAs for therapeutic purposes, such as small molecule inhibitors,
inhibiting micropeptides; RNA interference silencing by small interfering RNAs
(siRNAs); or short hairpin RNAs (shRNAs), antisense oligonucleotide targeting;
ribozyme, deoxyribozyme, plasmid, or viral vector-based targeting; and gene
editing by CRISPR/Cas9 system [255].
In addition, a variety of delivery vehicles or carriers have been developed in an
effort to target lncRNAs, such as peptide nucleic acid (PNA), lipid-based
nanocarriers, poly(lactic-co-glycolic acid nanoparticles (PLGA), poly(amine-co-
ester) tetrapolymers (PACE), and pHlow insertion peptides (pHLIP) [256].
Several preclinical and phaseI/II clinical trials have been initiated by using the
abovementioned approaches, such as the use of plasmid BC-819 expressing diph-
theria toxin under the control of H19 lncRNA promoter to induce tumor reduction
after intratumoral injection in order to treat bladder, ovarian, and pancreatic carci-
nomas [256]. Modified oligonucleotides which target antisense lncRNAs, also
referred as AntagoNATs, have been tested in vitro and in vivo to modulate lncRNA
expression. Administration of antisense oligonucleotides (ASOs) against MALAT1
effectively achieved inhibition of lung cancer tumor growth in mice xenografts
[257]. Although ASO therapeutic approaches are promising, major obstacles, such as
inadequate intracellular uptake or chemical toxicity, should be considered and
taken into account. It should also be noted that although lncRNAs are regulated by
cis or trans mechanisms targeting specific genes, putative effects on global gene
expression should be very carefully considered.
9. Conclusions and future perspectives
In this chapter, we reviewed the involvement of lncRNAs in the pathogenesis,
metastatic process, and drug resistance of osteosarcoma and summarized in
Tables 1 and 2. We also summarized the possible roles of lncRNAs as prognostic
and predictive biomarkers and their putative usefulness as therapeutic targets in
osteosarcoma clinical management. However, more studies are needed to further
elucidate and confirm the precise molecular mechanisms underlying these effects
along with translational research in osteosarcoma metastasis and drug resistance.
Translational studies are crucial in understanding if lncRNA modulation is applica-
ble in the clinical setting and beneficial for the patients. Considering the difficulty
to get osteosarcoma tissue samples at different stages of disease, it would be useful
to detect lncRNA expression levels in body fluids, such as plasma or urine, provid-
ing a real-time monitoring of osteosarcoma progression [45, 258].
Studies of structural biology are also needed in order to determine the secondary
and tertiary structures of lncRNAs and elucidate the molecular interactions with
other biomolecules. Structural studies could provide useful knowledge for designing
lncRNA mimics or pharmaceutical agents against them.
Future research should also focus on better understanding the cross-talk
between different signaling pathways related to osteosarcoma development and the
role of lncRNAs in these molecular interactions.
We anticipate that lncRNA-based diagnostic approaches and therapeutic inter-
ventions will be more efficient in treating this debilitating tumor and will offer
significant benefit for osteosarcoma patients.
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A Novel Strategy of Dual 
Inhibition of Distinct Metabolic 
Features in Osteosarcoma
Shingo Kishi, Kanya Honoki, Yasuhito Tanaka  
and Hiroki Kuniyasu
Abstract
Mitochondria are the places for the energy production of the cells, while reac-
tive oxygen species (ROS) are also produced alongside. In recent years, it has 
been reported that cancer stem cells metabolize predominantly through oxidative 
phosphorylation (OXPHOS) rather than glycolysis. Targeting OXPHOS achieved 
by suppression of ATP synthesis through mitochondrial ATP synthase could be a 
potential therapeutic option against cancer stem cells. Since c-Myc inhibition is 
considered to lead a metabolic flux to OXPHOS from glycolysis, the combinatory 
inhibition of both OXPHOS and glycolysis could be a strong candidate for the treat-
ment of malignant tumors. In this chapter, we will discuss about the mitochondria 
metabolism as the potential therapeutic target in osteosarcoma stem cells, and 
the synergistic effects of combination of OXPHOS inhibitor with c-Myc inhibitor, 
which target both OXPHOS-dominant cancer stem cells and glycolysis-dominant 
non-cancer stem cells, will be discussed.
Keywords: osteosarcoma, mitochondria, metabolism, OXPHOS, c-Myc
1. Introduction
Intratumor heterogeneity, which is the basis of tumor evolution, is the funda-
mental challenge in cancer medicine. Intratumor heterogeneity is considered to 
be involved in several important aspects in cancer biology such as disease relapse 
and metastatic behaviors as well as drug resistance. Over the past decades, a small 
subset of tumor cells, so-called cancer stem cells (CSCs), have been proposed to be 
a hierarchical organizer of the tumor heterogeneity [1] and play a critical role in 
tumor relapse, metastasis, drug resistance, and tumor propagation in many cancer 
types including osteosarcoma (OS) [2–6]. At the apex of the heterogeneity in the 
tumor, CSCs possess the capacity of self-renew and tumorigenicity which generate 
the bulk of tumor with more differentiated progenies [7]. Conventional anticancer 
therapies target the bulk of heterogeneous tumor mass resulting in tumor shrink-
age, but CSCs could trigger the relapse by differentiation into non-stem tumor cells. 
Thus, targeting CSCs could represent an integral component for developing more 
effective treatment strategies against cancer.
Now, we have evidences that cancer heterogeneity not only is generated by 
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phosphorylation (OXPHOS) rather than glycolysis. Targeting OXPHOS achieved 
by suppression of ATP synthesis through mitochondrial ATP synthase could be a 
potential therapeutic option against cancer stem cells. Since c-Myc inhibition is 
considered to lead a metabolic flux to OXPHOS from glycolysis, the combinatory 
inhibition of both OXPHOS and glycolysis could be a strong candidate for the treat-
ment of malignant tumors. In this chapter, we will discuss about the mitochondria 
metabolism as the potential therapeutic target in osteosarcoma stem cells, and 
the synergistic effects of combination of OXPHOS inhibitor with c-Myc inhibitor, 
which target both OXPHOS-dominant cancer stem cells and glycolysis-dominant 
non-cancer stem cells, will be discussed.
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1. Introduction
Intratumor heterogeneity, which is the basis of tumor evolution, is the funda-
mental challenge in cancer medicine. Intratumor heterogeneity is considered to 
be involved in several important aspects in cancer biology such as disease relapse 
and metastatic behaviors as well as drug resistance. Over the past decades, a small 
subset of tumor cells, so-called cancer stem cells (CSCs), have been proposed to be 
a hierarchical organizer of the tumor heterogeneity [1] and play a critical role in 
tumor relapse, metastasis, drug resistance, and tumor propagation in many cancer 
types including osteosarcoma (OS) [2–6]. At the apex of the heterogeneity in the 
tumor, CSCs possess the capacity of self-renew and tumorigenicity which generate 
the bulk of tumor with more differentiated progenies [7]. Conventional anticancer 
therapies target the bulk of heterogeneous tumor mass resulting in tumor shrink-
age, but CSCs could trigger the relapse by differentiation into non-stem tumor cells. 
Thus, targeting CSCs could represent an integral component for developing more 
effective treatment strategies against cancer.
Now, we have evidences that cancer heterogeneity not only is generated by 
genetically distinct subclones but is also driven by phenotypic and functional 
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heterogeneity within each subclone [8, 9]. One of the distinct phenotypes of CSCs is 
their cellular metabolism mechanisms for energy production. Tumor cells repro-
gram their metabolic machinery to meet their needs during tumor growth known as 
Warburg effect which shifts their ATP production from via oxidative phosphoryla-
tion (OXPHOS) to glycolysis even in the microenvironment with abundant oxygen 
concentration [10]. Over the past years, the metabolic phenotype of CSCs has 
been intensely investigated, and it was originally hypothesized that CSCs would 
reflect the normal tissue hierarchy where multipotent stem cells are fundamentally 
glycolytic, while differentiated somatic cells rely on OXPHOS [11]. Although 
the differentiated cells increase their dependency upon the glycolysis during the 
acquisition of the transformed phenotype, these changes might be cell specific, and 
some cells might adapt to neoplastic transformation by increasing their dependency 
on OXPHOS [12]. As a matter of fact, the metabolic phenotype of CSCs are con-
troversial suggesting that it could be a tumor-type- or cell line-dependent manner 
such as breast and nasopharyngeal CSCs relying on glycolysis [13, 14], while lung, 
glioblastoma and pancreatic ductal adenocarcinoma CSCs relying on OXSPHOS 
[15–17]. In osteosarcoma (OS), a CSC-like cell line, 3AB-OS, exhibited its metabolic 
dependency on glycolysis compared to the parental MG-63 cells [18]. However, this 
came from only one cell line chemically treated long time from MG-63 which bore 
the ras gene mutation unusually found in OS. Controversially, there is the evidence 
that the transformed mesenchymal stem cells (MSCs), which are supposed to be the 
sarcoma-initiating cells or sarcoma stem cells, showed the increased OXPHOS and 
had a capability to switch to glycolysis to adapt to their microenvironments [19]. 
The discrepancy in these metabolic profiles of CSCs would be due to multifactorial 
causes. The first possible explanation is the plasticity of these cells in response to the 
microenvironment and the stages of harvesting in terms of differentiation/dedif-
ferentiation [20]. Another possible cause would be the lack of precise definition of 
CSCs and their heterogeneity due to the various techniques for CSC isolation [21]. 
Furthermore, the metabolic status of CSCs can be affected by cross talk between 
CSCs and cancer-associated stroma in the microenvironment. For instance, OS cells 
directly increase their mitochondrial biogenesis using this energy-rich metabolite 
such as lactate that is abundantly provided by MSC as an effect of the altered 
microenvironmental conditions induced by OS cells, and the lactate produced by 
MSC promotes the migratory ability of OS cell [22].
Actually, there are several reports indicating that CSCs have augmented utiliza-
tion of extracellular catabolites such as pyruvate, lactate to support OXPHOS, [23] 
and mitochondrial metabolism could be a potential target for an effective elimina-
tion of CSCs [17]. Previous studies suggested that inhibition of the OXPHOS path-
way reduced sphere formation and tumor formation capacity, which demonstrated 
the vulnerability of CSCs to mitochondria-targeted therapies [24], and several 
agents such as salinomycin targeting CSCs through inhibition of mitochondrial bio-
genesis and OXPHOS are currently under investigation for cancer treatment [25].
Here, we will discuss about the mitochondrial metabolism as a potential thera-
peutic target in osteosarcoma, especially its stem-like cell populations.
2. Myc is a key regulator of cancer cell metabolism
Glucose is one of the major nutrients that mammalian cells utilize to synthe-
size new organelles as well as to generate high-energy molecules, such as ATP, 
NADH/NADPH, and FADH. c-Myc played an important role in regulation of 
glycolysis through its target glucose metabolism genes [26], and those genes 
directly regulated by c-Myc include glucose transporter GLUT1, hexokinase 2 
83
A Novel Strategy of Dual Inhibition of Distinct Metabolic Features in Osteosarcoma
DOI: http://dx.doi.org/10.5772/intechopen.82612
(HK2), phosphofructokinase (PFKM), and enolase 1 (ENO1) [27, 28].  Myc was 
also observed to upregulate lactate dehydrogenase A (LDHA) to generate NAD+, 
which is a cofactor required for the glycolysis particularly by GAPDH [29]. Through 
the upregulation of these genes, c-Myc contributes directly to the Warburg effect 
(aerobic glycolysis) and the ability of transformed cells to convert glucose to 
pyruvate even under adequate oxygen tension. Myc also regulates protein synthesis, 
ribosome biogenesis, nucleotide biosynthesis, as well as fatty acid and cholesterol 
metabolism. Cancer cells take advantage of these Myc’s broad reaches to reprogram 
and augment the most critical processes for survival, particularly metabolism.
In addition to the metabolic reprogramming, c-Myc also contributes to the cell 
cycle regulation in corporation with PI3K (phosphatidylinositol-3,4,5-triphos-
phate)/Akt/mTOR (mammalian target of rapamycin) and Wnt pathway. The role 
of PI3K-Akt-mTOR and Wnt pathways in regulation of the cell cycle progression 
in cancer cell has been proposed (Figure 1). The activation of insulin/insulin-like 
growth factor (IGF) receptor by nutrients/growth factors activates PI3K-Akt path-
way. The phosphorylated Akt activates mammalian target of rapamycin complex 1 
(mTORC1), and the activated mTORC1 upregulates the protein synthesis but inhib-
its autophagy. Inhibition of autophagy rescues Dvl (Dish homolog in mammalian), 
and this leads to activation of Wnt pathway. Wnt pathway is the key pathway in 
activation of cell cycle, and the activated Wnt pathway upregulates the CyclinD; the 
c-Myc; the matrix metalloproteinases, COX-2, peroxisome proliferator-activated 
receptors (PPARs); and the growth factors and their receptors and downregulates 
E-cadherin, the cell cycle inhibitor p16INK4a (ARF), and p53 [30]. Wnt pathway 
thus regulates the cancer cell entry into the cell cycle through the production of 
Figure 1. 
c-Myc contributes to the cell cycle regulation in corporation with PI3K/Akt/mTOR and Wnt pathway. The 
activation of insulin/IGF receptor by nutrients/growth factors activates PI3K-Akt pathway. The phosphorylated 
Akt activates mTORC1, which eventually leads to activation of Wnt pathway. Wnt pathway is the key 
pathway in activation of cell cycle, and the activated Wnt pathway upregulates the CyclinD, the c-Myc which 
would be involved in tumor initiation as well as tumor progression.
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c-Myc contributes to the cell cycle regulation in corporation with PI3K/Akt/mTOR and Wnt pathway. The 
activation of insulin/IGF receptor by nutrients/growth factors activates PI3K-Akt pathway. The phosphorylated 
Akt activates mTORC1, which eventually leads to activation of Wnt pathway. Wnt pathway is the key 
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CyclinD. CyclinD complexes with cyclin-dependent kinase 4/6 (Cdk4/6), inacti-
vates the tumor suppressor protein retinoblastoma (Rb), and promotes the entry 
of the cell from G0 to G1 phase of cell cycle as well as metabolic reprogramming 
through the c-Myc activation as described above. In this context, c-Myc is acknowl-
edged to play an important role to activate genes involved in predominantly cell 
cycle regulation, cellular metabolism, and protein synthesis, especially specific to 
G0-G-S transition as well as glycolysis and Krebs cycle, chromatin structure, and its 
transcriptional networks in cancer cells and embryonic stem cells as well [31, 32]. 
Given its crucial role in cancer progression and maintenance, c-Myc has been the 
ideal target for cancer therapy, and c-Myc targeting strategy in cancer therapy has 
been investigated in various means such as direct inhibition by antisense oligonucle-
otide [33] and siRNA [34], indirect inhibition by blocking transcription with BET 
bromodomain inhibitors such as JQ-1 [35], and blocking mRNA translation with 
mTOR inhibitor [36]. After a long time struggling on targeting c-Myc in cancer 
therapy, we are now witnessing a renewed interest in making Myc inhibition for 
the future cancer therapy. In the aspect of c-Myc contribution to the metabolism, 
c-Myc promotes a Warburg-like glycolytic phenotype through dual mechanism 
of upregulation of key glycolytic enzymes as described above, and suppression of 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) 
by direct inhibition through binding to its promoter [17]. PGC-1α is crucial for the 
anti-oxidative capacity and mitochondrial metabolism in cancer [37, 38] and con-
tributes to the maintenance of CSC’s phenotype of self-renewal through controlling 
intracellular ROS levels. Myc/PGC-1α balance controls the metabolic phenotype 
of cancer cells as c-Myc dominance shifts to Warburg phenotype of differentiated 
cancer cells and PGC-1α dominance shifts to OXPHOS-dependent phenotype of 
CSCs [17]. Therefore, combining OXPHOS inhibition with c-Myc inhibition could 
provide a new multimodal approach for targeting the distinct metabolic features in 
cancer therapy.
3. Cancer stem cell metabolism: a potential therapeutic target
CSCs also known as tumor-initiating cells (TICs) are a rare population of tumor 
cells with stem cell properties, which are thought to generate the tumor bulk and 
considered to drive the malignant growth, treatment resistance, minimal residual 
disease, and metastases. Along with the role of cancer drivers, CSCs also exhibit 
stem cell properties such as self-renewal and multilineage differentiation capacity 
[39]. CSCs are considered to be resistant to chemotherapy or radiations, both of 
which successfully destroy differentiated non stem-like cancer cells. As a matter of 
fact, even though current conventional anticancer therapies could achieve a tran-
sient control over the disease, a large number of patients experience tumor relapse 
or metastatic dissemination after an initial treatment with apparent disease-free 
period. Since CSCs, resisting to conventional therapies, attributes these biological 
behaviors, eradication of CSCs could be a promising target to totally exterminate 
the disease of cancer [40].
Although much is known regarding metabolic pathways important for cancer 
cell survival, the potential for therapeutic metabolic alteration of CSCs has not been 
fully uncovered [41], but recent studies indicate that metabolism and stemness are 
highly intertwined processes in tumor tissues, and CSCs possibly have different 
metabolic properties compared to non-CSCs.
Glucose homeostasis is reciprocally controlled by the catabolic glycolysis/
OXPHOS and by the anabolic gluconeogenesis pathway. In the catabolic reaction, 
when oxygen is absent, glycolysis predominantly controls the metabolism of ATP 
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production, while in the presence of oxygen, OXPHOS predominantly regulates 
the maximal ATP production in the mitochondria. Cancer cells preferentially 
metabolize glucose rather than OXPHOS even in the presence of oxygen defined 
as Warburg effect/aerobic glycolysis by the activation of some key genes such as 
c-Myc. In contrast to the somatic cells which primarily utilize OXPHOS, pluripotent 
stem cells including embryonal stem cells and induced pluripotent stem cells rely 
on glycolysis [42]. Therefore, it has to be pointed out that the biological functions 
of CSCs are different from those of differentiated cancer cells, making their pheno-
type more similar to normal stem cell, and metabolism is not the exception. Since 
aerobic glycolysis/Warburg effect has been widely accepted and recognized as a 
peculiar hallmark of cancer cells, it may be reasonable to expect that, conversely, 
CSC metabolism is mostly oriented toward mitochondrial OXPHOS. Actually, it is 
broadly accepted that ATP production in CSCs depends on glycolysis or OXPHOS in 
a tumor-type-dependent manner. The heterogeneity and plasticity of CSCs prob-
ably determine their primary source of energy to survive. The recent investigation 
has suggested that CSCs may display a broader repertoire of biochemical behavior 
in response to different environmental conditions, and accumulating evidence has 
indicated that CSCs utilize OXPHOS not only relying on the glycolysis [41, 43]. CSC 
metabolism show a highly plastic profile which allows to fulfill the energy require-
ments, according to the most suitable environmental condition. This metabolic 
flexibility of CSCs has been shown in diverse tumor types demonstrating that CSCs 
efficiently gain energy production from glycolysis when OXPHOS is blocked [44]. 
Recently, De Francesco et al. proposed the “two metabolic hit strategies” for eradi-
cation of CSCs (Figure 2) [45]. They demonstrated that the prolonged treatment 
with a mitochondria-interfering agent like doxycycline drastically impairs oxygen 
consumption rate (OCR) and mitochondrial respiration in MCF7 breast cancer 
cells. Such impairment in mitochondrial activity represents a first metabolic hit that 
constrains cellular metabolism of the surviving cancer cell subpopulation toward a 
Figure 2. 
The treatment with a mitochondria-interfering agent impairs oxygen consumption rate (OCR) and 
mitochondrial respiration in cancer cells as a metabolic first hit that constrains cellular metabolism of the 
surviving cancer cell subpopulation toward a predominantly glycolytic phenotype, resulting in metabolic 
inflexibility, as evidenced by the increased extracellular acidification rate (ECAR). The use of a glycolysis 
inhibitor may therefore act as the second metabolic hit that efficiently targets CSCs by halting their biochemical 
machinery (X axis, time (min); Y axis, pmoles/min/mg protein; red line, mitochondria inhibitor treatment; 
blue line, control).
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predominantly glycolytic phenotype, resulting in metabolic inflexibility, as evi-
denced by the increased extracellular acidification rate (ECAR). In this sequence, 
the glycolysis inhibitor potentially acts a second metabolic hit which effectively 
targets CSCs. Thus, specific metabolic-oriented pharmacological intervention 
could reverse CSC metabolic plasticity toward an inflexible biochemical phenotype, 
representing a new synthetic-lethal metabolic strategy for eradicating CSCs.
4. Targeting mitochondrial physiology in cancer stem cells
Mitochondria are key organelles involved in several processes related to cell 
proliferation and survival, and their most important function is the generation of 
ATP which holds cell metabolism. As the main energy producers, mitochondria 
produce ATP using tricarboxylic acid (TCA) cycle and OXPHOS. They also generate 
reactive oxygen species (ROS) during this process, which are sometimes harmful to 
the cells when produced excessively.
Because mitochondria play a key role in the alteration of oxidative stress and 
energy status, their functional characteristics have been considered to verify stemness 
like stem cell stability and pluripotency [46, 47]. Mitochondrial metabolic activity 
and antioxidant enzyme expression have shown to be closely related to the cell differ-
entiation [48, 49]. Thus, we could assume that stem cell mitochondria play important 
roles in maintaining stemness and differentiation. However, whether the roles of CSC 
mitochondria are similar to stem cell mitochondria or so-called differentiated cancer 
cells in general is not clear. Based on the previous reports, the CSCs might be more 
differentiated than normal stem cells, and the mitochondrial properties of CSCs are 
possibly different from those of stem cells or general cancer cells [39, 50].
Mitochondria have a multi-level network of antioxidant and OXPHOS systems 
(Figure 3). Mitochondrial redox balances are regulated by the mitochondrial 
inner membrane electrochemical gradient. As shown in Figure 3, nicotinamide 
adenine dinucleotide (NADH) from TCA cycle is oxidized by Complex I in the 
electron transport chain (ETC) of OXPHOS. Electrons from Complex I and II are 
Figure 3. 
Mitochondrial redox balances are regulated by the mitochondrial inner membrane electrochemical gradient. 
NADH from TCA cycle is oxidized by Complex I in the ETC. Electrons from Complex I and II are transferred 
to coenzyme Q10 and then passed on to Complex III, cytochrome c, Complex IV, and finally O2 to generate 
H2O. Complex V (F0F1-ATP synthase) generates ATP from ADP for the cellular energy source.
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transferred to coenzyme Q10 and then passed on to Complex III, cytochrome c, 
Complex IV, and finally O2 to generate H2O. Complex V (ATP synthase; F0-F1) 
generates ATP from ADP as well as inorganic phosphate Pi.
A powerful strategy focused on mitochondrial biogenetics as a target to eradi-
cate CSCs involves inhibition of the ETC complex, with consequent ROS overpro-
duction. Dong et al. demonstrated that the suppression of mitochondrial Complex 
I activity inhibited oxygen consumption and induced glycolysis in breast CSCs as a 
result of loss of fructose-1,6-biphosphatase implying that overproduction of ROS 
and reduction in glucose metabolism might be effective against breast CSCs [11]. 
Hirsch et al. also showed that metformin, the first-line antidiabetic drug, selectively 
killed the CSCs in breast cancer cell line through the inhibition of Complex I [51]. 
Furthermore, atovaquone, an FDA-approved antimalarial drug, inhibits the propa-
gation of breast cancer cell line MCF7-derived CSCs through the selective OXPHOS 
inhibition by targeting the CoQ10 dependence of mitochondrial Complex III [52]. 
This has been explored in the context of therapy as indicated by Alvero et al. using 
the novel isoflavone derivative NV-128 which significantly decreased mitochondrial 
function, as shown by a decrease in ATP, Complex I and Complex IV levels, and 
induced cell death in ovarian CSCs [53]. Finally, mitochondria-targeted vitamin 
E succinate (MitoVES) has been well characterized as an agent, which potentiates 
the ability to induce apoptosis in breast CSCs [54]. Reduction of mitochondrial 
membrane potential, overproduction of mitochondrial ROS, and inhibition of 
mitochondrial biogenesis have been demonstrated to affect CSC proliferation 
and survival [55]. These inputs indicate that the maintenance of CSC prolifera-
tion may not only be dependent on glycolysis, but is also based on mitochondrial 
activity. Therefore, the specific mitochondrial-targeted compounds which induce 
cell death in chemoresistant CSCs are promising novel therapeutic venue to treat 
cancer patients with relapsed or metastatic diseases. The most important point is 
that mitochondria from CSCs are not indistinguishable to those from differentiated 
non stem-like tumor cells in divergent aspects. Since CSCs are considered to be 
heterogeneous and adaptive metabolic profiles, the future therapy targeting cellular 
metabolism should be designed in a form of simultaneous or selective blockade of 
both glycolysis and mitochondrial respiration to completely eradicate CSCs [20]. 
Consequently, dual inhibition of glycolytic and mitochondrial energy pathways 
has proven to be effective against tumor growth in a number of preclinical cancer 
models. For instance, dual inhibition of glycolysis by 2-deoxyglucose (2-DG) and 
OXPHOS by metformin is effective in vivo against breast cancer cell xenograft 
model [56]. However, hexokinase inhibitors such as 2-DG and 3-bromopyruvate 
have been unfortunately discontinued in clinical trials. There has been an elegant 
study demonstrating sarcoma cells to be more sensitive than normal cells to dual 
inhibition of glycolysis with 2-deoxyglucose and OXPHOS with oligomycin or met-
formin [57]. Recently, Kang et al. have demonstrated that ALDH inhibitor gossypol 
combined with mitochondrial Complex I inhibitor phenformin resulted in up to 
80% ATP depletion in non-small cell lung cancer, which induced significant tumor 
regression in the cancer xenograft model [58]. These warrant that a key molecule 
regulating cancer energy metabolism can be a therapeutic target.
Meanwhile, other mitochondria-related processes like activation of developmen-
tal signaling pathways including Hedgehog, Notch, and Wnt are also the druggable 
targets; the drug targeting Notch and Hedgehog pathway has been developed [59], 
and numerous molecules acting on mitochondria has been used or being tested in 
clinical trials [60]. Adding these attempts targeting mitochondria, we will empha-
size that the dual inhibition of metabolic pathways could be an approach with 
greater potential to eradicate heterogeneous CSCs rather than singularly targeting 
glycolysis or OXPHOS pathway.
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predominantly glycolytic phenotype, resulting in metabolic inflexibility, as evi-
denced by the increased extracellular acidification rate (ECAR). In this sequence, 
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(Figure 3). Mitochondrial redox balances are regulated by the mitochondrial 
inner membrane electrochemical gradient. As shown in Figure 3, nicotinamide 
adenine dinucleotide (NADH) from TCA cycle is oxidized by Complex I in the 
electron transport chain (ETC) of OXPHOS. Electrons from Complex I and II are 
Figure 3. 
Mitochondrial redox balances are regulated by the mitochondrial inner membrane electrochemical gradient. 
NADH from TCA cycle is oxidized by Complex I in the ETC. Electrons from Complex I and II are transferred 
to coenzyme Q10 and then passed on to Complex III, cytochrome c, Complex IV, and finally O2 to generate 
H2O. Complex V (F0F1-ATP synthase) generates ATP from ADP for the cellular energy source.
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transferred to coenzyme Q10 and then passed on to Complex III, cytochrome c, 
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5. Novel approach to target cellular metabolism in osteosarcoma
Osteosarcoma and mitochondria have been investigated since 1970; however, 
those are mostly limited to the morphological characteristics by microscopic or 
electron microscopic observation [61, 62].
Giang et al. demonstrated that highly invasive and metastatic cell lines were 
more relied on Warburg effect-like glycolysis than their parental cell lines which 
showed similar mitochondrial oxygen consumption rate to fetal osteoblasts, sug-
gesting that highly metastatic and invasive cell lines were in the state of suppression 
of mitochondrial function and upregulation of glycolysis. They suggested that the 
mechanism of mitochondrial dysfunction was the results of mitochondrial perme-
ability transition such as mitochondrial swelling, depolarization, and membrane 
permeabilization, and they also demonstrated that this mitochondrial dysfunc-
tion and the Warburg effect are reversed by the treatment with mitochondrial 
permeability transition inhibitor sanglifehrin A [63]. These results indicated that 
osteosarcoma cells might possess the metabolic plasticity in response to their 
microenvironment especially hypoxia-reoxygenation caused by an irregular blood 
supply within tumors, an immature and leaky vasculature, and an abnormal and 
constantly changing vessel network architecture.
Another biochemical mechanism which contributes to the glycolytic rate of 
tumor cells is the inhibition of mitochondrial ATP synthase (F1F0-ATPase) by the 
natural inhibitor protein IF1 [64]. Barbato et al. reported that IF1 modulates the 
mitochondrial membrane potential and oxidative phosphorylation rate in osteosar-
coma cells suggesting that interaction between IF1 and FoF1-ATPase might regulate 
the OXPHOS and glycolysis [65]. However, the detailed mechanisms regulating the 
cellular bioenergetics by IF1 have been still controversial in cancer cells under the 
complex microenvironment.
Recently, novel strategy targeting CSCs through phytochemicals and their 
analogs has been proposed, and mitochondria are one of their potential targets 
[66]. Among the various compounds, pterostilbene (PTE), which is a methyl-
ated resveratrol derived from plants, has been shown to inhibit CSC properties 
in breast cancer [67, 68], glioma [69], hepatocellular carcinoma [70], and lung 
cancer [71] through the inhibition of multiple pathways which are possibly 
related to the CSC propagation such as Wnt, Hedgehog, Notch, and PI3K/Akt. 
Honokiol (HNK), which is the extract from Magnolia obovata, has shown its 
various antitumor effects through the inhibition of several pathways such as 
PI3K/Akt/mTOR, Wnt, and c-Myc [72–74]. Besides these effects of PTE and 
HNK, we have identified that PTE in combination with HNK could be the pos-
sible metabolism-targeted therapy against osteosarcoma as a “two hit” or “dual 
inhibition” of metabolic pathways, OXPHOS and glycolysis. PTE treatment on 
human osteosarcoma cell lines SaOS2, U2OS, and MG63 reduced viabilities of 
all cell lines in dose-dependent manner, and expression of stem cell marker such 
as Oct3, NS, and CD44 and the ability of sphere formation were also decreased 
in terms of sphere number and size (Figure 4a). PTE reduced the activity of 
F0F1-ATP synthase, Complex V predominantly (Figure 4b), and the mito-
chondrial oxygen consumption rates and synthetic amount of ATP were also 
decreased in spheroid condition (Figure 4c). These results suggest that PTE 
possibly targets stem cell population which preferably relies on OXPHOS, sup-
pressing ATP synthesis via F0F1-ATP synthase inhibition as well as increased 
ROS production in osteosarcoma cells, and changes metabolic flax to glycolysis-
dependent feature.
As aforementioned before, c-Myc promotes a Warburg-like glycolytic 
phenotype through the upregulation of key glycolytic enzymes along with the 
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suppression of PGC-1α. There are several reports regarding the anticancer 
activity of HNK which is possibly associated with c-Myc as well as JQ1, a BET 
bromodomain inhibitor [74]. Thus, we conducted dual inhibition of OXPHOS by 
PTE and c-Myc inhibition by HNK or JQ1. The results showed that both of these 
agents synergistically inhibited osteosarcoma cell growth in a dose-dependent 
manner (Figure 5). Now, we are conducting an investigation of dual metabolic 
inhibition via in vivo experiments using our own established rat osteosarcoma 
model.
Figure 4. 
(a) Pterostilbene (PTE) treatment on human osteosarcoma cells reduced the ability of sphere formation in 
terms of sphere number and size. (b) PTE reduced the activity of F0F1-ATP synthase, Complex V. (c) The 
mitochondrial OCR rates and synthetic amount of ATP were also decreased in spheroid condition (Kishi et al. 
unpublished data).
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The above results suggested that c-Myc inhibitor could lead to metabolic flux to 
OXPHOS and PTE could lead to metabolic flux to glycolysis. Thus, these exerted a 
great synergistic effect with “two metabolic hits” or “dual metabolic inhibition” of 
distinct metabolic features, OXPHOS and glycolysis, and it could be a novel thera-
peutic strategy against osteosarcoma, possibly targeting both stemlike cell popula-
tion and general tumor cell population.
Figure 5. 
Dual inhibition of OXPHOS by PTE and c-Myc inhibition by Honokiol (HNK) or JQ1 showed the synergistic 
effect on inhibition of osteosarcoma cell growth in a dose-dependent manner (Kishi et al. unpublished data).
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6. Conclusions
Prognosis of the patients with osteosarcoma has been improved; actually, we 
could say “dramatically,” over the last quarter-century. However, it is also true that it 
has reached to plateau without any breakthroughs, and nearly 30% of patients still 
have to face very severe poor prognosis, especially with metastatic disease. We need 
to develop a novel treatment to combat such a poor prognostic situation. Targeting 
the distinct metabolic features of OXPHOS and glycolysis with the concept of “two 
metabolic hits”/“dual metabolic inhibition” strategy could bring a new insight into 
the field of osteosarcoma treatment, and some natural compounds such as pteros-
tilbene and honokiol could be the possible candidates to achieve this aim.
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Treatment of Children with 
Osteosarcoma
Maxim Yu. Rykov and Elmira R. Sengapova
Abstract
Osteosarcoma accounts for 3% of all malignant tumors, 35–50% of all  
malignant bone tumors in pediatric patients. The chapter contains statistical data 
describing the incidence of the child population of osteosarcomas, classification 
of osteosarcomas, staging principles, a description of the main localizations, as 
well as a detailed description of the existing treatment protocols for children 
with osteosarcomas, including personalized therapy. The literature data are 
described in detail—the results of treatment of children with osteosarcoma 
with various courses of chemotherapy, as well as new approaches in treatment, 
including personalized therapy. But the results of treatment of children with 
primary metastatic osteosarcoma, relapse, and refractory course of the disease 
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1. Introduction
Osteosarcoma is a primary malignant bone tumor that develops from primitive 
mesenchymal stem cells capable of differentiating into bone, cartilage, or fibrous 
tissue [1].
Osteosarcoma accounts for 3% of all malignant tumors, 35–50% of all malignant 
bone tumors in pediatric patients. The frequency of occurrence is 4 cases per 1 mil-
lion children and adolescents per year. About 60% of cases of osteosarcoma detec-
tion are recorded at the age of 10–20 years (mainly in the prepubertal and pubertal 
periods). The gender ratio (boys/girls) is 1.3–1.6:1 [2].In 50% of cases, the tumor is 
located in the projection of the knee joint (distal femur, proximal tibial bone). The 
third place in terms of frequency of occurrence is the lesion of the proximal meta-
diaphysis of the humerus. The defeat of the axial skeleton (pelvis, spinal column) is 
detected in 12% of cases [3–5].
In the treatment of children with osteosarcoma, chemotherapy is the main 
method. Nonadjuvant and adjuvant chemotherapy courses are important. In the 
middle of the twentieth century, when the main treatment was surgical, the fre-
quency of relapse and metastasis was extremely high. Increased patient survival 
is due precisely to the intensification of chemotherapeutic treatment, which has 
reduced the frequency of relapses and metastasis.
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2. Classification and staging
2.1  WHO classification of soft tissue and bone tumors of 2013  
(fourth revision)
A localized (locally advanced) variant of osteosarcoma, which occurs in 80% 
of cases and a disseminated (primary metastatic) variant, which occurs in 20% of 
cases, are distinguished [3, 6].
2.2 Histological classification
• low grade, central osteosarcoma
• classic (conventional) version of osteosarcoma:
 ○ chondroblastic osteosarcoma
 ○ fibroblastic osteosarcoma
 ○ osteoblastic osteosarcoma
 ○ osteosarcoma, unspecified accuracy
• telangiectatic osteosarcoma
• small cell osteosarcoma
• high degree of malignancy, superficial osteosarcoma.
2.3 TNM classification 2018:
2.3.1 TNM classification 2018 for the extremities
T—primary tumor
Tx—the primary tumor cannot be determined [7].
T0—no signs of primary tumor.
T1—the largest tumor size ≤8 cm.
T2—the largest tumor size>8 cm.
T3—several unrelated tumors in the primary zone of bone damage.
N—regional lymph nodes:
Nx—the presence of metastatic lesions in the regional lymph nodes cannot be 
determined.
N0—no regional metastases in the lymph nodes.
N1—regional lymph node metastases.
M—distant metastases:
Mx—the presence of distant metastases could not be determined or the study 
was not conducted.
M0—distant metastases are absent.




Gx—the degree of differentiation could not be determined or the study was not 
conducted.
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G1–2—low degree of malignancy.
G3–4—a high degree of malignancy.
2.3.2 TNM classification 2018 for the spine
2.3.3 TNM classification 2018 for the pelvis
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor confined to one vertebral segment or two adjacent vertebral segments
T2 Tumor confined to three adjacent vertebral segments
T3 Tumor confined to four or more adjacent vertebral segments, or any nonadjacent vertebral segments
T4 Extension into the spinal canal or great vessels
T4a Extension into the spinal canal
T4b Evidence of gross vascular invasion or tumor thrombus in the great vessels
NX Regional lymph nodes cannot be assessed.
Because of the rarity of lymph node involvement in bone sarcomas, the designation NX may not be 
appropriate, and cases should be considered N0 unless clinical node involvement clearly is evident
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
cM0 No distant metastasis
cM1 Distant metastasis
cM1a Lung
cM1b Bone or other distant sites
pM1 Distant metastasis, microscopically confirmed
cM1a Lung, microscopically confirmed
cM1b Bone or other distant sites. Microscopically confirmed
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor confined to one pelvic segment with no extraosseous extension
T1a Tumor ≤8 cm in greatest dimension
T1b Tumor >8 cm in greatest dimension
T2 Tumor confined to one pelvic segment with extraosseous extension or two segments without 
extraosseous extension
T2a Tumor ≤8 cm in greatest dimension
T2b Tumor >8 cm in greatest dimension
T3 Tumor spanning two pelvic segments with extraosseous extension
T3a Tumor ≤8 cm in greatest dimension
T3b Tumor >8 cm in greatest dimension
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Staging according to the TNM classification is presented in Table 1.
3. Treatment
The methods of treatment of osteosarcoma over the past 30 years have not 
changed. There are five main drugs (cisplatin, adriamycin, methotrexate, ifos-
famide, and etoposide) that have been used in various combinations and doses 
[8–13].
The rates of treatment outcome in the world remain at about the same level. In 
patients with a localized variant of osteosarcoma, 5-year overall survival (OS) does 
not exceed 75% and 5-year event-free survival (EFS)—62% (Table 2).
In patients with primary metastatic osteosarcoma, the results are much 
worse, despite attempts to use high doses of drugs, including high-dose poly-
chemotherapy with transplantation of autologous hematopoietic stem cells. At 
the same time, the 5-year OS does not exceed 35% on average and the 5-year 
EFS–25% (Table 2).
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T4 Tumor spanning three pelvic segments or crossing the sacroiliac joint
T4a Tumor involves sacroiliac joint and extends medial to the sacral neuroforamen
T4b Tumor encasement of external iliac vessels or presence of gross tumor thrombus in major pelvic 
vessels
NX Regional lymph nodes cannot be assessed.
Because of the rarity of lymph node involvement in bone sarcomas, the designation NX may not be 
appropriate, and cases should be considered N0 unless clinical node involvement clearly is evident
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
cM0 No distant metastasis
cM1 Distant metastasis
cM1a Lung
cM1b Bone or other distant sites
pM1 Distant metastasis, microscopically confirmed
cM1a Lung, microscopically confirmed
cM1b Bone or other distant sites. Microscopically confirmed
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3.1 Traditional treatment
The most significant interest in the treatment of children with a localized version 
of osteosarcoma are the studies of the Italian and Scandinavian groups (Italian and 
Scandinavian sarcoma group–ISG/SSGI, SSG XIV), the French Pediatric Oncological 
Group (Societe Francaise d’Oncologie Pediatrique–SFOP OS94), and EURAMOS1.
Ferrari et al. showed the data of the joint study of the Italian and Scandinavian 
groups (ISG/SSG I), which was conducted from 1997 to 2000. The study included 
182 patients.
A special feature of neoadjuvant chemotherapy was the use of two courses 
of monotherapy with high-dose ifosfamide (in a course dose of 15 g/m2) and 
two courses of MAR (methotrexate (M) 12 g/m2, adriamycin (A) 75 mg/m2, and 
cisplatin (P) 120 mg/m2) in alternating mode. Adjuvant chemotherapy started at 
week 14. In this case, the course dose of adriamycin was increased to 90 mg/m2, the 
dose of cisplatin to 150 mg/m2, and a high-dose ifosfamide was administered in PIM 
chemotherapy courses (cisplatin, ifosfamide, and methotrexate) and PAI (cisplatin, 
adriamycin, and ifosfamide).
After removal of the primary tumor focus, a good histological response (thera-
peutic pathomorphism of grade 3–4) was achieved in 63% of patients, a poor histo-
logical response (treatment pathomorphism of grade 1–2) in 37%. At the same time, 
the 5-year OV and EFS accounted for 77 and 64%. Consequently, the use of high-
dose ifosfamide in an alternating mode with the MAP scheme led to an increase in 
the frequency of achieving a good histological response, but did not affect the rates 
of OS and EFS [15, 16, 31].
Smeland et al. presented the data of the study of the Scandinavian Group (SSG 
XIV), which was conducted from 2001 to 2005. The study included 63 patients.





IOR/OS2 the Istituto Ortopedico Rizzoli [14] 75 63
ISG/OS1 (Italian Sarcoma Group) [15] 74 64
ISG/SSG1 (Italian and Scandinavian Sarcoma Group) [16] 77 64
COSS 88/96 (Cooperative Osteosarcoma Study Group) [17] 79
SSG XIV (Scandinavian Sarcoma Group) [18] 65
NECO93J/95J (Neoadjuvant Chemotherapy for Osteosarcoma) [19] 78 65
BOTG III/IV (Brazilian Osteosarcoma Treatment Group) [20] 61 45
POG8651 (Pediatric Oncology Group) [21] 78 65
SFOP94 (Société Française d’Oncologie Pédiatrique) [22] 76 62
St.Jude CRH OS91 (Children Research Hospital) [23] 74 65
St.Jude CRH OS99 (Children Research Hospital) [24] 79 67
INT0133-COG (+MTP/-MTP) Children’s Oncology Group [25] 78/70 67/61
MSKC NY (+PAM) Memorial Sloan-Kettering Cancer Center, NY [26] 94 72
COG INT0133, CCG7943, AOST0121 [27] 47 22
ISG/SSG II (Italian and Scandinavian Sarcoma Group) [28] 55 46
EURAMOS1 [29, 30] 75 59
Table 2. 
The results of the treatment of pediatric patients with localized osteosarcoma.
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Neoadjuvant chemotherapy consisted of two courses of IDA. High-dose ifos-
famide (in the course dose of 10 g/m2) was used in monotherapy in patients with a 
poor histological response to treatment, only after five courses of MAP.
After removal of the primary tumor lesion, a good histological response was 
achieved in 45% of patients and a poor histological response in 55%. At the same 
time, the 5-year OV and BSV accounted for 76–65% and the 5-year EFS in the 
group with a good histological response for 89%, with a poor histological response 
48%. Consequently, the use of ifosfamide after MAP courses in the adjuvant mode 
did not lead to an increase in OS and EFS, and the frequency of achieving a good 
histological response was lower than in studies in which the MAP scheme was used 
in alternating mode with ifosfamide [18].
Le Deley et al. presented the results of the randomized SFOP OS94 study, which 
was conducted from 1994 to 2001. The study included 239 patients (120 in group A 
and 119 in group B).
Neoadjuvant therapy included seven courses of high-dose methotrexate and two 
courses of monotherapy with adriamycin (in a course dose of 70 mg/m2) in group 
A or seven courses of high-dose methotrexate and two courses of IE (ifosfamide (I) 
12 g/m2 and etoposide (E) 300 mg/m2) in group B. In the adjuvant mode, chemo-
therapy was replaced with IE courses in group A, and AP in group B for patients 
with a poor histological response detected after removal of the primary focus. The 
operative stage of treatment was carried out at 12 and 14 weeks in groups A and B, 
respectively.
A good histological response was achieved in group A in 43% of patients, in 
group B in 64%, poor histological response in group A in 57%, and in group B in 
36% (p = 0.009). The 5-year OS in group A was 75%, in group B—76%, the 5-year 
EFS in group A—58%, and in group B—66%. A 3-year EFS in group A in patients 
showed a good histological response for 82%, with a poor histological response for 
49%, in group B—77 and 60%, respectively.
Consequently, the use of methotrexate, ifosfamide and etoposide in neoadjuvant 
chemotherapy led to a statistically significant increase in the frequency of achieving 
a good histological response, but not to an increase in OS and EFS [22].
Of particular interest in the treatment of children with primary metastatic 
osteosarcoma are the Pediatric Oncology Group (POG) IE and ISG/SSG II 
studies.
Goorin et al. presented the results of a phase II/III nonrandomized clinical trial 
of high-dose ifosfamide and etoposide in patients with primary metastatic osteosar-
coma. The study included 43 patients.
Neoadjuvant chemotherapy was represented by two courses of IE (ifosfamide 
(I) 17.5 g/m2 and etoposide (E) 500 mg/m2). Removal of the primary tumor lesion 
was performed after two courses of IE at 7–8 weeks of therapy. The timing of the 
removal of metastatic foci was chosen individually during adjuvant chemotherapy, 
which included four courses of MAP chemotherapy and three courses of iE (with a 
course dose of ifosfamide (i) 12 g/m2) in an alternating mode.
A good histological response was achieved in 65% of patients and poor in 35%. 
However, the 2-year OS and EFS were 55 and 45%, respectively. Consequently, 
the use of high-dose ifosfamide in combination with etoposide therapy led to an 
increase in the frequency of achieving a good histological response, but not indica-
tors of OS and EFS [32].
Boye et al. showed the results of the nonrandomized study ISG/SSG II, which 
was conducted from 1996 to 2004. The study included 57 patients with primary 
metastatic osteosarcoma.
Neoadjuvant chemotherapy included two courses of MAPI. Surgical removal of 
the primary tumor lesion was performed at week 14.
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In the adjuvant mode, two courses of ACyVP (adriamycin (A) 90 mg/m2, 
cyclophosphamide (Cy) 4 g/m2, and vepesid (VP) 600 mg/m2) and two courses 
of high-dose chemotherapy VPCarbo (vepesid (VP) 600 mg/m2 and carboplatin 
(Carbo) 1.5 g/m2) with the support of autologous hematopoietic stem cells. Surgical 
removal of the primary tumor lesion was performed at week 14.
A good histological response was achieved in 29% of patients and poor in 71%. 
The 5-year OM and BSV were 31 and 27%, respectively [28].
Marina et al. presented the results of the EURAMOS1 study in patients with 
a poor histological response after neoadjuvant MAP chemotherapy. Within the 
protocol, patients are randomly assigned to the MAP treatment lines (methotrexate 
(M) 12 g/m2, adriamycin (A) 75 mg/m2, and cisplatin (P) 120 mg/m2) and MAPIE 
(ifosfamide (I) 14 g/m2 and etoposide 500 mg/m2). In the age group up to 30 years, 
the MAPIE line of therapy was carried out in 310 patients, the MAPIE line in 308 
patients, in the age group up to 20 years—259 (84%) and 271 (88%) patients. 
Groups of patients are statistically significantly comparable by sex, age, localization 
of the primary tumor lesion, the presence of metastatic lesions, and the histological 
variant of the tumor.
In the group of 541 patients with a localized version of osteosarcoma, 247 events 
were identified, 118 in patients who received the MAP therapy line and 129 in 
patients who received the MAPIE therapy line. At the same time, the 3-year EFS was 
60 and 57%. In the group of patients with primary metastatic osteosarcoma, 3-year 
EFS was 24 and 18%, for MAP and MAPIE, respectively. Therefore, this study 
showed that the use of alternating chemotherapy courses for MAP, IE, and Ai in an 
adjuvant regimen did not lead to an increase in EFS indices [33].
3.2 Experimental treatment
Treatment outcomes for children with primary metastatic osteosarcoma remain 
extremely low and the optimal therapeutic strategy is unknown.
New programs are being developed around the world taking into account the 
molecular biological features of tumor cells that determine sensitivity to chemo-
therapy (ERCC1 to cisplatin, TOPO2α to anthracyclines and etoposide, MGMT 
to epigenetic therapy and cisplatin, RFC1 to methotrexate) [34–39] and invasive 
and metastatic potential of a tumor (stem cell markers—CD133, OCT4; transcrip-
tion factors—p-STAT3, C-MYC; cytokine-associated signaling pathways—ErbB2, 
VEGFR1, VEGFR2, PDGFRα, and PDGFRβ) [40–43].
Cui et al. presented the results of a study to determine the expression of MGMT 
protein (methylguanine–DNA–methyltransferase) and MGMT gene methylation 
in patients with osteosarcoma in the age group up to 40 years (mean age 17 years) 
who were treated with cisplatin in single mode, in a course dose of 120 mg/m2 
Determination of MGMT protein expression in immunohistochemical (IHC) study 
was performed in biopsy tumor material in 76 patients and MGMT gene methyla-
tion in 51 patients. The result of IHC was considered positive with a high level of 
expression—more than 30% (3+), with an average level of expression—20–30% 
(2+), and with a low level of expression—10–20% (1+). MGMT protein expression 
was detected in 52 (68%) patients, low expression level in 27 (35%), medium level 
in 18 (24%), and high level in 7 (9%).
A statistically significant relationship was established between the presence of 
MGMT protein expression and an increase in the frequency of a poor histological 
response (p = 0.004). The expression level above 20% was detected in 22 out of 
43 (51%) patients in the group of patients with 1–2°of therapeutic pathomorpho-
sis and only in 3 out of 33 (9%) patients in the group with 3–4° of therapeutic 
pathomorphosis.
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Neoadjuvant chemotherapy consisted of two courses of IDA. High-dose ifos-
famide (in the course dose of 10 g/m2) was used in monotherapy in patients with a 
poor histological response to treatment, only after five courses of MAP.
After removal of the primary tumor lesion, a good histological response was 
achieved in 45% of patients and a poor histological response in 55%. At the same 
time, the 5-year OV and BSV accounted for 76–65% and the 5-year EFS in the 
group with a good histological response for 89%, with a poor histological response 
48%. Consequently, the use of ifosfamide after MAP courses in the adjuvant mode 
did not lead to an increase in OS and EFS, and the frequency of achieving a good 
histological response was lower than in studies in which the MAP scheme was used 
in alternating mode with ifosfamide [18].
Le Deley et al. presented the results of the randomized SFOP OS94 study, which 
was conducted from 1994 to 2001. The study included 239 patients (120 in group A 
and 119 in group B).
Neoadjuvant therapy included seven courses of high-dose methotrexate and two 
courses of monotherapy with adriamycin (in a course dose of 70 mg/m2) in group 
A or seven courses of high-dose methotrexate and two courses of IE (ifosfamide (I) 
12 g/m2 and etoposide (E) 300 mg/m2) in group B. In the adjuvant mode, chemo-
therapy was replaced with IE courses in group A, and AP in group B for patients 
with a poor histological response detected after removal of the primary focus. The 
operative stage of treatment was carried out at 12 and 14 weeks in groups A and B, 
respectively.
A good histological response was achieved in group A in 43% of patients, in 
group B in 64%, poor histological response in group A in 57%, and in group B in 
36% (p = 0.009). The 5-year OS in group A was 75%, in group B—76%, the 5-year 
EFS in group A—58%, and in group B—66%. A 3-year EFS in group A in patients 
showed a good histological response for 82%, with a poor histological response for 
49%, in group B—77 and 60%, respectively.
Consequently, the use of methotrexate, ifosfamide and etoposide in neoadjuvant 
chemotherapy led to a statistically significant increase in the frequency of achieving 
a good histological response, but not to an increase in OS and EFS [22].
Of particular interest in the treatment of children with primary metastatic 
osteosarcoma are the Pediatric Oncology Group (POG) IE and ISG/SSG II 
studies.
Goorin et al. presented the results of a phase II/III nonrandomized clinical trial 
of high-dose ifosfamide and etoposide in patients with primary metastatic osteosar-
coma. The study included 43 patients.
Neoadjuvant chemotherapy was represented by two courses of IE (ifosfamide 
(I) 17.5 g/m2 and etoposide (E) 500 mg/m2). Removal of the primary tumor lesion 
was performed after two courses of IE at 7–8 weeks of therapy. The timing of the 
removal of metastatic foci was chosen individually during adjuvant chemotherapy, 
which included four courses of MAP chemotherapy and three courses of iE (with a 
course dose of ifosfamide (i) 12 g/m2) in an alternating mode.
A good histological response was achieved in 65% of patients and poor in 35%. 
However, the 2-year OS and EFS were 55 and 45%, respectively. Consequently, 
the use of high-dose ifosfamide in combination with etoposide therapy led to an 
increase in the frequency of achieving a good histological response, but not indica-
tors of OS and EFS [32].
Boye et al. showed the results of the nonrandomized study ISG/SSG II, which 
was conducted from 1996 to 2004. The study included 57 patients with primary 
metastatic osteosarcoma.
Neoadjuvant chemotherapy included two courses of MAPI. Surgical removal of 
the primary tumor lesion was performed at week 14.
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In the adjuvant mode, two courses of ACyVP (adriamycin (A) 90 mg/m2, 
cyclophosphamide (Cy) 4 g/m2, and vepesid (VP) 600 mg/m2) and two courses 
of high-dose chemotherapy VPCarbo (vepesid (VP) 600 mg/m2 and carboplatin 
(Carbo) 1.5 g/m2) with the support of autologous hematopoietic stem cells. Surgical 
removal of the primary tumor lesion was performed at week 14.
A good histological response was achieved in 29% of patients and poor in 71%. 
The 5-year OM and BSV were 31 and 27%, respectively [28].
Marina et al. presented the results of the EURAMOS1 study in patients with 
a poor histological response after neoadjuvant MAP chemotherapy. Within the 
protocol, patients are randomly assigned to the MAP treatment lines (methotrexate 
(M) 12 g/m2, adriamycin (A) 75 mg/m2, and cisplatin (P) 120 mg/m2) and MAPIE 
(ifosfamide (I) 14 g/m2 and etoposide 500 mg/m2). In the age group up to 30 years, 
the MAPIE line of therapy was carried out in 310 patients, the MAPIE line in 308 
patients, in the age group up to 20 years—259 (84%) and 271 (88%) patients. 
Groups of patients are statistically significantly comparable by sex, age, localization 
of the primary tumor lesion, the presence of metastatic lesions, and the histological 
variant of the tumor.
In the group of 541 patients with a localized version of osteosarcoma, 247 events 
were identified, 118 in patients who received the MAP therapy line and 129 in 
patients who received the MAPIE therapy line. At the same time, the 3-year EFS was 
60 and 57%. In the group of patients with primary metastatic osteosarcoma, 3-year 
EFS was 24 and 18%, for MAP and MAPIE, respectively. Therefore, this study 
showed that the use of alternating chemotherapy courses for MAP, IE, and Ai in an 
adjuvant regimen did not lead to an increase in EFS indices [33].
3.2 Experimental treatment
Treatment outcomes for children with primary metastatic osteosarcoma remain 
extremely low and the optimal therapeutic strategy is unknown.
New programs are being developed around the world taking into account the 
molecular biological features of tumor cells that determine sensitivity to chemo-
therapy (ERCC1 to cisplatin, TOPO2α to anthracyclines and etoposide, MGMT 
to epigenetic therapy and cisplatin, RFC1 to methotrexate) [34–39] and invasive 
and metastatic potential of a tumor (stem cell markers—CD133, OCT4; transcrip-
tion factors—p-STAT3, C-MYC; cytokine-associated signaling pathways—ErbB2, 
VEGFR1, VEGFR2, PDGFRα, and PDGFRβ) [40–43].
Cui et al. presented the results of a study to determine the expression of MGMT 
protein (methylguanine–DNA–methyltransferase) and MGMT gene methylation 
in patients with osteosarcoma in the age group up to 40 years (mean age 17 years) 
who were treated with cisplatin in single mode, in a course dose of 120 mg/m2 
Determination of MGMT protein expression in immunohistochemical (IHC) study 
was performed in biopsy tumor material in 76 patients and MGMT gene methyla-
tion in 51 patients. The result of IHC was considered positive with a high level of 
expression—more than 30% (3+), with an average level of expression—20–30% 
(2+), and with a low level of expression—10–20% (1+). MGMT protein expression 
was detected in 52 (68%) patients, low expression level in 27 (35%), medium level 
in 18 (24%), and high level in 7 (9%).
A statistically significant relationship was established between the presence of 
MGMT protein expression and an increase in the frequency of a poor histological 
response (p = 0.004). The expression level above 20% was detected in 22 out of 
43 (51%) patients in the group of patients with 1–2°of therapeutic pathomorpho-
sis and only in 3 out of 33 (9%) patients in the group with 3–4° of therapeutic 
pathomorphosis.
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Methylation of the promoter portion of the MGMT gene was observed in 12 of 
51 (23.5%) patients and the lack of expression of MGMT protein in 14 of 51 (27.5%) 
patients. A statistically significant relationship between the absence of methylation 
and the presence of MGMT protein expression (p < 0.001) was established. In the 
group of patients with 1–2 degrees of therapeutic pathomorphosis, the absence of 
MGMT gene methylation was detected in 36 of 38 (94.7%) patients and with 3–4 
degrees of therapeutic pathomorphosis in 3 of 13 (23%) patients (p < 0.001).
Consequently, the data obtained indicate the formation of tumor resistance to 
treatment with an alkylating agent—cisplatin in patients whose biopsy material 
revealed the absence of methylation of the promoter portion of the MGMT gene 
and the presence of expression of the MGMT protein [34, 35].
Pitano-Garcia et al. (Spain sarcoma group) conducted a study to determine the 
expression of RFC1 micro-RNA (reduced folate carrier 1, a transmembrane protein 
that provides folate and methotrexate transport to the cell) by real-time polymerase 
chain reaction (PCR) in a tumor substrate in children with osteosarcoma.
In 34 samples, biopsy tumor material in 14 children and metastatic foci tumor 
material in 20 children were analyzed. In 13 of 14 (92.9%) biopsy specimens and 
in 11 of 20 (68.8%) metastatic specimens, a low level of RFC1 expression was 
detected.
A poor histological response after neoadjuvant chemotherapy (three  
courses of intravenous administration of doxorubicin at a dose of 75 mg/m2, 
three courses of intraarterial administration of cisplatin at a dose of 105 mg/m2, 
four courses of intravenous administration of methotrexate at a dose of 14 g/m2)  
in 45% of cases. The biopsy tumor substrate in this group of patients was 
characterized by a low level of expression of RFC1 micro-RNA in 90% of cases 
compared to 60% in patients with a good histological response (p = 0.053). The 
average level of expression was statistically significantly lower in the biopsy 
material than in the metastatic tumor foci (p = 0.024) [38, 44].
Therefore, in this study, there was a tendency to an increase in the frequency 
of detection of low expression levels of RFC1 micro-RNA in patients with a poor 
histological response.
Hattinger et al. (Italian sarcoma group) presented the results of the study, the 
purpose of which was to determine the prognostic significance of ERCC1 protein 
expression (excision repair crosscomplementation group 1) in biopsy tumor mate-
rial in patients with localized osteosarcoma, who underwent programmed treat-
ment of ISG/OS-oss and ISG/SSG1. A tumor sample was considered positive in the 
presence of a score of 2–3: score 1 (1–10% of positive nuclei), score 2 (11–50% of 
positive nuclei), and score 3 (more than 50% of positive nuclei).
ERCC1-positive tumor (score 2–3) was detected in 30 patients (30%). During 
the ISG/OS-oss program in groups of patients with ERCC1-negative/score 1 and 
ERCC1-positive (score 2–3), the 5-year-old OS and BSV tumor variants were 91, 
38, and 57, 25% (p = 0.001; p = 0.042), with the ISG/SSG1 program–82, 64, and 69, 
36% (p = 0.022; p = 0.028), and with both therapy programs–82, 50 and 62, 34% 
(p < 0.001; p = 0.006). Consequently, a statistically significant relationship has 
been established between the ERCC1-positive variant of the tumor and lower rates 
of 5-year OS and BSV [36].
Nguyen et al. (SFOP) presented the results of a study to determine the prog-
nostic significance of TOP2A protein expression (topoisomerase DNA 2 alfa) and 
the presence of rearrangement of the TOP2A gene in biopsy tumor material in 105 
children with osteosarcoma treated with the SFOP protocol OS94. Patients with a 
primary metastatic osteosarcoma variant accounted for 17%. After neoadjuvant 
chemotherapy, a good histological response was detected in 56 patients (53%) 
and a poor histological response in 49 (47%). Real-time PCR amplification of the 
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TOP2A gene and the TOP2A gene deletion were detected in 21 (21.2%) and 25 
(25.3%) patients. In 53 children (53.5%), rearrangements of the TOP2A gene were 
not detected. A statistically significant relationship was established between the 
presence of the TOP2A gene rearrangement (amplification and deletion) and the 
presence of a good histological response after neoadjuvant polychemotherapy 
(p = 0.004). There was also a tendency to achieve lower rates of 5-year OM and BSV 
in patients whose tumor cells had amplified the TOP2A gene (p = 0.09 and 0.06). 
The expression of the TOR2A protein was determined in 17 patients by immunohis-
tochemistry. Medium (2+) and high (3+) levels of expression were detected in all 
patients; expression was above 30% in 12 of 17 children (70.5%). There is no statis-
tically significant relationship between the expression of the TOR2A protein above 
30% and the presence of amplification or deletion of the TOP2A gene (p > 0.05) 
due to an insufficient number of observations [37].
Xiao et al. presented the results of a study of a personalized approach to the 
prescription of chemotherapy depending on the presence or absence of markers of 
drug resistance in 28 patients with localized osteosarcoma. The average age in the 
patient group was 20.1 g. To determine the sensitivity to chemotherapy, the follow-
ing markers were used: for doxorubicin–expression of TOP2A micro-RNA, muta-
tion of the ABCB1 gene, and mutation of the GSTP1 gene; for cisplatin–expression 
of microcryptal ERCC1, BRCA1, and mutation of genes XRCC1-exon6 and XRCC1-
exon10, and for ifosfamide–mutation of CYP2C9 * 3.
At the same time, a high level of sensitivity to ifosfamide was detected in all 
patients (100%), to cisplatin in 11 out of 28 (39.2%), to doxorubicin in 6 out of 28 
(21.4%); medium and high levels of sensitivity to cisplatin in 17 of 28 (60.7%), 
to doxorubicin in 20 of 28 (71.4%). Chemotherapy, taking into account the sen-
sitivity of the tumor to drugs, was performed in 8 of 28 patients (28.5%). In this 
group, only one relapse of the disease was detected, while in the rest of the 20 
patients, four relapses of the disease were detected: in one case, progression during 
neoadjuvant chemotherapy and in another case, fatal outcome from toxicity of 
therapy. The average duration of observation for groups was not indicated, and no 
statistically significant difference was obtained due to the insufficient number of 
observations [39].
In addition, the study of markers of stem tumor cells CD133 (Prominin 1) and 
Octamer-binding transcription factor 4 (OCT4), as well as the transcription factors 
signal transducer and activator of transcription 3 (STAT3), and myelocytomatosis 
viral oncogene homolog (C-MYC), which determines the invasive and metastatic 
potential of a tumor [45–47].
So in the work of He et al., there was a significant correlation between the 
expression of CD133 in tumor cells and a higher frequency of metastatic lesions, a 
lower median of overall survival. A CD133-positive variant was detected in 46 of 70 
(65.7%) patients, in 6 out of 16 (37.5%) in the group with a localized osteosarcoma 
variant, and in 40 out of 54 (74%) in the group with the primary metastatic osteo-
sarcoma (p = 0.002). The median overall survival rate was statistically significantly 
lower in the group with CD133-positive tumor (p = 0.000). When conducting the 
study “Transwell invasion,” a significantly higher invasive potential of the CD133-
positive variant of the tumor was established (p < 0.05). Real-time PCR established 
a higher level of expression of micro-RNA OCT4 in a CD133-positive variant of the 
tumor (p < 0.05) [41].
Li et al. in an experimental model on cell lines showed that about 80% of cells 
in a CD133-positive variant of the tumor are in the G0/G1 phases of the cell cycle 
(p < 0.01). Also, real-time PCR revealed a significantly higher level of expression 
of the multidrug-resistant gene (MDR1) in the CD133-positive variant of the tumor 
(p < 0.05) [48].
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Methylation of the promoter portion of the MGMT gene was observed in 12 of 
51 (23.5%) patients and the lack of expression of MGMT protein in 14 of 51 (27.5%) 
patients. A statistically significant relationship between the absence of methylation 
and the presence of MGMT protein expression (p < 0.001) was established. In the 
group of patients with 1–2 degrees of therapeutic pathomorphosis, the absence of 
MGMT gene methylation was detected in 36 of 38 (94.7%) patients and with 3–4 
degrees of therapeutic pathomorphosis in 3 of 13 (23%) patients (p < 0.001).
Consequently, the data obtained indicate the formation of tumor resistance to 
treatment with an alkylating agent—cisplatin in patients whose biopsy material 
revealed the absence of methylation of the promoter portion of the MGMT gene 
and the presence of expression of the MGMT protein [34, 35].
Pitano-Garcia et al. (Spain sarcoma group) conducted a study to determine the 
expression of RFC1 micro-RNA (reduced folate carrier 1, a transmembrane protein 
that provides folate and methotrexate transport to the cell) by real-time polymerase 
chain reaction (PCR) in a tumor substrate in children with osteosarcoma.
In 34 samples, biopsy tumor material in 14 children and metastatic foci tumor 
material in 20 children were analyzed. In 13 of 14 (92.9%) biopsy specimens and 
in 11 of 20 (68.8%) metastatic specimens, a low level of RFC1 expression was 
detected.
A poor histological response after neoadjuvant chemotherapy (three  
courses of intravenous administration of doxorubicin at a dose of 75 mg/m2, 
three courses of intraarterial administration of cisplatin at a dose of 105 mg/m2, 
four courses of intravenous administration of methotrexate at a dose of 14 g/m2)  
in 45% of cases. The biopsy tumor substrate in this group of patients was 
characterized by a low level of expression of RFC1 micro-RNA in 90% of cases 
compared to 60% in patients with a good histological response (p = 0.053). The 
average level of expression was statistically significantly lower in the biopsy 
material than in the metastatic tumor foci (p = 0.024) [38, 44].
Therefore, in this study, there was a tendency to an increase in the frequency 
of detection of low expression levels of RFC1 micro-RNA in patients with a poor 
histological response.
Hattinger et al. (Italian sarcoma group) presented the results of the study, the 
purpose of which was to determine the prognostic significance of ERCC1 protein 
expression (excision repair crosscomplementation group 1) in biopsy tumor mate-
rial in patients with localized osteosarcoma, who underwent programmed treat-
ment of ISG/OS-oss and ISG/SSG1. A tumor sample was considered positive in the 
presence of a score of 2–3: score 1 (1–10% of positive nuclei), score 2 (11–50% of 
positive nuclei), and score 3 (more than 50% of positive nuclei).
ERCC1-positive tumor (score 2–3) was detected in 30 patients (30%). During 
the ISG/OS-oss program in groups of patients with ERCC1-negative/score 1 and 
ERCC1-positive (score 2–3), the 5-year-old OS and BSV tumor variants were 91, 
38, and 57, 25% (p = 0.001; p = 0.042), with the ISG/SSG1 program–82, 64, and 69, 
36% (p = 0.022; p = 0.028), and with both therapy programs–82, 50 and 62, 34% 
(p < 0.001; p = 0.006). Consequently, a statistically significant relationship has 
been established between the ERCC1-positive variant of the tumor and lower rates 
of 5-year OS and BSV [36].
Nguyen et al. (SFOP) presented the results of a study to determine the prog-
nostic significance of TOP2A protein expression (topoisomerase DNA 2 alfa) and 
the presence of rearrangement of the TOP2A gene in biopsy tumor material in 105 
children with osteosarcoma treated with the SFOP protocol OS94. Patients with a 
primary metastatic osteosarcoma variant accounted for 17%. After neoadjuvant 
chemotherapy, a good histological response was detected in 56 patients (53%) 
and a poor histological response in 49 (47%). Real-time PCR amplification of the 
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TOP2A gene and the TOP2A gene deletion were detected in 21 (21.2%) and 25 
(25.3%) patients. In 53 children (53.5%), rearrangements of the TOP2A gene were 
not detected. A statistically significant relationship was established between the 
presence of the TOP2A gene rearrangement (amplification and deletion) and the 
presence of a good histological response after neoadjuvant polychemotherapy 
(p = 0.004). There was also a tendency to achieve lower rates of 5-year OM and BSV 
in patients whose tumor cells had amplified the TOP2A gene (p = 0.09 and 0.06). 
The expression of the TOR2A protein was determined in 17 patients by immunohis-
tochemistry. Medium (2+) and high (3+) levels of expression were detected in all 
patients; expression was above 30% in 12 of 17 children (70.5%). There is no statis-
tically significant relationship between the expression of the TOR2A protein above 
30% and the presence of amplification or deletion of the TOP2A gene (p > 0.05) 
due to an insufficient number of observations [37].
Xiao et al. presented the results of a study of a personalized approach to the 
prescription of chemotherapy depending on the presence or absence of markers of 
drug resistance in 28 patients with localized osteosarcoma. The average age in the 
patient group was 20.1 g. To determine the sensitivity to chemotherapy, the follow-
ing markers were used: for doxorubicin–expression of TOP2A micro-RNA, muta-
tion of the ABCB1 gene, and mutation of the GSTP1 gene; for cisplatin–expression 
of microcryptal ERCC1, BRCA1, and mutation of genes XRCC1-exon6 and XRCC1-
exon10, and for ifosfamide–mutation of CYP2C9 * 3.
At the same time, a high level of sensitivity to ifosfamide was detected in all 
patients (100%), to cisplatin in 11 out of 28 (39.2%), to doxorubicin in 6 out of 28 
(21.4%); medium and high levels of sensitivity to cisplatin in 17 of 28 (60.7%), 
to doxorubicin in 20 of 28 (71.4%). Chemotherapy, taking into account the sen-
sitivity of the tumor to drugs, was performed in 8 of 28 patients (28.5%). In this 
group, only one relapse of the disease was detected, while in the rest of the 20 
patients, four relapses of the disease were detected: in one case, progression during 
neoadjuvant chemotherapy and in another case, fatal outcome from toxicity of 
therapy. The average duration of observation for groups was not indicated, and no 
statistically significant difference was obtained due to the insufficient number of 
observations [39].
In addition, the study of markers of stem tumor cells CD133 (Prominin 1) and 
Octamer-binding transcription factor 4 (OCT4), as well as the transcription factors 
signal transducer and activator of transcription 3 (STAT3), and myelocytomatosis 
viral oncogene homolog (C-MYC), which determines the invasive and metastatic 
potential of a tumor [45–47].
So in the work of He et al., there was a significant correlation between the 
expression of CD133 in tumor cells and a higher frequency of metastatic lesions, a 
lower median of overall survival. A CD133-positive variant was detected in 46 of 70 
(65.7%) patients, in 6 out of 16 (37.5%) in the group with a localized osteosarcoma 
variant, and in 40 out of 54 (74%) in the group with the primary metastatic osteo-
sarcoma (p = 0.002). The median overall survival rate was statistically significantly 
lower in the group with CD133-positive tumor (p = 0.000). When conducting the 
study “Transwell invasion,” a significantly higher invasive potential of the CD133-
positive variant of the tumor was established (p < 0.05). Real-time PCR established 
a higher level of expression of micro-RNA OCT4 in a CD133-positive variant of the 
tumor (p < 0.05) [41].
Li et al. in an experimental model on cell lines showed that about 80% of cells 
in a CD133-positive variant of the tumor are in the G0/G1 phases of the cell cycle 
(p < 0.01). Also, real-time PCR revealed a significantly higher level of expression 
of the multidrug-resistant gene (MDR1) in the CD133-positive variant of the tumor 
(p < 0.05) [48].
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In the studies presented, He and Li et al., the mechanisms of drug resistance, 
invasion, and metastasis in case of CD133-positive variant of the tumor were 
established.
In the works of Tu et al., the significance of activation of the IL6R/STAT3/p-
STAT3tyr705 mesenchymal stem cell signaling pathway to increase the metastatic 
potential of tumor cells was exemplified by the example of cell lines (Saos 2 and 
U2-OS). The relationship between the increased expression of p-STAT3tyr705 and 
increased expression of the drug resistance markers multidrug resistance protein 
(MRP) and MDR1 has been established. An increase in sensitivity to doxorubicin, 
but not to cisplatin, was also noted with inhibition of this signaling pathway [43, 49].
Han et al. using cell lines (MG63 and SAOS2) as an example showed that an 
increase in C-MYC expression leads to activation of the MEK–ERK signaling 
pathway and an increase in the expression of MMP2 and MMP9, which enhance the 
invasive and metastatic potential of a tumor [50].
Wu et al. investigated the prognostic significance of C-MYC expression in 
biopsy tumor material in 56 children with osteosarcoma who were treated with 
methotrexate, cisplatin, and adriamycin. Expression of the C-MYC protein was 
detected in 48 of 56 (85.7%) patients. A statistically significant relationship was 
established between the presence of C-MYC expression and a decrease in the apop-
totic index (p < 0.05). In addition, in the group of patients with C-MYC-positive 
variant of the tumor and the intensity of expression, at 2+ and 3+, a significantly 
lower 3-year-old OM was established (p < 0.05) [51].
Consequently, in the works of Tu, Han, and Wu et al., the significance of tran-
scription factors in the development of drug resistance, invasion, and metastasis of 
the tumor has been established.
3.3 Theoretical treatment
Innovative therapeutic approaches are used mainly in patients with metastatic 
osteosarcoma, relapse, and refractory course of the disease. Currently, the follow-
ing key areas are distinguished: (1) the use of monoclonal antibody preparations, 
(2) tumor-modifying therapy using nitrogen-containing bisphosphonates, (3) the 
use of chemotherapeutic drugs that affect various cellular signaling pathways (mul-
tikinase inhibitors and mTOR inhibitors), and (4) the use of drugs that promote the 
activation of tumor-associated macrophages.
Rossi et al. presented the results of a study aimed at determining the expression 
of vascular endothelial growth factor (VEGF) in a biopsy tumor substrate and 
in tumor material after neoadvanting chemotherapy (two courses of MAP) in 16 
patients with localized osteosarcoma, who received programmed treatment using 
the SSG XIV protocol. Four levels of expression were evaluated: negative and low–at 
an expression level <25%, medium—at 25–50% (1+), high—at 50–75% (2+), and 
very high—at>75% (3+). Medium and high levels of VEGF expression in biopsy 
tumor material were detected in 11 (6 in medium and 5 in high) out of 16 patients 
(68.7%). After neoadjuvant chemotherapy and the removal of the primary tumor 
site, VEGF expression was established in all samples, and there was an increase in 
expression in samples that were positive in the initial study.
High and very high levels of expression, increased expression after neoadjuvant 
chemotherapy was statistically significantly correlated with the localization of the 
primary tumor lesion in the femur (p = 0.02), with the appearance of local recur-
rence (p = 0.04) and/or early metastatic lesions in the lungs (p = 0.04), with a fatal 
outcome from the refractory course of the disease (p = 0.04).
Therefore, the presence of VEGF expression in the biopsy material and an 
increase in the expression of VEGF after neoadjuvant chemotherapy are factors for 
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poor prognosis of the disease [42]. But this study requires the continuation of the 
fact that it includes a small number of patients.
In addition, Ohba et al. showed in an in vivo experiment using human osteosar-
coma cell lines (TE85 and 143B) the mechanism of autocrine stimulation of tumor 
transformation and proliferation using the example of the VEGF/VEGFR signaling 
pathway. In this study, the expression of VEGF-A and VEGFR micro-RNA was 
evaluated [52].
Currently, little experience has been gained with the use of the drug bevaci-
zumab in children with osteosarcoma.
Bevacizumab (Avastin) is a partially humanized monoclonal antibody to 
VEGF-A, IgG1, which realizes its activity through a second type of immunopatho-
logical reaction (antibody-mediated complement-dependent cytotoxicity and 
antibody-mediated cell-dependent cytotoxicity) [53].
Turner et al. (St. Jude Children’s research hospital) presented preliminary results 
of using bevacizumab in combination with neoadjuvant chemotherapy (two courses 
of IDA) in 27 children with osteosarcoma. The drug was used at a dose of 15 mg/kg. 
There are three introductions for neoadjuvant chemotherapy. A satisfactory toxicity 
profile has been established. The study NCT00667342 continues [54, 55].
Back in 1999, employees of the Memorial Sloan-Kettering Cancer Center 
presented the results of a study assessing the effect of ErbB2 expression (Erb-B2 
receptor tyrosine kinase 2) on the nature of the histological response after neoad-
juvant polychemotherapy and on the rates of OS and BSV. The study included 53 
patients. ErbB2 overexpression was detected in 42% of patients in the entire study 
group, in 50% with metastatic variant and in 76% at the time of detection of relapse 
or refractory course of the disease, and also statistically significantly correlated 
with poor histological response (p = 0.02) and BSV (p = 0.05). The 5-year BSV in 
patients with a localized version of osteosarcoma and ErbB2-positive status was 
47%, with ErbB2-negative status—79% [40].
Conflicting data on the prognostic significance of ErbB2-positive status in 
patients with localized osteosarcoma were obtained.
In 2002, the Japanese Osteosarcoma Group (Japanese Osteosarcoma Group) 
published the results of a study that included 155 patients with localized osteo-
sarcoma from 1984 to 1995. At the same time, 5-year BSV in patients with ErbB2-
positive status was 45%, with ErbB2-negative status—72% [56].
In 2014, the Children Oncology Group (COG) presented completely different 
results of the study, which from 1999 to 2002 included 135 patients with localized 
osteosarcoma. Only 13% of patients showed ErbB2-positive status. The 5-year RR in 
patients with ErbB2-positive status was 73%, and with the ErbB2-negative sta-
tus—72%, the 5-year RR was 59 and 69%, respectively. No statistically significant 
difference in survival was observed [57].
Thus, it was confirmed that ErbB2 can be considered as a potential target for 
targeted therapy in metastatic variant, relapse, and refractory course of the disease.
COG presented the results of a phase 2 clinical trial of the drug Trastuzumab 
(Herceptin) in combination with MAPIE polychemotherapy in 96 patients with 
primary metastatic osteosarcoma. This study was conducted from 2001 to 2005.
Trastuzumab is a partially humanized IgG1κ monoclonal antibody to ErbB2, 
which also realizes its activity through a second type of immunopathological reac-
tion (antibody-mediated complement-dependent cytotoxicity and antibody-medi-
ated cell-dependent cytotoxicity). The drug was administered at a dose of 4 mg/kg 
in the first week, and then 2 mg/kg 1 time per week (34 in total) only in patients in 
whose tumor substrate ErbB2 expression was detected.
Surgical removal of the primary tumor lesion was performed at week 11. 
Adjuvant chemotherapy began at week 13.
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In the studies presented, He and Li et al., the mechanisms of drug resistance, 
invasion, and metastasis in case of CD133-positive variant of the tumor were 
established.
In the works of Tu et al., the significance of activation of the IL6R/STAT3/p-
STAT3tyr705 mesenchymal stem cell signaling pathway to increase the metastatic 
potential of tumor cells was exemplified by the example of cell lines (Saos 2 and 
U2-OS). The relationship between the increased expression of p-STAT3tyr705 and 
increased expression of the drug resistance markers multidrug resistance protein 
(MRP) and MDR1 has been established. An increase in sensitivity to doxorubicin, 
but not to cisplatin, was also noted with inhibition of this signaling pathway [43, 49].
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increase in C-MYC expression leads to activation of the MEK–ERK signaling 
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very high—at>75% (3+). Medium and high levels of VEGF expression in biopsy 
tumor material were detected in 11 (6 in medium and 5 in high) out of 16 patients 
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site, VEGF expression was established in all samples, and there was an increase in 
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poor prognosis of the disease [42]. But this study requires the continuation of the 
fact that it includes a small number of patients.
In addition, Ohba et al. showed in an in vivo experiment using human osteosar-
coma cell lines (TE85 and 143B) the mechanism of autocrine stimulation of tumor 
transformation and proliferation using the example of the VEGF/VEGFR signaling 
pathway. In this study, the expression of VEGF-A and VEGFR micro-RNA was 
evaluated [52].
Currently, little experience has been gained with the use of the drug bevaci-
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Bevacizumab (Avastin) is a partially humanized monoclonal antibody to 
VEGF-A, IgG1, which realizes its activity through a second type of immunopatho-
logical reaction (antibody-mediated complement-dependent cytotoxicity and 
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Turner et al. (St. Jude Children’s research hospital) presented preliminary results 
of using bevacizumab in combination with neoadjuvant chemotherapy (two courses 
of IDA) in 27 children with osteosarcoma. The drug was used at a dose of 15 mg/kg. 
There are three introductions for neoadjuvant chemotherapy. A satisfactory toxicity 
profile has been established. The study NCT00667342 continues [54, 55].
Back in 1999, employees of the Memorial Sloan-Kettering Cancer Center 
presented the results of a study assessing the effect of ErbB2 expression (Erb-B2 
receptor tyrosine kinase 2) on the nature of the histological response after neoad-
juvant polychemotherapy and on the rates of OS and BSV. The study included 53 
patients. ErbB2 overexpression was detected in 42% of patients in the entire study 
group, in 50% with metastatic variant and in 76% at the time of detection of relapse 
or refractory course of the disease, and also statistically significantly correlated 
with poor histological response (p = 0.02) and BSV (p = 0.05). The 5-year BSV in 
patients with a localized version of osteosarcoma and ErbB2-positive status was 
47%, with ErbB2-negative status—79% [40].
Conflicting data on the prognostic significance of ErbB2-positive status in 
patients with localized osteosarcoma were obtained.
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published the results of a study that included 155 patients with localized osteo-
sarcoma from 1984 to 1995. At the same time, 5-year BSV in patients with ErbB2-
positive status was 45%, with ErbB2-negative status—72% [56].
In 2014, the Children Oncology Group (COG) presented completely different 
results of the study, which from 1999 to 2002 included 135 patients with localized 
osteosarcoma. Only 13% of patients showed ErbB2-positive status. The 5-year RR in 
patients with ErbB2-positive status was 73%, and with the ErbB2-negative sta-
tus—72%, the 5-year RR was 59 and 69%, respectively. No statistically significant 
difference in survival was observed [57].
Thus, it was confirmed that ErbB2 can be considered as a potential target for 
targeted therapy in metastatic variant, relapse, and refractory course of the disease.
COG presented the results of a phase 2 clinical trial of the drug Trastuzumab 
(Herceptin) in combination with MAPIE polychemotherapy in 96 patients with 
primary metastatic osteosarcoma. This study was conducted from 2001 to 2005.
Trastuzumab is a partially humanized IgG1κ monoclonal antibody to ErbB2, 
which also realizes its activity through a second type of immunopathological reac-
tion (antibody-mediated complement-dependent cytotoxicity and antibody-medi-
ated cell-dependent cytotoxicity). The drug was administered at a dose of 4 mg/kg 
in the first week, and then 2 mg/kg 1 time per week (34 in total) only in patients in 
whose tumor substrate ErbB2 expression was detected.
Surgical removal of the primary tumor lesion was performed at week 11. 
Adjuvant chemotherapy began at week 13.
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In the group with trastuzumab, a good histological response was detected in 
56% of patients and without trastuzumab, it was 40%, a poor histological response 
of 44–60%, respectively. At the same time, the 3-year OS and BSV in the group of 
patients who received treatment with trastuzumab accounted for 59 and 32%, and 
in the group of patients who received treatment without trastuzumab for 50 and 
32%. Consequently, the use of trastuzumab with polychemotherapy MAPIE led to 
an increase in the frequency of achieving a good histological response, but not to an 
increase in the rates of OS and EFS [58].
Of particular interest is tumor-modifying therapy using nitrogen-containing 
bisphosphonates. Currently, the following mechanisms of action of nitrogen-con-
taining bisphosphonates have been identified, which are represented by the activa-
tion of tumor cell apoptosis by the caspase mechanism (indirectly through protein 
Rb and P53) and without the participation of the caspase mechanism (an increase 
in AIF—apoptosis of the inducing factor); increased expression of TNF-related 
apoptosis-inducing ligand–death receptor 5 (TRAIL-DR5, TRAIL-induced apop-
tosis); reduction of receptor activator of nuclear factor kappa-B ligand (RANKL) 
expression–ligand of nuclear factor activation receptor kB in osteosarcoma cells, 
which leads to suppression of tumor cell proliferation, osteoclast activity, changes in 
the tumor microenvironment, bone resorption, and risk of metastasis; γδT activation 
of cellular cytotoxicity; and tumor activation of associated macrophages [59–62].
In addition, the potentiating effect of nitrogen-containing bisphosphonates on 
cisplatin and adriamycin has been confirmed [63].
Currently, a rather small experience has been gained in using these drugs in 
children with osteosarcoma.
Meyers et al. published the results of a study on the combined use of pami-
dronate with MAP chemotherapy. The study included 40 patients, 32 in the age 
group under 18, 29 with a localized version of osteosarcoma, and 11 with a primary 
metastatic option of osteosarcoma.
In accordance with the program, pamidronate was administered once a 
month at a dose of 2 mg/kg 48–72 h after adriamycin, methotrexate, a total of 12 
administrations.
Surgical removal of the primary tumor lesion was performed at week 11. 
Adjuvant chemotherapy began at week 13. Removal of metastatic foci was carried 
out individually at the stage of adjuvant therapy.
The frequency of achieving a good and poor histological response is not indi-
cated. However, relatively high rates of 5-year OS and EFS were obtained: 93 and 
72% in patients with localized osteosarcoma and 64 and 45% in patients with 
metastatic osteosarcoma [26].
COG presented the results of the pilot protocol AOST06P1 aimed at studying the 
combined use of zoledronic acid with MAPIE polychemotherapy in children with 
the primary metastatic osteosarcoma. This study included 24 patients. Zoledronic 
acid was administered at a dose of 1.2–3.5 mg/m2 in each course of chemotherapy.
The maximum tolerated dose of zoledronic acid was established, which was 
2.3 mg/m2. Indicators of a 2-year OV and EFS were 60 and 32%, respectively [63].
Piperno-Neumann et al. presented the results of a phase 3 randomized study OS 
2006, the purpose of which was to identify the potentiating effect of zoledronic acid 
when used together with polychemotherapy MIE and MAP.
The study included 217 children, 107 in the control group, and 110 in the group 
with zoledronic acid. Groups of patients were statistically significantly comparable 
by sex, age, foci of primary and metastatic lesions, and histological variant of the 
tumor.
Zoledronic acid was administered at a dose of 0.05 mg/kg (maximum dose of 
4 mg) with each course of chemotherapy (IE and AP).
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Neoadjuvant chemotherapy consisted of two courses of IE (ifosfamide (I) 12 g/m2, 
etoposide 300 mg/m2) and seven administrations of high-dose methotrexate ((M) 
12 g/m2). Surgical removal of the primary tumor lesion was performed at week 
14. Adjuvant chemotherapy included two courses of MIE in the group with a good 
histological response and five courses of MAP in the group with a poor histological 
response. A good histological response after neoadjuvant polychemotherapy was 
achieved in 73% of patients. However, there was no statistically significant differ-
ence in achieving a good histological response, in terms of OS and BSV in groups 
of patients who received programmed treatment with or without zoledronic acid. 
The number of events in the group with zoledronic acid was 42% (47/110) and 
in the group without zoledronic acid was 31% (34/107). Consequently, this study 
shows the high effectiveness of chemotherapy courses with IE in combination with 
methotrexate in the neoadjuvant regimen. The presence of the potentiating effect of 
zoledronic acid has not been proven [64].
In the treatment of refractory forms of osteosarcoma, drugs are also used that 
affect various cellular signaling pathways. Understanding the mechanisms of tumor 
activation opens up the possibility of using multikinase and mammalian target of 
rapamycin complex (mTOR) inhibitors.
Takagi and Peng et al. in an in vitro experiment on cell lines (SaOS2, MG63, 
HOS), pathogenetic mechanisms of cytokine-induced tumor transformation and 
proliferation were shown through the activation of VEGF/VEGFR/PI3K (phospha-
tidylinositol-4,5-bisphosphate 3-kinase)/AKT (protein kinase B) and the platelet-
derived growth factor receptor (PDGFR)/PI3K/AKT signaling pathways [65, 66]. 
The most studied drugs from this group are currently sorafenib (nexavar) and 
everolimus (afinitor) [67]. Sorafenib is a nonselective multikinase inhibitor that 
inhibits the activity of various cellular signaling pathways, in particular VEGFR1, 
VEGFR2, PDGFRα, and PDGFRβ, while everolimus is an mTOR inhibitor [68].
Ymera et al. of the Italian Sarcoma Group published the results of a preclinical 
study (in vitro and in vivo), which noted the mutually potentiating antitumor 
effect of everolimus and sorafenib on osteosarcoma cell lines (KHOS, MNNG-HOS, 
and U2OS). The effect of everolimus and sorafenib on mTORC1/mTORC2 is mani-
fested in a decrease in the expression of mTORC1 and an increase in the expression 
of mTORC2, which provides proapoptotic and antiproliferative effects. With the 
combined use of everolimus and sorafenib, there is a decrease in the expression of 
both mTORC1 and mTORC2 [69].
From 2008 to 2009, Grignani et al. of the Italian Sarcoma Group conducted a 
second phase of clinical trials of the drug sorafenib in patients with relapse and 
refractory osteosarcoma. The study included 35 patients with osteosarcoma in the 
age group over 14 years. Partial response was achieved in 5 (14%) patients and 
stabilization of the disease in 12 (34%) patients. The overall response rate was 48%. 
At the same time, 4-month progression-free survival was 45% (15 out of 35) [70].
From 2011 to 2013, Grignani et al. conducted a second phase of clinical trials of 
a combination of drugs of everolimus and sorafenib in patients with relapse and 
refractory osteosarcoma after performing standard polychemotherapy MAP (study 
NCT01804374). The study included 38 patients over the age of 18 years. Everolimus 
was administered in a dose of 5 mg once a day and sorafenib 400 mg two times a 
day. The duration of chemotherapy was 28 days. Partial response was achieved in 
4 (10%) patients and stabilization of the disease in 20 (53%) patients. The overall 
response rate is 63%. This figure is 15% more than in the study, where sorafenib 
was used in monomode. A 4-month progression-free survival was 58% and for 
6-month, it was 45% (17 out of 38) [71].
Thus, taking into account the data of studies in 2008 (application of sorafenib in 
mono mode) and 2011 (using a combination of sorafenib with everolimus), it can 
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be said that the combination of sorafenib with everolimus leads to an increase in the 
overall response rate and an increase in survival rate without disease progression 
within 6 months. However, by the year, this difference disappears.
At ASCO 2016, preliminary results were presented in a pilot study of the use of 
everolimus/sorafenib in children with relapse and refractory osteosarcoma, which 
was carried out at the Institute of Pediatric Oncology and Hematology N.N. Blokhin 
Medical Research Center of Oncology from 2013 to 2016. This protocol included 
14 patients. The first line of therapy is represented by the program “Osteosarcoma 
2006” in seven patients and “Osteosarcoma 2014” in seven patients. All patients 
underwent therapy, which included doxorubicin, cisplatin, high-dose methotrex-
ate, high-dose ifosfamide, and gemcitabine and docetaxel.
The number of courses of therapy for everolimus/sorafenib ranged from 2 to 18. 
The toxicity of therapy was erythema cutaneous in all patients (100%), palmar and 
plantar syndrome in 1 (7%), and mucositis 1–2 in 4 (28.5%). Hematologic toxicity 
did not exceed 1–2 degree in all patients. A transient increase in transaminases up to 
five norms in all patients (100%) was also noted.
Partial response to treatment was achieved in 5 of 14 (35.7%) patients and sta-
bilization of the disease in 9 (64.3%). The overall response rate was 100%. Survival 
without disease progression for more than 6 months was detected in 6 out of 14 
(43%) patients. The mean follow-up was 7 ± 1.2 months. The maximum period 
without progression of the disease is 18.4 months.
The findings suggest that everolimus/sorafenib combination resulted in a partial 
response in 35.7% of cases with a satisfactory toxicity profile [72].
Compared to international data (Italian sarcoma group) in the presented study, 
the achievement of a partial response, stabilization of the disease, and the overall 
response rate were significantly higher.
Currently, a number of studies aimed at studying the role of tumor-associated 
macrophages. Activation of tumor-associated macrophages can be achieved 
through the use of preparations of liposomal tripeptides (mifamurtide) and inter-
feron preparations (interferon alpha-2A).
Meyers et al. presented the results of the randomized study CCG 7921/POG 
9351, which was conducted from 1993 to 1997. The study included 662 patients with 
a localized version of osteosarcoma.
A feature of line A therapy was the use of two courses of neoadjuvant chemo-
therapy for MAP, and in line B therapy, two courses of neoadjuvant chemotherapy 
MAi, alternating courses of MAR and MAi at the stage of adjuvant chemotherapy, 
was used. Surgical removal of the primary tumor lesion was performed at week 10. 
Mifamurtide (MTP) was administered at a dose of 2 mg/m2 two times a week for 
12 weeks, and then once a week for 24 weeks in accordance with randomization.
The mechanism of action of mythamurtide (MTP) is to activate monocytes/
macrophages with antitumor activity, which is realized by binding to specific recep-
tors toll-like receptor 4 (TLR4) and nucleotide-binding oligomerization domain 
2 receptor (NOD2), followed by altering the activity of cellular signal pathways 
(ERK1/2—extracellular-signal regulated kinase 1/2), NF-kB—nuclear factor kappa-
B, and AP1—adapter protein 1 [73].
After removal of the primary tumor focus, a good histological response in group 
A was achieved in 42% of patients and in group B in 48%, and a poor histologi-
cal response in group A was 58% and in group B was 52%. At the same time, the 
6-year-old RH was 74%, without the use of MTP was 70% and with the MTP was 
78%; BSV was 64%, without the use of MTR was 61% and with MTP was 67%. In 
group A: OS without the use of MTR was 71% and with MTR was 75%; BSV without 
MTR was 64% and with MTR was 63%. In group B: OS without the use of MTR was 
71% and with MTR was 75%; BSV without MTR was 64% and with MTR was 63%. 
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The addition of MTP to polychemotherapy led to a statistically significant increase 
in the 6-year OS from 70 to 78% (p = 0.03), and there was also a tendency to an 
increase in BSV, mainly in group B (p = 0.08) [25].
Kubo et al. published the results of a pilot study that determined the prognostic 
significance of the expression level of interferon α/β receptors in 40 patients with 
localized osteosarcoma who received treatment according to the NECO95J program. 
Expression of interferon α/β receptors was detected in 45% of patients. When 
conducting multivariate statistical analysis, a significant association was observed 
between the expression of interferon α/β receptors and 5-year-old OM and survival 
free of metastatic lesions (VSMP). The 5-year OM, in the presence of expression 
of the α/β interferon receptor in the tumor substrate, was 81%, with no expression, 
47% (p = 0.043), and in the 5-year HSMP, it was 75 and 41% (p = 0.023). This 
study confirms the possibility of using interferon preparations in the treatment of 
osteosarcoma in patients with overexpression of α/β interferon receptors [74].
Bielack et al. presented the results of the EURAMOS1 study in patients with a 
good histological response after neoadjuvant MAP chemotherapy. In the age group 
up to 30 years, the MAP line of therapy was carried out to 359 patients, the MAP 
INF line α–2b—to 357 patients, in the age group up to 20 years—333 (92.7%) and 
332 (92.9%) patients. Groups of patients are statistically significantly comparable 
by sex, age, localization of the primary tumor lesion, the presence of metastatic 
lesions, and the histological variant of the tumor.
In accordance with the program, pegylated INF–α–2b was administered at a dose 
of 0.5 mg/kg (at a maximum dose of 50 mg) once a week for 4 weeks, and then 
1 mg/kg (at a maximum dose of 100 mg) 1 time per week (from 30 to 104 weeks of 
programmed treatment).
In a group of 630 patients with a localized version of osteosarcoma, 135 events 
were detected: 72 in patients who received the MAP therapy line and 63 in patients 
who received the MAP INF therapy line–2b. At the same time, the 3-year EFS was 
77 and 80%, respectively. Therefore, the use of INF–α–2b as maintenance therapy 
after MAP in patients with a good histological response did not lead to an increase 
in EFS [75].
The data set out in paragraph 3 are summarized in Table 3.
4. Conclusion
Thus, the results of treatment of children with primary metastatic osteo-
sarcoma, relapse, and refractory course of the disease remain unsatisfactory. 
Molecular biological factors that determine sensitivity to chemotherapy, invasive, 
Authors Agents
Ferrari S. Ifosfamide, adriamycin, cisplatin
Le Deley M.C. Methotrexate, adriamycin, ifosfamide, etoposide
Cui Q. Cisplatin
Pitano-Garcia A. Doxorubicin, cisplatin
Wu X. Methotrexate, cisplatin, adriamycin
Ohba T. Bevacizumab (Avastin)
Children Oncology Group Trastuzumab
Table 3. 
Trials/authors and agents.
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1 mg/kg (at a maximum dose of 100 mg) 1 time per week (from 30 to 104 weeks of 
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were detected: 72 in patients who received the MAP therapy line and 63 in patients 
who received the MAP INF therapy line–2b. At the same time, the 3-year EFS was 
77 and 80%, respectively. Therefore, the use of INF–α–2b as maintenance therapy 
after MAP in patients with a good histological response did not lead to an increase 
in EFS [75].
The data set out in paragraph 3 are summarized in Table 3.
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Molecular biological factors that determine sensitivity to chemotherapy, invasive, 
Authors Agents
Ferrari S. Ifosfamide, adriamycin, cisplatin
Le Deley M.C. Methotrexate, adriamycin, ifosfamide, etoposide
Cui Q. Cisplatin
Pitano-Garcia A. Doxorubicin, cisplatin
Wu X. Methotrexate, cisplatin, adriamycin
Ohba T. Bevacizumab (Avastin)
Children Oncology Group Trastuzumab
Table 3. 
Trials/authors and agents.
Osteosarcoma – Diagnosis, Mechanisms, and Translational Developments
112
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Maxim Yu. Rykov1,2* and Elmira R. Sengapova1
1 Institute of Pediatric Oncology and Hematology, N.N. Blokhin Medical Research 
Center of Oncology, Moscow, Russian Federation
2 I.M. Sechenov First Moscow State Medical University (Sechenov University), 
Moscow, Russian Federation
*Address all correspondence to: wordex2006@rambler.ru
and metastatic potential of the tumor, as well as the prognosis of the disease, among 
which special attention is deserved are as follows: expression of MGMT protein, 
methylation of the promoter part of the MGMT gene, expression of ERCC1 pro-
teins, VEGF, CD133, p-STAT3tyr705, C-MYC, expression of RFC1 micro-RNA, and 
the presence of rearrangement of the TOR2A gene. It is important to note that there 
was no comprehensive assessment of the value of these markers for the histologi-
cal response to neoadjuvant chemotherapy and survival rates in patients with 
osteosarcoma.
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